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Abstract
Regulation of protein synthesis is an important aspect of growth control. A major 
determinant of this process is the availability of tRNA and 5S rRNA, which are 
synthesised by RNA Polymerase (pol) III. Pol III transcription is tightly linked to growth 
conditions, decreasing when nutrients or serum factors are low and increasing upon 
mitogenic stimulation. Therefore, it seems inevitable that mechanisms have evolved to 
couple production of the biosynthetic machinery with the needs of the cell. The target of 
rapamycin (TOR) signalling pathway, in conjunction with signalling through the 
phosphoinositide 3-kinase (PI3K) pathway, is central to this process in a diverse number of 
organisms.
Mammalian cell lines were investigated to assess if pol III transcription is under the control 
of the PI3K and mammalian TOR (mTOR) pathways. Levels of pol III transcripts were 
reduced in vivo and pol III transcription was reduced in vitro in response to inhibition of 
the pathways. Inhibition of the mTOR and PI3K pathways was not found to alter the 
abundance of the pol Ill-specific transcription factors TFIIIB and TFIIIC, or indeed of pol 
III itself. Moreover, the effects of inliibition of the pathways on pol III transcription were 
found to be independent of known regulators of pol III, such as c-Myc, Retinoblastoma 
protein (RB) or extracellulai- signal-regulated kinase (ERK) signalling, but were shown to 
be due, in part, to signalling through the translational effector kinase S6K1.
When the mTOR pathway is blocked by rapamycin, the interactions between TFIIIB and 
TFIIIIC, and between TFIIIB and pol III are ablated, which correlates with the finding that 
mTOR activity is required for normal promoter occupancy at pol III promoters. These data 
may be explained by the finding that the mTOR pathway regulates phosphorylation of 
TFIIIB and TFIIIC subunits.
II
Maf 1, a known negative regulator of pol III transcription in yeast, was investigated, since it 
has been reported to be under the control of the TOR signalling pathway. Mafl was found 
to repress transcription of all class III genes in mammalian cells, and this repression can be 
relieved by the addition of a purified fraction of TFIIIB. Direct interaction of Mafl with 
pol III and with the Brfl subunit of TFIIIB was demonstrated, and further investigation 
shows that M afl, pol III and Brfl follow the same pattern of promoter occupancy on 
tRNA*^ ®” genes in response to stress. In vivo phospho-labelling and in vitro kinase assays 
demonstrated that Mafl is a phosphoprotein, and the phosphorylation of Mafl was found 
to be inhibited by both serum-starvation and rapamycin-treatment of cells. This suggests 
that Mafl may receive signals from these signalling pathways to co-ordinate pol III 
activity, and hence the growth capacity of the cell, with nutrient availability.
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Chapter 1
Introduction
1.1 Transcription
Cellular functions such as cell proliferation, differentiation or apoptosis, are determined by 
the expression of specific genes. The process of transcription, whereby an RNA product is 
produced from DNA, is an essential element in gene expression. Failure to produce the 
initial RNA transcript will render all subsequent processes redundant, and these include 
RNA splicing, transport to the cytoplasm, or translation into protein. The importance of 
transcription in the process of gene expression makes it an attractive control point for 
regulating the expression of genes in a particular cell type, or in response to environmental 
changes and metabolic requirements. Defects in transcription are responsible for a wide |
range of human diseases, since they play a crucial part in the development of cancer, as 
well as other types of disease and developmental abnormalities.
1.2 The three RNA polymerases
Transcription involves the polymerisation of ribonucleotide precursors into an RNA 
molecule using a DNA template. The enzymes which carry out this reaction are known as 
RNA polymerases. All eukaryotes contain three nuclear RNA polymerases (pols), namely 
RNA polymerases I, II and III. These catalyse the production of three different sets of 
genes, and can be distinguished by their sensitivities to the fungal toxin a-amanitin (Table 
1.1; adapted from Sentenac, 1985). Each of these polymerases transcribes a different set of 
genes known as class I, II or III genes, respectively. RNA polymerase I (pol I) transcribes a 
single RNA species, the large ribosomal RNA precursor molecule (pre-RNA), from which 
the genes encoding the 28S, 18S and 5.8S ribosomal RNAs are processed. RNA 
polymerase II (pol II) transcribes the protein-coding mRNAs and the small nuclear RNAs 
involved in splicing. RNA polymerase III (pol III) transcribes tRNAs and 5S rRNA, which 
are required for protein synthesis, U6, HI and MRP RNAs, which are involved in 
processing of RNA transcripts, VAl RNAs encoded by adenovirus, which function to
subvert the translational machinery, and other transcripts with no known function, such as 
the short interspersed repeat (SINE) gene families, such as Alu (reviewed in Willis, 1993; 
White, 1994) (see Table 1.1). Although it synthesises only one product, pol I may be 
responsible for 70-80 % of all nuclear transcription in actively growing cells, whilst pol III 
contributes approximately 10-20% (White, 2001).
Each of the three pols consist of a large number of interacting subunits which form a 
highly complex multimeric enzyme (Acker et ah, 1997). Homology between pols I, II and 
III has been reported (Memet et ah, 1988). In fact, five of the subunits are common to all 
three polymerases and other subunits are highly related (Sentenac, 1985; Woychik et ah, 
1990; McKune et ah, 1995). Such relationships indicate a basic functional similarity 
between the three eukaryotic pols and may also be indicative of a common evolutionary 
origin.
Table 1,1: Eukaryotic RNA polymerases
RNA
Polymerase
Genes transcribed Sensitivity to a-amanitin
I Ribosomal RNA (45S precursor of 28S, 
18S and 5.8S rRNA)
Insensitive
II All protein-coding genes, small nuclear 
RNAs
Very sensitive
(50% inhibition at 25ng/ml)
III Transfer RNA, 5S ribosomal RNA, small 
nuclear RNA U6, SINE: Alu, B1 and B2, 
7SK, 7SL, HI, MRP and VAl RNA
Moderately sensitive 
(50 % inhibition at 20pg/ml)
1.3 Class III genes
Pol III is the largest and most complex of the polymerases, having 17 subunits which have 
been purified and characterised in yeast and in mammals (reviewed in Schramm and 
Hernandez, 2002). The genes transcribed by pol III encode a variety of small RNA 
molecules, usually less than 400bp, which are not translated (White, 2001) (see Table 1.1). 
Although greatly out numbered by pol Il-transcribed, mRNA encoding genes, pol III genes 
are transcribed at very high frequencies and in fact constitute a much larger fraction of the 
total cellular RNA. Confocal and electron microscopy of HeLa cells revealed that pol III 
transcription occurs at around 2000 sites within the nucleus. Each site has a radius of 
around 20nm and contains, on average five molecules of active pol III (Pombo et al., 
1999).
1.3.1 tRNA
The initial transcripts produced from tRNA genes are precursor molecules, which are 
processed into mature tRNAs between 70 to 90 nucleotides in length. tRNAs are essential 
in translation and serve as adaptor molecules, translating the genetic information contained 
within mRNA into the specific order of amino acid residues of the protein it encodes. The 
three residue anti-codon sequence of a given tRNA is specific for a particular amino acid. 
Consequently, base-pairing of the tRNA anti-codon with the complementary codon of the 
mRNA ensures the accurate synthesis of the polypeptide chain encoded by the mRNA 
nucleotide sequence. Eukaryotic cells possess 50-100 distinct tRNA species (Sharp et al., 
1985), although the proportions of different tRNAs vary significantly between cell types 
(Garel, 1976). The human haploid genome contains 821 tRNA related loci, 497 of which 
are tRNA genes, the other 324 are tRNA-derived putative pseudogenes (International 
Human Genome Consortium, 2001). The considerable redundancy displayed among tRNA 
genes results in an average copy number of around 10 genes for each amino acid tRNA 
adaptor.
1.3.2 5S rRNA
At approximately 120 nucleotides long, 5S rRNA is the smallest of the ribosomal RNAs 
and the only one transcribed by pol III (White, 2001). Following synthesis in the 
nucleoplasm, 5S rRNA is transported to the nucleolus where it is processed and integrated 
into the large ribosomal subunit and has a critical role in translation. Eukaryotic genomes 
contain a wide range of numbers of 5S rRNA genes, ranging from 140 in the haploid 
genome of Saccharomyces cerevisiae, to more than 20,000 copies mXenopus laevis (Elion 
and Warner, 1984). The majority of the latter 5S genes are required to sustain rapid growth 
during development of the oocyte (Wolffe and Brown, 1988). The human haploid genome 
contains 200-300 5S rRNA genes, many of which occur in clusters of tandem repeats 
(International Human Genome Consortium, 2001).
1.3.3 SINEs
The various genes families with short interspersed elements (SINEs) constitute 
quantitatively important classes of pol III template in higher organisms (Jelinek and 
Schmid, 1982; Singer, 1982). SINE DNA accounts for a substantial proportion (~ 13%) of 
mammalian genomes; however, a functional role for these templates has not been 
unequivocally demonstrated (reviewed by Howard and Sakamoto, 1990). The principal 
SINE in primates is the Alu family, of which there are in the region of one million copies 
in the haploid human genome (International Human Genome Consortium, 2001). In rodent 
species the most abundant SINEs are the B1 and B2 genes (Bennett et a l, 1984). B1 genes 
show approximately 80% homology with human Alu genes, whilst the B2 family is 
specific to rodents (Bennett et a l, 1984; Rodgers, 1985). B1 genes are ~130bp in length 
and are present at about 100, 000 copies per haploid mouse genome (Bennett et a l, 1984; 
Krayev et a l,  1980). B2 genes are -180bp long, with -80, 000 copies per haploid mouse 
genome (Bennett et a l, 1984; Rodgers, 1985). tRNA genes seem the likely evolutionary
source of SINE families such as B2 (Daniels and Deininger, 1985), whilst the Alu and B1 
sequences are believed to have evolved from the 7SL gene (Ullu and Tschudi, 1984).
1.3.5 U6 snRNA
U6 snRNA genes also fall into the class III gene family. U6 is the smallest of five snRNA 
species that comprise a ribonucleoprotein (RNP) complex termed a spliceosome (Kunkel et 
al., 1986; Moenne et ah, 1990). Spliceosomes function in post-transcriptional processing 
of pre-mRNA (Maniatis and Reed, 1987), removing introns to generate mature mRNA. 
The 106 nucleotide U6 transcript is the most highly conserved of the spliceosomal RNAs 
(Brow and Guthrie, 1988), and the only one that is not transcribed by pol II (Kunkel et al., 
1986; Moemie et al., 1990).
1.3.4 Viral class III genes
Several viruses contain short class III transcriptional units within their genomes. The best 
characterised of these is adenovirus, which encodes two small (~ 160 bp) pol III transcripts 
called VAl and VAII, that are synthesised at high levels during the late stages of viral 
infection (Soderlund et ah, 1976). The VA RNAs function to subvert the host cell’s 
translational apparatus to allow the synthesis of VA viral proteins (Thimmappaya et ah, 
1982). The genome of Epstein-Barr virus (EBV) also contains two small adjacent genes; 
EBERl and EBER2 that are transcribed by pol III. During adenovirus infection EBERs can 
functionally substitute for VAl (Bhat and Thimmappaya, 1985). Like the VA RNAs, this 
would allow the EBERs to subvert the host cell’s translational apparatus to allow the 
synthesis of viral proteins.
1.3.6 HI and MRP
Pol III is also responsible for the transcription of other components of ribonucleoprotein 
complexes including H I, MRP, 7SK and 7SL. HI is a 369 nucleotide RNA, that forms part 
of RNase P, an endoribonuclease involved in processing the 5’ termini of pre-tRNA (Lee 
and Engelke, 1989; Morrissey and Tollervey, 1995), and which exhibits some sequence 
homology to MRP RNA (Gold et ah, 1989). MRP is a 265 nucleotide RNA that forms part 
of RNase MRP, another endoribonuclease, which plays an important role in the 
endonucleolytic processing of pre-RNA (Morrissey and Tollervey, 1995; Schmitt and 
Clayton, 1993).
1.3.7 7SK
The 7SK gene encodes a snRNA transcript of 330 nucleotides in length. The 7SK product 
had no known function until recently. It was found to act as a negative regulator of the pol 
11 elongation factor P-TEFb; a factor responsible for the phosphorylation of pol IPs 
carboxyl-terminal domain (Nguyen et al., 2001; Yang et al., 2001).
1.3.8 7SL
The pol 111 product 7SL RNA, forms the scaffold of the signal recognition particle (SRP) 
that plays an essential role in intracellular localisation of proteins. This occurs through its 
involvement in the insertion of nascent polypeptides into the endoplasmic reticulum 
(Walter and Blobel, 1982). There are four 7SL genes in the human genome, encoding a 
highly conserved 300 nucleotide transcript (Ullu and Tschudi, 1984; Ullu and Weiner, 
1984).
1.4 Class III gene promoters
A general feature of all class III genes is that they are able to form stable transcription 
complexes (Schaack et al., 1983; Lassar et al., 1983). However, genes transcribed by pol 
III differ substantially in the type and arrangement of individual promoter elements 
(presented schematically in Figure 1.1). Whilst pol III possesses the enzymatic activity 
necessary for transcription, it cannot function independently. Consequently, transcription 
involves numerous transcription factors, which must interact with the polymerase and with 
each other if  transcription is to occur. The role of these factors is to organise a stable 
transcriptional complex which contains pol III and is able to undergo repeated rounds of 
transcription.
1.4.1 Type I Promoters
Type I promoters are uniquely found on 5S rRNA genes and in Xenopus laevis consist of 
three gene-internal sequence elements; a highly conserved 5’ A block (+50 to +64), an 
intermediate element (+67 to +72) and a 3’ C block (+80 to +97) (Pieler et a l, 1987; 
Figure 1.1). The promoter is relatively intolerant of changes in the spacing between 
individual elements (Pieler et a l, 1987). The elements contained within the minimal 
internal control region (ICR) (+50 to +97), are highly conserved between species, and 
mutations in the A- and C- blocks abolish transcription (Keller et a l,  1990). In contrast, 
the flanking sequences have limited conservation, and despite having strong modulatory 
effects, they are significantly more resilient to mutations (White, 2001).
1.4.2 Type II promoters
The most commonly used promoter arrangement of class III genes is found in tRNA and 
adenovirus VA genes and also many major SINE families. This type II promoter consists
of two highly conserved sequence elements called the A and B blocks and, like the type I 
promoter, these sequence elements are located within the transcribed region (Figure 1.1). 
The A block is positioned close to the transcription start site (usually about 10-20bp) (Galli 
et al., 1981). Since the A block is common to both type I and II promoters and is 
homologous, it can be interchanged in some cases, and this can occur despite the A blocks 
of type II promoters being much closer to the start site than type I promoters. The B block 
is downstream of the A block; however, the distance is extremely variable (Baker et al., 
1987). An A- to B-block separation of 30-60bp is usual; however, a distance of up to 
365bp can still support transcription (Baker, 1987; Fabrizio, 1987).
1.4.3 Type III promoters
A typical type III core promoter, commonly represented by 7SK, MRP and U6 genes, 
contains a TATA box, a proximal sequence element (PSE) and a distal sequence element 
(DSE). The best characterised type III promoter belongs to the U6 gene (Figure 1.1). The 
PSE covers about 15 bp and is located around 55 bp upstream of the transcriptional start 
site (Kunkel and Pederson, 1988). The TATA box is located 25bp downstream of the PSE 
at -30 (Kunkel and Pederson, 1989; Lobo and Hernandez, 1989). There is a specific 
distance that separates the PSE and TATA box on type III promoters (Lescure et al., 1991; 
Goomer and Kunkel, 1992). These elements constitute a basal promoter which is subject to 
activation by a variety of factors that bind to a DSE that is located between -244 and -214 
(White, 2001).
Type I promoter 
e.g. Xenopus somatic 5S rRNA genes
Tn
5S rDNA
A filock C Block
+ \ +50 +64 +70 +80 +97 +120
Type II promoter 
e.g. Saccharomyces SUP4 tRNA genes
+1 +8 +19
Tn
tDNA
A Block B Block
+52 +62 +73
Type III promoter 
e.g. Human U6 snRNA gene
-244 -214 -66 -47
U6 DNA TATAPSEDSE
-30 -25 +1
Fig. 1.1: Promoter structure of class III genes (adapted from White, 
2001)
Schematic representation of the three general types of promoter utilised by 
pol III. Transcription initiation and termination sites are indicated by +1 and 
Tn, respectively. The relative positions of the promoter elements that 
characterise each promoter type are represented. Included are the 
intermediate elements (IE) of the type I promoter, and the proximal (PSE) 
and distal sequence elements (DSE) found in type III promoters.
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1.4.4 Other class III promoters
Some class III genes such as 7SL do not fit into promoter types I, 11 or III as they use 
combinations of promoter elements which are different to those that have been described 
(Willis, 1993). The underlying theme, however, is that the promoter elements and their 
associated transcription factors bring the pol III factor TFIIIB to the start site of 
transcription and stabilise it there (Persinger et al., 1999). Before transcription can 
commence, a pre-initiation complex must assemble at the appropriate promoter, leading to 
recruitment of the polymerase.
1.5 Transcription complex assembly at type II promoters
(see Figure 1.2)
Transcription factor IIIC (TFIIIC) binds directly to the intragenic promoter sequences of 
type II promoters (Lassar et aL, 1983). Type II promoters require transcription factor IIIB 
(TFIIIB) and TFIIIC (Segall et aL, 1980) for the formation of a stable complex (Lassar et 
aL, 1983). Human TFIIIC was initially resolved by ion exchange chromatography into two 
components, TFIIIC 1 and TFIIIC2 (Yoshinaga et aL, 1987). TFIIIC 1 has not been well 
characterised, but previous studies have shown that it can stabilise and extend promoter 
interactions of TFIIIC2 (Yoshinaga et aL, 1987; Wang and Boeder, 1998) and can interact 
with TFIIIC2 in the absence and presence of promoter DNA (Sinn et aL, 1995). A recent 
study has questioned whether TFIIIC 1 is a bona fide  component of TFIIIC and this will be 
further discussed (Weser et aL, 2004).
TFIIIC2 can be separated into five subunits of 220, 110, 102, 90 and 63 kDa according to
their molecular masses (Yoshinaga et at., 1989; Kovelman and Boeder, 1992). TFIIIC2 can
be isolated into both active (TFIIIC2a) and inactive (TFIIIC2b) forms, which bind DNA
with equal affinity and show equivalent DNase footprint patterns (Hoeffler et aL, 1988;
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Kovelman and Boeder, 1992). Silver staining revealed that TFIlIC2a contains a llOkDa 
subunit (TFIIIC 110) whilst the inactive form laeks this polypeptide (Sinn et aL, 1995). 
Immuno depletion with an antibody against llOkDa quantitatively removed TFIIIC 1 and 
TFIIIC2 activity suggesting that llOkDa is an essential component of TFIIIC2a and that 
TFIIIC 1 is tightly associated with TFIIIC2a in nuclear extracts (Sinn et aL, 1995).
TFIIIC functions as an assembly factor and TFIIIC2, through interactions with the 
promoter element and TFIIIC 1, serves to recruit TFIIIB (L’Etoile et aL, 1994; Wang and 
Boeder, 1996), which is regarded as the pivotal initiation factor of the pol III system. 
Mammalian TFIIIB was initially found to contain TBP (TATA-binding protein; 35kDa) 
(White and Jackson, 1992; Lobo et aL, 1992) and Brfl (TFIIB-related factor; 90 kDa) 
(Mittal et aL, 1996; Wang and Boeder, 1995), which tightly associate with each other in 
HeLa cell extracts (Mittal et aL, 1996; Wang and Boeder, 1995). A more loosely 
associated polypeptide B double prime (Bdpl), was identified in S. cerevisaie (Kassavetis 
et aL, 1995; Boberts et aL, 1996). However, it was not until several years later that the 160 
kDa human homologue of Bdpl, was cloned, characterised and shown to be required for 
transcription from all pol III promoter types (Schramm et aL, 2000).
Pol III is only recruited after TFIIIB enters the transcription complex (Schramm and 
Hernandez, 2002). All tliree subunits of TFIIIB are required for pol III recruitment; 
however, the majority of direct interactions occur between Brfl and pol III subunits 
(BPC32, BPC39 and BPC62) (Wang and Boeder, 1997), although TBP can also associate 
with RPC39 (Wang and Boeder, 1997).
Cloning and characterisation of human TFIIIC subunits established their high degree of 
conservation with yeast counterparts and in vitro data demonstrates interactions between 
the subunits of TFIIIB, TFIIIC and pol III (Hsieh et aL, 1999a and b).
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tDNA +1
Tn
A Block B Block
TFIIIC
Tn
1 TFIIIB
Tn
pol III
pol III
i ï l i Tn
IIB
Fig. 1.2: A model for transcription initiation at a type II promoter
Diagram indicating the order of interaction of transcription factors and pol III 
with a typical type II promoter such as that of a tRNA gene. The site of 
transcription initiation is depicted by +1 and the site of termination is indicted 
by Tn.
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The human TFIIIC 102, TFIIIC63 and TFIIIC90 subunits bind to Brfl (Hsieh et aL, 1999b; 
Hsieh et aL, 1999a) and the TFIIIC 102 and TFIIIC63 subunits bind to TBP (Hsieh et aL, 
1999b). These interactions between the TFIIIC 102 and TFIIIC63 subunits, taken together 
with the fact that TFIIIC63 interacts with the A box (Hsieh et aL, 1999b); provides a link 
between the TFIIIB-interacting and DNA-interacting subunits of TFIIIC, In addition, 
TFIIIC63 was found to interact with a pol III subunit (RPC62) (Hsieh et aL, 1999b), 
therefore, contacts between TFIIIC and TFIIIB and TFIIIC-pol III may facilitate the 
recruitment of both TFIIIB and pol III.
1.6 Transcription complex assembly at type I promoters
(see Figure 1.3)
Competition assays using separated transcription factors derived from human cell extracts 
showed that a fraction containing TFIIIC is required to form stable transcription complexes 
with most pol III promoters (Lassar et aL, 1983). However, TFIIIC binding on 5S rRNA 
genes must be preceded by its interaction with a 5S rRNA-specific factor, transcription 
factor IIIA (TFIIIA) (Lassar et aL, 1983). Purified TFIIIA was found to have a repeated 
structure and be associated with between 7 and 11 atoms of zinc per molecule of purified 
protein (Miller et al., 1985). Thus, in addition to TFIIIA's critical role in regulating 
transcription of 5S rRNA (Lassar et aL, 1983), it was the founding member of the Cysz- 
His2"Containing zinc finger family (Miller et aL, 1985). The DNA binding ability of 
TFIIIA is dependent on the presence of zinc, which allows the zinc fingers to form; this 
highly repeated zinc finger motif is required as TFIIIA contacts a large regulatory region in 
the DNA. The zinc regions bind to the A-block (Clemens et aL, 1992), the intermediate 
element (Nolte et aL, 1998) and the C-block (Clemens et aL, 1992; Nolte et aL, 1998), the 
latter of these with the highest affinity; C-block binding contributes about 95% of the total
binding affinity of full length TFIIIA (Clemens et aL, 1992; Nolte et aL, 1998).
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Tn
5S rDNA +1
+1
A Block IE C Block
+50 +64 +70 +80 +97
TFIIIA
+120
1
TFIIIA
1 TFIIIC
TFIIIC
TFUIA
1 TFIIIB
TFIIIC
TFIIIA
TFIIIC
TFIIIA
Fig. 1.3: A model for transcription initiation at a type I promoter
Diagram indicating the order of transcription factors binding and the 
recruitment of pol III to the 5S rRNA promoter. The site of transcription 
initiation is depicted by +1 and the site of termination is indicated by Tn. IE is 
the intermediate element.
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Thus, TFIIIA is considered an adaptor factor which allows TFIIIC to be recruited onto 
genes for which it has little affinity. The way in which TFIIIA recruits TFIIIC remains 
largely unknown; however, both factors must be bound prior to recruitment of TFIIIB at 
5S rRNA promoters (Bicker et aL, 1985; Carey et aL, 1986a; Setzer and Brown, 1985). 
Binding of TFIIIB just upstream of the transcription start site allows recruitment of pol III 
to specific genes through direct interactions between pol III and a subunit of TFIIIB 
(Huang and Maraia, 2001).
It can be concluded that TFIIIC performs at least three functions; it recognises promoter 
elements, either directly in the case of type II promoters or with the help of TFIIIA in the 
case of type I promoters; it recruits TFIIIB, and it contributes to the recruitment of pol III.
1.7 Transcription complex assembly at type III promoters
(see Figure 1.4)
Type III promoters are different to those found in other class III genes as they reside 
exclusively upstream of the coding sequence. Examples of genes which have extragenic 
promoter elements are U6, 7SK and RNase MRP (Das et al., 1988; Kunkel and Pederson, 
1989; Lobo and Hernadez, 1989). Type III promoters, unlike type I and II promoters, do 
not require TFIIIA or TFIIIC for promoter recognition (Lagna et aL, 1994; Oettel et aL,
1997). Instead, other factors are recruited to the upstream sequence elements and these 
allow initiation complexes to form so that transcription can proceed.
The DSE is typically composed of several protein binding sites, one of which is an octamer
sequence (Lobo and Hernandez, 1994). The octamer sequence is recognised by the POU
domain activator Oct-1 (Herr et aL, 1988). This factor can activate transcription of 7SK
genes both in vitro and in vivo (Murphy, 1997; Murphy et aL, 1989).
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PSE occupancy is of primary importance in assembling a stable pre-initiation complex on a 
type III promoter. The U6 promoter is highly similar to class II snRNA promoters,which 
consist of only the PSE (Henry et a l, 1995); therefore, the pol II and pol III PSEs are 
interchangeable (Boyd et al., 1995) and recruit a five-subunit complex known as SNAPc 
(snRNA activator protein complex) or PTF (the proximal element transcription factor) 
(Sadowski et ah, 1993; Henry et aL, 1998; Murphy et aL, 1992). As a result, purified or 
recombinant SNAPc can function as a basal transcription factor for both types of snRNA 
gene (Yoon and Roeder, 1996; Henry et aL, 1998).
SNAPc and Oct-1 bind cooperatively to their two spatially separated PSE and DSE (Mittal 
et aL, 1996; Muiphy et aL, 1992; Ford and Hernandez, 1997). As the PSEs aie low affinity 
binding sites for SNAPc, the Oct-1 POU domain recruits SNAPc to the PSE (Murphy et 
aL, 1992; Mittal et aL, 1996). The Oct-1 binding of the DSE is then stabilised by 
interacting with DNA-bound SNAPc subunit, PSE occupancy is stimulated and this results 
in activation of transcription (Henry et aL, 1995; Murphy et aL, 1992; Mittal et aL, 1996; 
Ford et aL, 1998). The poor DNA binding ability of SNAPc as a single factor is due to its 
negative control of binding, which is achieved by masking the DNA binding domain with 
its C-terminal part (Mittal et aL, 1996). This repression can be relieved by direct protein- 
protein interactions with the Oct-1 POU domain, which identified SNAPc as a target for 
the activator Oct-1 (Ford et aL, 1998; Mittal et aL, 1999).
The type III promoters have distinct factor requirements from most pol III templates and 
variants of the TFIIIB complex used to transcribe U6 genes with a type III promoter were 
identified as different to the form used to transcribe genes with type II promoters (Lobo et 
aL, 1992; Teiclimaim and Seifart, 1995; Mittal et aL, 1996). These two TFIIIB assemblies 
were further investigated and PSE-bound SNAPc and the TATA box were found to recruit 
a different TFIIIB activity (Brf2-TFIIIB) (Schramm et aL, 2000; Teichmann et aL, 2000)
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than type 1 and II promoters (Schramm et aL, 2000). The Brf2-TFIIIB activity which 
contains TBP, Brf2 and Bdpl, does not appear to form a tight complex in the absence of 
DNA (Schramm et aL, 2000). Consistent with the absence of type III promoters in S. 
cerevisiae and S. pombe, Brf2, Oct-1 and homologues of the SNAPc subunits are not found 
in these organisms (Huang and Maraia, 2001).
Because it contains TBP, TFIIIB can bind independently to a TATA box. Accordingly, the 
TATA box in U6 promoters recruits TBP (Lobo et aL, 1991). SNAPc has also been 
reported to recruit and stabilise TBP on the TATA hox (Goomer and Kunkel 1992; Mittal 
and Hernandez, 1997). A nucleosome positioned between the DSE and PSE assists stable 
initiation complex assembly through the cooperative interactions of TFIIIB, SNAPc and 
Oct-1 by bringing them into spatial proximity (Zhao et aL, 2001). However, it is thought 
that together SNAPc and TBP can recruit the other pol III transcription factors and pol III 
and increase pol III transcription independently of the DSE and Oct-1. Brf2 can then form 
a complex with, and stabilise, TBP on a TATA-containing template, which extends the 
TBP footprint both upstream and downstream of the TATA box (Cabart and Murphy,
2001). Bdpl is specifically recruited to the U6 promoter-bound TBP-Brf2 complex (Cabart 
and Murphy, 2002). TBP and Brf2 can associate strongly in this DNA-TBP-BrfZ complex, 
whereas Bdpl remains loosely associated (Cabart and Murphy, 2001). Since the N- 
terminal region of Brf2 inhibits the direct association of Brf2 with Bdpl in solution, it is 
thought that TBP bridging can relieve this auto-inliibition and promote cooperative 
assembly of TBP, Brf2 and Bdpl subunits (Cabart and Murphy, 2002), Direct interaction 
between Bdpl and DNA has not been reported to date.
U6 genes found in S. cerevisiae lack both the DSE and PSE, and instead resemble the 
human type II promoter since they contain A and B blocks. Interaction of TFIIIC with the 
B block allows it to displace nucleosomes from the U6 template, whereas TFIIIB does not
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have this effect (Burnol et ah, 1993), so it also seems to weaken the interaction of 
nucleosomes with the transcribed region of at least some class III genes. This is consistent 
with reports that the three largest subunits of TFIIIC2 have histone acetyltransferase 
(HAT) activity (Hseih et aL, 1999b; Kundu et aL, 1999).
Only TFIIIC 1, but not TFIIIC2, is used by type III promoters (Oettel et aL, 1997; Yoon et 
aL, 1995). Little is known about TFIIIC 1, but sedimentation analysis suggests it has a 
mass of up to 200 kDa (Yoshinaga et aL, 1987). The active components of TFIIIC 1 have 
not been defined and remain under some debate; however, several candidates have been 
proposed (Oettel et aL, 1997; Wang et al., 2000; Wang and Roeder, 1996; 1997). These 
include NF-1 polypeptides, DNA topoisomerase I and PC4, which have been reported to 
participate in pol III transcription as part of TFIIIC 1 (Wang et aL, 2000; Wang and Roeder,
1998).
A recent report has found that Bdpl is an essential component of TFIIIC 1 (Weser et aL, 
2004), since Bdpl was found to strictly co-elute with TFIIIC 1 activity and this activity 
could be specifically depleted with anti-Bdpl antibodies (Weser et aL, 2004). Highly 
purified recombinant Bdpl was able to replace TFIIIC 1 activity in a reconstituted system; 
in fact, a splice variant of Bdpl which contains only the N-terminal third of full length 
Bdpl was sufficient to exert all essential TFIIIC 1 functions in such a system (Weser et aL, 
2004). Considering this new information, it is possible that TFIIIC 1 activity may simply 
correspond to that of Bdpl. In support of this, Bdpl is required for transcription from all 
types of pol III promoters, like TFIIIC 1 (Yoon et aL, 1995; Yoshinaga et aL, 1987). There 
is a plausible explanation for this initial confiision, since using the phosphocellulose 
column which was traditionally used to separate pol III transcription factors, Bdpl could 
have eluted at a slightly higher salt concentration than Brfl and TBP, If this had occurred, 
Bdpl may have ended up in the TFIIIC rather than the TFIIIB fraction. Regardless of
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U6 DNA PSEDSE TATA
-244 -214 1 SNAPc
-66 -47 -30 -25 +1
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1 TBP Brf2 Bdpl
TFIIIBOct-1 SNAPc
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Fig. 1.4: A model for transcription initiation at a type III promoter
Diagram indicating the order of interaction of transcription factors and pol III 
with a type III promoter such as is found in a 7SK gene. The site of 
transcription initiation is depicted by +1.
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whether it is Bdpl or TFIIICl that is recruited, this occurs at a later stage in complex 
assembly on type III promoters. Relatively little is known about the recruitment of pol III 
that follows.
1.8 Stepwise assembly versus holoenzyme
The majority of our knowledge about how pol III is brought to specific promoters stems 
from in vitro studies in which transcription factors are assembled in a stepwise fashion into 
transcription initiation complexes. These studies provide detailed information about the 
protein-DNA and protein-protein interactions that facilitate recruitment of pol III. 
However, there remains the possibility that in vivo pol III is recruited along with the factors 
that mediate promoter recognition as part of a holoenzyme. Indeed, observation of such a 
holoenzyme has been reported (Wang et aL, 1997). When pol III was purified from a HeLa 
cell line that expresses a FLAG epitope-tagged subunit of pol III, it was observed that a 
number of polypeptides co-purify with the enzyme (Wang et aL, 1997). The BN51 subunit,
■■y!'
which is specific to pol III (Wang and Roeder, 1997), was found associated with TBP,
Brfl, TFIIIC220 and TFIIICl 10 (Wang et aL, 1997). This finding raises the possibility that 
in vivo, pol III is recruited together with its accessory factors (Wang et aL, 1997).
1.9 Pol III transcription initiation, elongation and termination
Pol III alone has little specificity for particular DNA sequences. Its recruitment to specific
genes requires the presence of TFIIIB, which sits just upstream of the transcription start
site and positions pol III for initiation (Kassavetis et aL, 1990; Bartholomew et aL, 1991).
In yeast, the opening of the transcription bubble occurs in an ATP-independent manner
after recruitment of pol III by TFIIIB (Kassavetis et aL, 1990, 1992). Since the transcribing
pol III never leaves the vicinity of the promoter, and DNA bending by transcription factors
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further compresses the domain occupied by the transcription unit, it is probable that pol III 
is repeatedly recycled on the same gene without being released from the template 
(Geiduschek and Kassavetis, 2001). Indeed, the small size of class III genes might favour 
pol III retention for consecutive transcription cycles. In support of this hypothesis, pol III is 
retained in the original transcription complex on VA and tRNA genes after the initial round 
of transcription (White, 2001). The process is likely to involve a direct coupling between 
termination and re-initiation as demonstrated by findings that run-off termination on 
truncated class III genes does not allow efficient recycling and re-initiation (Deici and 
Sentenac, 1996), and by the recent observation that a peptide nucleic acid positioned 
downstream of the terminator interferes with re-initiation (Guffanti et ah, 2004).
Pol III can recognise a simple run of T residues as a termination signal, whereas pol I and 
II require accessory factors in order to terminate transcription. The termination signal has 
been reported to stimulate re-initiation by pol III (Wang and Roeder, 1998), whereas 
mutation of this signal diminishes the efficiency of single- and multiple- round 
transcription of VAl in HeLa cell extract (Wang and Roeder, 1996). In higher eukaryotes, 
a number of factors have been implicated in efficient termination and pol III recycling; 
these include the La protein, and components of the holoTFIIIC; NFl polypeptides, DNA 
topoisomerase I and PC4 (Schramm and Hernandez, 2002). In addition, TFIIIC has been 
reported to contact the terminator regions of tRNA genes (Oettel et ah, 1997).
Recent work in yeast has provided some insight into the pol III re-initiation mechanism by 
showing that facilitated recycling relies on a specific polymerase recapture pathway 
involving promoter-bound TFIIIB and TFIIIC (Ferrari et ah, 2004). A TFIIIC-less 
transcription system comprising reconstituted TFIIIB was sufficient to direct efficient 
recycling on short (-lOObp) class III genes. However, on longer (>300bp) transcription 
units the involvement of TFIIIC was required to establish a high re-initiation rate (Ferrari
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et a l,  2004), probably due to its ability to cause higher order rearrangements of the DNA 
(Burnol et aL, 1993) and through its contacts with the polymerase (Hseih et aL, 1999a/b).
1.10 The effect of chromatin structure on transcription
DNA and its protein scaffold exist in a complex tertiary structure referred to as chromatin. 
The fundamental unit of chromatin is the nucleosome; a repeating motif consisting of 
146bp of DNA wrapped around a histone octamer that comprises 2 molecules each of the 
histones H2A, H2B, H3 and H4 (Richmond et aL, 1984; Burlingame et aL, 1985). 
Adjacent nucleosomes are connected by linker HI DNA, which binds at the point where 
DNA enters and exits the subunits (Crane-Robinson, 1997), and progressive coiling of 
nucleosomes leads to compact higher-order chromatin structures. DNA that is contained 
within this highly compacted chromatin is termed heterochromatin and is inaccessible to 
the transcription machinery (Wolffe, 1990). Therefore, appropriate regulation of gene 
expression requires the interplay of complexes that remodel chromatin structure and 
thereby regulate the accessibility of individual genes to sequence-specific transcription 
factors and the basal machinery (Struhl, 1999).
Remodelling of chromatin is the consequence of two distinct mechanisms; the first leads to 
covalent modification of nucleosomal histones (Reviewed in Geiman and Robertson, 2002; 
Peterson, 2002; Neely and Workman, 2002), including phosphorylation, acétylation, 
méthylation and ubiquitination, which can themselves affect chromatin structure or recruit 
proteins that can do this. The second utilises the energy of ATP hydrolysis to alter 
chromatin structure (Peterson, 2002). The two processes are by no means mutually 
exclusive; the first has been shown to allow recruitment of factors which carry out the 
second (Agalioti et aL, 2002).
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Chromatin remodelling and histone modification have been largely analysed in the context 
of class II genes, but chromatin structure has also been shown to play an important role in 
class III gene transcription (Paule and White, 2000; White, 2001). For example, the ability 
of nucleosomes to block assembly of pol III transcriptional initiation complexes has been 
reported. This can occur when a nucleosome is positioned over the C-block of the 5S 
rRNA promoter, which obscures the initial DNA binding recognition sites of TFIIIA. As a 
consequence, TFIIIA can no longer bind and 5S rRNA synthesis is repressed (Gottesfeld, 
1987; Hayes et aL, 1991; Lee et aL, 1993). This repression can be relieved when the 
nucleosome is positioned further upstream, as the C-block is left open and accessible to 
TFIIIA. Consequently, transcription proceeds, albeit at a reduced rate (Tremethick et aL, 
1990; Almouzni et aL, 1991; Clark and Wolffe, 1991; Hansen and Wolffe, 1994).
Class III genes that have assembled into highly condensed structures are unable to support 
significant levels of transcription (Hansen and Wolffe, 1992). However, the susceptibility 
of class III genes to nucleosomal repression is template-dependent (Reviewed in Paule and 
White, 2000). Most tRNA genes are resistant to chromatin-mediated repression, whereas 
middle repetitive genes such as B2 are highly susceptible (Carey and Singh, 1988). The 
differential effects of histones on pol III transcription in vivo can be seen using studies 
from Xenopus, where the ability of nucleosomes to block assembly of transcriptional 
initiation complexes at pol III promoters is enhanced by Histone HI-mediated chromatin 
condensation. Changes in the level of Histone HI in developing frog embryos cause 
selective regulation of oocyte 5S rRNA genes (Bouvet et aL, 1994). Injection of mRNA 
encoding histone HI causes an increase in the abundance of this linker histone and 
repression of oocyte 5S rRNA genes. Conversely, depletion of endogenous HI using 
ribozymes causes increased expression of these genes (Bouvet et aL, 1994; Kandolf, 1994). 
These effects are specific, since transcription of genes encoding tRNA, somatic 5S rRNA, 
U1 or U2 snRNA is unaffected by these manipulations (Bouvet et aL, 1994; Kandolf,
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1994). Xenopus 5 S rRNA genes have also been used to demonstrate that histone 
acétylation facilitates the access of transcription factors to chromatinised promoter 
sequences (Lee et aL, 1993), thus diminishing the block of assembly of transcriptional 
initiation complexes.
1.11 Regulators of pol III transcription
1.11.1 Overexpression of the transcription factors TFIIIA and TFIIIC
The most obvious way to increase pol III transcription is by raising the level of one or 
more of the limiting transcription factors on which it depends (White, 2004a). Whilst a 
high rate of pol III transcription is dependent on a high level of TFIIIB, assembly factors 
such as TFIIIA and TFIIIC can be the target for processes which regulate the rate of 
transcription (White, 2001). Although these factors play an accessory role in transcription 
itself, they are still essential for complex assembly.
The ability to affect cellular transcriptional regulatory processes is crucial to the ability of
many different viruses to transform cells. For example, the large T antigens of the small
DNA tumour viruses SV40 and polyoma, and the El A protein of adenovirus can all affect
cellular gene expression and this ability is essential for the transforming ability of these
viruses (Moran, 1993). The large T antigens of both SV40 and polyomavirus have been
shown to increase pol III transcription (Scott et aL, 1983; Singh et aL, 1985; Carey et aL,
1986b; Felton-Edkins and White, 2002; Larminie et aL, 1999). mRNAs encoding all five
subunits of TFIIIC are found at elevated levels in fibroblasts transformed with
polyomavirus or SV40 (Felton-Edkins and White, 2002), TFIIIC is also specifically up-
regulated in ovarian tumours and contributes to the abnormal abundance of pol III
transcripts in these tumours (Winter et aL, 2000). The mechanisms for raising TFIIIC are,
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as yet unidentified, but do not seem to reflect a response to accelerated proliferation 
(Winter et aL, 2000; Scott et aL, 2001).
Cells transformed by adenovirus have the ability to subvert the pol III transcription 
machinery to enable high level expression of the viral VAI and VAII gene products during 
late stages of viral infection (Weinman et al., 1974; Soderlund et al., 1976). Thus, cells 
infected with adenovirus also show a marked increase in TFIIIC activity (Hoeffler and 
Roeder, 1985; Yoshinaga et aL, 1986; Sinn et aL, 1995; Hoeffler et aL, 1998). 
Adenoviruses express the oncoprotein E l A, which can alter the ratio of active TFIIIC2a 
versus inactive TFIIIC2b, a mechanism which is also used by the SV40 large T antigen to 
increase TFIIIC2 activity (White et aL, 1990; Sinn et aL, 1995; Hoeffler et aL, 1998).
Subversion or amplification of the transcription factor TFIIIA by viruses has not been 
reported, however, alterations in the level of TFIIIA during Xenopus development control 
the nature of the 5S rRNA genes which aie transcribed at different developmental stages 
(reviewed by Wolffe and Brown, 1988). Enormous stockpiles of ribosomal components are 
generated to sustain them through the initial stages of embryogenesis when biosynthesis is 
curtailed. The high expression of 5S rRNA is possible due to excessive amounts of TFIIIA 
molecules which results in disproportionate 5S rRNA synthesis compared to production of 
18S and 28S rRNA.
Whilst overexpression and activation of TFIIIA and TFIIIC has been discussed, TFIIIB is 
also subject to these molecular controls and the de-repression of TFIIIB has also been 
reported as a mechanism for raising pol III output (reviewed in White, 2004a). The 
mechanisms of how TFIIIB can be targeted by tumour suppressors and transforming 
proteins, and the way in which it is subject to cell cycle control will be discussed in the 
following sections.
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1.11.2 RB
The retinoblastoma protein (RB) is a nuclear protein of 105 kDa that is encoded by an 
important tumour suppressor gene (Weinberg, 1992; Whyte, 1995). RB functions as a 
negative regulator of cell-cycle progression, mediated through its ability to bind and 
regulate the activity of a variety of transcription factors required for entry into S phase, 
including the E2F family of transcription factors (Chellappan et aL, 1991; Hiebert et aL, 
1992). RB is phosphorylated and dephosphorylated in a cell cycle-dependent manner and 
it is clear that these changes regulate its activity. Phosphorylation and deactivation of RB 
during G1 involves sequential phosphorylation by the cyclin D- and cyclin E-dependent 
kinases (Hunter and Pines, 1994; Sherr, 1994).
In addition to regulating transcription by pol II, RB family members can also repress 
transcription by pol I (Cavanaugh et aL, 1995; Voit et aL, 1997) and pol III (White et aL, 
1996; Larminie et aL, 1997; Sutcliffe et al, 1999). The specific repression of pol III by RB 
was first demonstrated by White and co-workers. Evidence from in vitro transcription 
assays and transient transfection assays showed for the first time that high levels of RB can 
inhibit pol III activity (White et aL, 1996). Comparison of 2 osteosarcoma cell lines 
showed that an RB-negative (SA0S2) cell line could express a transfected pol III template 
five times more actively than a matched cell line (U20S) which contained wild type RB, 
moreover, the level of pol III activity was elevated specifically in primary cells taken from 
RB-knockout mice (White et aL, 1996).
Several lines of evidence suggested that RB could repress pol III transcription by 
physically interacting with TFIIIB (Larminie et aL, 1997). It was shown that RB 
inactivation of pol III transcription can be overcome by the addition of purified TFIIIB. 
Also, Brfl and TBP could be co-immunoprecipitated with RB from partially fractionated 
HeLa cell extracts (Larminie et aL, 1997). The interaction of RB with TFIIIB was
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abolished in S A0S2 osteoscaroma cells which contain a truncated form of RB (Larminie et 
ah, 1997). Moreover, the level of TFIIIB activity was elevated specifically in primary cells 
taken from RB-knockout mice (Larminie et aL, 1997). TFIIIB is therefore regarded as the 
principal target for RB-mediated repression of pol III, although a subsidiary interaction 
with TFIIIC may also contribute to the effect (Chu et aL, 1997).
The hypophosphorylated form of RB was found to interact with TFIIIB to suppress pol III 
transcription (Sutcliffe et aL, 1999; Scott et aL, 2001). In fact, the hypophosphorylated 
form of RB and RB-related pocket proteins, p i07 and p i30 all bind Brfl (Sutcliffe et aL,
1999). It has been demonstrated that the hypophosphorylated form of RB associates with 
TFIIIB during late GO and early G1 phases, and that this interaction substantially decreases 
as cells approach S phase (Scott et aL, 2001). The hyperphosphorylated form of RB was 
found to release B rfl, and this correlated well with the previous demonstration that TFIIIB 
activity increases at the Gl-S transition (White et aL, 1995), as this is the same time that 
RB is inactivated due to hyperphosphorylation. Consistent with these observations, pol III 
transcription is stimulated strongly when cells are transfected with vectors encoding cyclin 
D/cdk4 and cyclin E/cdk2 (Scott et aL, 2001).
RB is postulated to block pol III transcription by preventing TFIIIB from interacting with 
TFIIIC and by preventing pol III recruitment to the initiation complex. Since the majority 
of genes that are transcribed by pol II are not affected directly by the presence of RB 
(White et aL, 1996), RB is considered a gene-specific regulator of pol II, whereas it acts as 
a general regulator of pol III.
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1.11.3 c-Myc
c-Myc was first identified as a cellular counterpart of the transforming gene from avian 
myelocytomatosis virus MC29 (Sheiness and Bishop, 1979). c-Myc has been shown to 
play an extensive role in cancer, as it can collaborate with other oncogenes to induce 
cellular transformation (Land et a l, 1983). This can be achieved as c-Myc affects cell 
cycle regulation, apoptosis and metabolism positively, whereas it affects cellular 
differentiation and cell adhesion negatively (Dang et a l, 1999; Eisenman, 2001). As a 
result, aberrant c-Myc expression is observed in many human cancers, leukaemias and 
lymphomas (Spencer and Groudine, 1991). In fact, it is estimated that 1/3 of all human 
cancers display deregulated c-Myc activity (Prendergast, 1999). Consistent with potent 
growth-promoting properties of this protein, c-Myc was found to stimulate pol III 
transcription (Gomez-Roman et a l, 2003). Pol III activity was induced in primary human 
fibroblasts by c-Myc-oestrogen receptor (Myc-ER) expressed from a retroviral vector. In 
contrast, when myc- knockout and matched wild type fibroblasts were compared, the 
knockouts show 7-fold lower expression of pol III transcripts, demonstrating that pol III 
activity is compromised in c-myc cells. Chromatin immunoprécipitation (ChIP) analysis 
showed that whilst no c-Myc was present at tRNA promoters o f serum-starved cells, c- 
Myc was present at pol Ill-transcribed genes in tamoxifen-treated cells carrying the Myc- 
ER construct (Gomez-Roman et aL, 2003). This recruitment was found to occur by 
protein-protein interactions of TFIIIB with the N-terminal transactivation domain of c- 
Myc, which directly activates transcription (Gomez-Roman et aL, 2003).
In a different study, specific depletion of endogenous c-Myc by RNAi selectively reduced 
tRNA and 5S rRNA gene expression in HeLa cells (Felton-Edkins et aL, 2003b). This 
report demonstrates that c-Myc can regulate the expression of several type I and II pol Ill- 
specific genes. However, type III genes such as 7SK do not appear to be regulated by c-
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Myc (Schlosser et a l, 2003), which suggests that c-Myc regulation of pol III transcription 
is via a type I and II promoter-specific TFIIIB activity.
Since activation of c-Myc results in increased translation and growth, and loss of c-Myc 
diminishes growth and protein synthesis (Sclimidt, 1999), the growth-promoting potential 
of c-Myc may be mediated, in part, tluough the regulation of pol III transcription.
1.11.4 Regulation of pol III transcription during cellular stresses
p53 is a major tumour suppressor that is lost or mutated in more than half of human 
cancers (Hollstein et aL, 1991). p53 protects cells in response to physiological stress 
conditions by either activating or repressing a variety of cellular promoters (Cox and Lane, 
1995; Ko and Prives, 1996; Levine, 1998; Giacci and Kastan, 1998; Vogelstein et aL,
2000). A well characterised example is the p21/WAF/CIP gene, which is activated by p53 
and plays an important role in G1 arrest (El-Deiry et aL, 1993). It has been shown that p53 
serves as a general repressor of pol III transcription and that TFIIIB is the target 
(Chesnokov, 1996; Cairns and White, 1998). Endogenous p53 can interact with TFIIIB and 
compromise its function (Cairns and White, 1998), and this interaction appears to be 
mediated through TBP (Crighton et aL, 2003). ChIP assays show that TFIIIB is excluded 
from promoters when bound by p53, and coimmunoprecipitations reveal that TFIIIB can 
no longer bind to TFIIIC and pol III (Crighton et aL, 2003). As a consequence fibroblasts 
from p53-knockout mice display markedly elevated synthesis of tRNA and 5S rRNA 
(Cairns and White, 1998).
Genotoxic agents such as Ultra Violet (UV) or methane methylsulphonate (MMS) can 
trigger a rapid and coordinate suppression of rRNA and tRNA synthesis in S. cerevisiae 
that is mediated, in part, by CK2 (Casein Kinase II) (Ghavidel and Schultz, 2001). CK2
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was found to associate with and activate the TBP subunit o f TFIIIB under normal 
(unstressed) conditions. However, upon DNA damage, CK2-dependent transcriptional 
repression is induced, which coincides with the down-regulation of TBP-associated CK2 
(Ghavidel and Schultz, 2001). This suggests that TBP-associated CK2 acts as the effector 
kinase in a genotoxic stress signalling pathway.
Recent experiments in S. cerevisiae have identified a structurally novel and 
phylogenetically conserved protein, Mafl (Pluta et aL, 2001), as a negative regulator of pol 
III transcription in response to diverse cellular conditions (Upadhya et aL, 2002; Desai et 
aL, 2004). An absolute requirement of Mafl in the repression of pol III transcription has 
been demonstrated in mafl-deletion strains following interruption of the secretory 
pathway, and in response to DNA damage, growth to stationary phase and treatments with 
rapamycin and the anti-fungal compound chlorpromazine (Upadhya et aL, 2002; Desai et 
aL, 2004). This suggests that a common mechanism functioning downstream of Mafl acts 
to repress the pol III transcription machinery in yeast. Indeed, several studies have shown 
that this regulation is via TFIIIB (Upadhya et aL, 2003; Willis et aL, 2004; Desai et aL, 
2004).
1.11.5 Regulation of pol 111 transcription during differentiation
Pol III transcription has been found to decrease dramatically during parietal endoderm 
formation, both in culture and in the developing mouse (Vasseiir et aL, 1985; White et aL, 
1989). This appears to be due to loss of TFIIIB activity (Alzuherri and White, 1998; White 
et aL, 1989). Experiments revealed that there is a significant decrease in the Brfl subunit 
of TFIIIB (Alzuherri and White, 1998) and some decrease in the level of TBP (Alzhurri 
and White, 1998, 1999; Perletti et aL, 2001). Despite the fact that TBP is utilised to
31
&
transcribe all three classes of genes, there is no overall change to pol II transcriptional 
activity (White et al., 1989). This suggests that at least one of the TFIIIB-related factors is 
specifically downregulated in response to differentiation.
1.12 Kinases that regulate pol III transcription
Protein phosphorylation represents a qualitative mechanism that can up-regulate or repress 
transcription. Transcription factors can be kinase substrates themselves or their activity can 
be controlled indirectly by modifying proteins that modulate their function (Hunter and 
Karin, 1995). In the case of pol III transcription, specific examples exist for 
phosphorylation as a mechanism of transcriptional regulation, one such example being the 
mitotic repression of pol III transcription in Xenopus egg extracts. This can occur by 
inactivation of Brfl-TFIIIB through direct phosphorylation by cdc2-kinase, as well as 
through an alternative pathway involving an unidentified kinase (Gottesfeld et ah, 1994; 
Leresche et al., 1996). Repression in mitotic HeLa cell extracts is, however, independent of 
cdc2 kinase activity, and instead is by an unidentified kinase, whose activity renders Brfl 
and Bdpl functionally limiting (Fairley et ah, 2003).
In addition, the ERK (extracellular signal-regulated kinase), Wnt and mTOR (mammalian 
target of rapamycin) signalling pathways have been identified as regulators of pol III 
transcription in response to growth factor stimulation. Positive or negative regulation 
reflects whether (or not) the cell’s environment is conducive for growth.
1.12.1 ERK signalling
The ERK MAPK (mitogen-activated protein kinases) are stimulated in response to
mitogens through a signalling cascade involving Ras, Raf and MEK (Downward, 2002).
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ERK has been shown to stimulate the assembly of pol III transcription complexes via the 
direct binding and phosphorylation of the Brfl subunit of TFIIIB (Felton-Edkins et aL, 
2003a). Consequently, a substitution in the ERK docking domain or phosphoacceptor site 
of Brfl substantially reduces pol III transcription (Felton-Edkins et aL, 2003a). Blocking 
ERK signalling in cells with an inhibitor of MEK reduces the interaction of TFIIIB with 
both TFIIIC and pol III, as determined by coimmunoprecipitation, whilst ChIP analysis 
showed a reduction in the occupancy of Brfl and pol III at tRNA and 5S rRNA promoters 
(Felton-Edkins et aL, 2003a). In direct contrast, activating mutations in upstream effectors 
of the ERK signalling cascade such as Ras or Raf, stimulate expression of a pol III reporter 
in transfected fibroblasts (Felton-Edkins et aL, 2003a). Mitogenic stimulation of ERK 
activity therefore increases cell growth by direct transcriptional activation of 5S rRNA and 
tRNA. However, since phosphorylation of Brfl is only partially reduced by blocking ERK 
activity, it is probable that other kinases are also involved.
1.12.2 CK2
Another factor implicated in the activation of pol III transcription is CK2 (Hockman and 
Schultz, 1996; Ghavidel and Schultz, 1997, 2001; Johnston et aL, 2002). CK2 is a highly 
conserved enzyme which forms part of the Wnt signalling pathway in both flies and 
mammals (Willert et aL, 1997; Song et aL, 2000). Many studies have shown that increased 
abundance or activity of CK2 is associated with cell growth and proliferation, and that 
overexpression of CK2 results in transformation and tumorigenesis (reviewed in Johnston 
et aL, 2002; White, 2004b). One aspect of CK2’s grovrth-promoting activity may be 
through its reported role in regulating pol III transcription (Hockman and Schultz, 1996; 
Ghavidel and Schultz, 1997; 2001; Johnston et aL, 2002). In yeast cells with reduced CK2 
activity, pol III transcription is repressed (Hockman and Schultz, 1996). These genetic 
studies first demonstrated the requirement for CK2 in yeast, since shifting a strain carrying
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a temperature sensitive version of CK2a to a non-permissive temperature, specifically 
inhibits both growth and pol III transcription (Hockman and Schultz, 1996).
The function of CK2 appears to be conserved in mammalian cells as CK2 has been 
reported to co-purify with TFIIIB activity in both yeast and humans (Ghavidel and Schultz, 
1997; 2001; Jolinston et aL, 2002). Experiments performed with partially purified pol III, 
TFIIIC and TFIIIB fractions suggested that CK2 associates with and phosphorylates 
TBP in yeast (Ghavidel and Schultz, 1997; 2001). In contrast, endogenous co- 
immunoprecipitations and phospholabelling studies have shown that CK2 associates with 
and phosphorylates Brfl in mammalian cells (Johnston et aL, 2002), In yeast, 
phosphorylation of a TFIIIB fraction by CK2 is required for efficient association of TFIIIB 
with TFIIIC (Ghavidel and Schultz, 1997; 2001). Dephosphorylation of this fraction with a 
phosphatase greatly diminishes its transcriptional activity (Ghavidel and Schultz, 2001). 
The addition of competitive and chemical inhibitors of CK2 showed that phosphorylation 
of TFIIIB by CK2 is necessary for TFIIIB to interact with TFIIIC in vitro and in fibroblasts 
(Johnston et aL, 2002).
A recent report proposes that CK2 phosphorylation of pol III itself is required for 
transcription, and disputes that phosphorylation of components TFIIIB are activating for 
pol III transcription at a type III promoter (Hu et aL, 2003). Further work from this group 
suggests that CK2 is directed to phosphorylate different targets within the basal pol III 
transcription machinery at different times during the cell cycle, with opposite 
transcriptional effects (Hu et aL, 2004). CK2 treatment of the pol III complex is required 
for transcription, whereas treatment of Brf2-TFIIIB is inhibitory (Hu et aL, 2003, 2004) 
and occurs through the phosphorylation of Bdpl during mitosis (Hu et aL, 2004). 
However, inhibition of CK2 in S phase extracts debilitates transcription (Hu et aL, 2004). 
These findings from Hu and co-workers may be explained by the fact that a minimal
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system was used and that type I and II promoters are not regulated in the same way as type 
III. Furthermore, this regulation remains to be shown in vivo. Nevertheless, it is agreed that 
pol III transcription at human type I, II and III promoters requires CK2 activity (Johnston 
et al., 2002; Hu et al., 2003; Hu et al., 2004). These results suggest that CK2 can activate 
pol III transcription from type I and II promoters by phosphorylating TBP in the yeast 
system and Brfl and pol III in the human system (Ghavidel and Schultz, 1997; 2001; 
Johnston et al, 2002) and can inhibit pol III transcription at type III promoters by 
phosphorylating Bdpl during mitosis (Hu et a l, 2004).
1.12.3 mTOR
The adaptation of growth in response to nutritional changes is essential for the proper 
development of all organisms. Mammalian target of rapamycin (mTOR) has been proposed 
as a central component of a pathway which integrates both nutrient and mitogenic signals 
to regulate growth (increased mass and cell size) and cell division (Reviewed in Fingar and 
Blenis, 2004). A key downstream target of mTOR is protein synthesis (Chou and Blenis, 
1995; Lawrence and Abraham, 1997). However, studies in mammals also indicated that 
synthesis of rRNA is rapamycin sensitive, and thus transcription by pols I and III is 
controlled by mTOR (Majahan, 1994). Run-on transcription experiments using nuclei from 
rapamycin-treated cells indicated a dose-dependent inhibition of rRNA genes which could 
be relieved when rapamycin was removed from the media (Mahajan, 1994). Yeast TOR 
was also found to control rRNA and tRNA synthesis via pol I and pol III (Zaragoza et al., 
1998; Powers and Walter, 1999); extracts from cells treated for just 1 hr were 2- to 4-fold 
less active for pol III transcription than controls. In addition, TOR was found to regulate 
ribosome biogenesis in yeast, as rapamycin treatment rapidly and severely reduces pol II- 
mediated transcription of genes encoding ribosomal proteins (Cardenas et aL, 1999; 
Powers and Walter, 1999).
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The finding that TOR positively controlled both the biosynthesis and the activity of the 
translation machinery underscored the central role of TOR in mediating cell growth 
(Schmelzle and Hall, 2000). More recent studies in both yeast (Claypool et al,, 2004) and 
mammalian cells (Hannan et ah, 2003; Mayer et ah, 2004), have gone some way toward 
identifying mTOR-regulated targets of the pol I system. However, relatively little is known 
about how mTOR regulates pol III transcription.
1.13 Coordinate regulation of pol I and pol III
Organisms adjust their translational capacity to meet but not exceed the need for protein 
synthesis. Consequently, the production of the eukaryotic translational apparatus involves 
the coordinate synthesis of the 28S, 18S and 5.8S ribosomal RNAs transcribed by pol I and 
5S rRNA and tRNAs transcribed by pol III. Under balanced growth conditions, the levels 
of both pol I- and III-specific transcription increases proportionally with growth rate 
(Clarke et ah, 1996). Moreover, the outputs of pols I and III in mammalian cells increase in 
parallel following serum stimulation and fluctuate together during passage through the cell 
cycle (Johnson et ah, 1974; Mauck and Green, 1974; Klein and Grummt, 1999; White et 
ah, 1995). One method to co-ordinate transcription by pols I and III would be to target 
shared components of the transcription machinery. However, regulation of pols I and III by 
key regulators, and signalling pathways involved in growth is achieved by targeting unique 
rather than shared components of the pol I and III machineries.
The synthesis of rRNA and tRNA can be initiated by the phosphorylation of key
transcription factors that regulate pols I and III. As an example, CK2 activity was found to
be necessary for the efficient interaction of TFIIIB with TFIIIC in vitro and in vivo
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(Johnston et a l, 2002). Thus, the phosphorylation of TFIIIB by this enzyme regulates pre­
initiation complex formation and increases pol III transcription (Johnston et aL, 2002). 
Phosphorylation of the pol I transcription factor UBF, is reported to be directly dependent 
on mitogenic stimuli and cell cycle progression, as UBF is hypophosphorylated and 
transcriptionally inactive in quiescent cells (O’Mahony et aL, 1992; Voit et aL, 1992; Voit 
et aL, 1995). Since UBF phosphorylation regulates its ability to bind and recruit SLl 
(Kihm et aL, 1998; Tuan et aL, 1999), it can be seen that phosphorylation controls 
promoter recruitment of the TBP-containing initiation factors (SLl or TFIIIB) in both the 
pol I and pol III systems.
In healthy cells, pols I and III are subject to repression by p53 as well as RB (Cairns and 
White, 1998; Cavanaugh et aL, 1995; White et aL, 1996; Zhai and Comai, 2000). p53 has 
been shown to repress pol I transcription by directly binding SLl and preventing it from 
binding UBF (Zhai and Comai , 2000). This binding interferes with the assembly of a 
protein complex that is required for transcriptional initiation on the rRNA promoter (Zhai 
and Comai, 2000). In the pol III system, it was found that the interaction of p53 with 
TFIIIB represses pol III transcription (Cairns and White, 1998; Chesnokov et aL, 1996). 
This is mediated by direct contacts with the TBP subunit (Crighton et aL, 2003), which 
prevents the association of TFIIIB complexes with TFIIIC and pol III, thus impeding the 
formation of functional transcription complexes (Crighton et aL, 2003),
In addition to regulation by c-Myc, and by ERK, Wnt and mTOR signalling, two important 
tumour suppressors target pol I and pol III transcription. In cancer cells which harbour 
inactivating mutations of p53 and RB, deregulation of growth through increased pol I and 
III activity might contribute to tumorigenesis. In fact, the activities of pols I and III are 
known to be elevated in murine tumours and by transforming agents (reviewed by White, 
1997). Ribosome biogenesis is a high energy- and nutrient- consuming process, as it
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accounts for a major portion (80%) of the total cellular biosynthetic output (Warner, 1999; 
Moss and Stefanovsky, 2002; Grummt, 2003). Pols I and III products are essential in the 
process of ribosome biogenesis and it is apparent that they are both entangled in a network 
of regulatory interactions that help coordinate their outputs and encourage the balanced 
production of ribosomal components.
1.14 Cell cycle progression is not required for cell growth
As a high proportion (80-90%) of the cell’s dry mass is protein (Zetterberg and Killander,
1965), it follows that growth (defined as an increase in cell mass), is directly proportional .1
to the rate of protein accumulation (Baxter and Stanners, 1978). By analysing temperature
I-sensitive cdc mutants in S. cerevisiae, Hartwell and co-workers gained important insight 
into the relationship between cell growth and division. They found that when cell division 
is blocked upon the inactivation of cdc genes, cell growth continues and the yeast arrest at 
a large size (Johnston et aL, 1977). In contrast, when cells are deprived of nutrients or 
when biosynthetic proteins are inactivated (via conditional cdc knockouts), cell division 
and cell growth are co-ordinately blocked. Similarly, work in D. melanogaster showed 
that when cell cycle regulatory genes (dE2F or cdc2) are disrupted then cells arrest at a 
large size (Weigmann et aL, 1997; Neufeld et aL, 1998). More recently Fingar and co­
workers found that inducing a G1 phase cell cycle block in mammalian fibroblasts by 
overexpression of the cyclin D/cdk4 inhibitor p i6 induces a shift to increase cell size 
(Fingar et aL, 2002). These initial findings and subsequent studies by others demonstrated 
that a critical mass must be reached to allow cell cycle progression (Fingar et aL, 2002,
Nuefeld and Edgar, 1998, Johnston et aL, 1977; Zetterberg and Killander 1965; Sudbery
2002). Interestingly, whilst cell growth is required for cell cycle progression, the reverse is 
not true, cell cycle progression is not required for cell growth (Johnston et aL, 1977; Fingar 
et aL, 2002). The molecular mechanisms by which cell growth is coupled to cell division
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are poorly understood. However, this dissociation of cell growth and cell division is 
indicative that distinct pathways control these essential processes and that cross talk must 
occur for one to be dependent on the other.
1.15 mTOR and the regulation of growth
Increased protein synthesis is one of the major anabolic events required for the growth 
response (Kozma and Thomas, 2002). The availability of tRNA and rRNA is clearly an 
important determinant of the rate of translation. A high level of transcription by pols I and 
III is therefore essential to maintain rapid growth. As discussed previously, regulation of 
protein synthesis is an important aspect of growth control. A major determinant of this 
process is rate of rRNA gene transcription by pol I (Stefanovsky et aL, 2001), and the 
availability of tRNA and 5S rRNA, which are synthesised by pol III (White, 2004b). The 
combined activities of pol I and pol III account for more than 80 % of cellular transcription 
in growing cells. Abnormally high rates of transcription by pols I and III are a general 
feature of transformed and tumours cells (Schwartz et aL, 1974), highlighting their 
importance in the control of growth. mTOR is known to positively control both the 
biosynthesis and activity of the translation machinery, and therefore the rate of cellular 
protein synthesis. This suggests a central role of mTOR in mediating growth which may 
occur tlirough the coordinate regulation of transcription by pols I and III, and translation.
1.16 Aims
The mTOR signalling pathway promotes both growth and proliferation (Thomas and Hall,
1997; Sclimelzle and Hall, 2000) and increased rates of tRNA and rRNA synthesis are
necessary for accelerated rates of proliferative growth (Thomas, 2000; Moss and
Stefanovsky, 2002; Brown et aL, 2000). On the basis of these observations, we
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hypothesised that mTOR, in addition to its effects on translation, might directly regulate 
the function of molecules that control synthesis of tRNA and rRNAs. In support of this 
idea, mTOR has been identified as a regulator of pol I transcription in mammalian cells. 
Therefore, the overall objective of this Ph.D. was to identify if  pol III transcription is also 
under the control of the mTOR pathway and investigate possible mechanisms of this 
control.
The first aim was to find if the mTOR and PI3K inhibitors rapamycin and LY294002 can 
regulate pol III transcription. After this had been established, an analysis of whether these 
effects were independent of the existing known mechanisms was to be carried out, and 
further mechanisms of control considered. The remainder o f the investigation was 
concerned with whether M afl; a negative regulator of pol III in yeast, had a conserved 
function in mammalian cells and to elucidate the mechanisms responsible for this 
regulation.
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Chapter 2
Materials and Methods
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2.0 Materials and Methods
(for list of suppliers see Appendix 1)
2.1 Cell culture
BALB/c 3T3 (A31) and CCL39 cells were cultured in DMEM (Dulbecco’s Modified Eagle 
Medium), which was supplemented with 10% (v/v) fetal bovine serum (FBS, Sigma), 2 
mM L-glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin. RAT lA  cells 
expressing haemagglutin (HA)-tagged Brfl were cultured in DMEM supplemented with 
5% (v/v) FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin and 50 
mg/ml G418 sulphate. All cell types were grown in humidified atmosphere containing 5% 
CO2 at 37°C. Cell culture was performed in a class II hood, using aseptic technique and 
sterile equipment and reagents. Cells were routinely passaged when subconfluent, 
approximately every 2 to 3 days. After media was aspirated from the flask, 2 ml of 
buffered trypsin-EDTA (0.05% (w/v) trypsin, 0.02% (w/v) EDTA) was added to the cells, 
and then aspirated immediately. A further 2 ml was added and left for approximately 2 
minutes at 37°C. Following trypsinisation, fresh media was immediately added to the 
dissociated cells in order to neutralise the trypsin.
Cell lines were stored by cryofreezing. To do this, cells were trypsinised as described 
above and, following pelleting by centrifugation, cells were resuspended in a solution of 
70% (v/v) DMEM, 20% (v/v) FBS (no supplements) and 10% (v/v) dimethyl sulfoxide 
(DMSO). Aliquots of cells were put into cryo-tubes at density of 2 x 10  ^cells/ml/tube and 
frozen in stages by initially being placed at ~80°C overnight and subsequently being 
transferred to liquid nitrogen storage. Thawing of cells was performed rapidly by placing 
cryo-tubes in a water bath at 37°C until just thawed. Cells were then mixed with fresh 
growth media, centrifuged and the supernatant aspirated off to ensure removal of DMSO 
prior to re-suspension in 10% (v/v) FBS DMEM. For rapamycin (Calbiochem) treatment 
of the cells, cells were grown to 70% confluency and treated with 100 nM final 
concentration of rapamycin for specific times. Similarly, LY294002 (Calbiochem) 
treatment was carried out using 50 pM final concentration of the drug. Both Rapamycin 
and LY294002 stocks were diluted in DMSO.
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2.1.1 Amino acid starvation of A31 cells
A31 fibroblasts cultured in normal growth media were washed 2 times with Earle’s 
Balanced Salt Solution (EBSS) (Gibco), then incubated in EBSS containing 10% (v/v) 
dialysed FBS (dFBS) plus 2 mM L-glutamine, 100 U/ml penicillin, 100 pg/ml 
streptomycin and 4.5g/Utre glucose to match that in DMEM, for the times indicated. The 
effect of amino acid starvation was compared to cells grown in DMEM plus 10% (v/v) 
dFBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin.
2.1.2 Re-addition of amino acids to A31s
A31 fibroblasts cultured in normal growth medium were serum-starved by incubating in 
DMEM medium without FBS for 16 hours. The cells were then washed twice with 
Dulbecco’s phosphate-buffered saline (D-PBS) containing 4.5g/litre glucose to match that 
in DMEM and incubated in the same buffer for 1 hour. Re-addition of the amino acids 
involved changing the medium to D-PBS with 4.5g/litre glucose containing 1 x amino 
acids (Gibco) for 1 hour. The concentration of each amino acid designated as 1 x is as 
follows (in mg/L); L-Arg, 84; L-Cys, 48; L-Glu, 584; L-His, 42; L-Ile, 195; L-Leu, 105; L- 
Lys, 146; L-Met, 30; L-Phe, 66; L-Thr, 95; L-Trp, 16; L-Tyr, 72; L-Val, 94. A mixture of 
these amino acids, each at this concentration is determined “ 1 x amino acid mixture”. In 
some cases, 10% (v/v) dFBS was also added with the 1 x amino acid mixture for 2 hours.
2.1.3 Cardiomyocytes
Hearts were excised from 1- to 5-day-old Sprague Dawley rats by Central Biological
Services (Institute of Biomedical and Life Sciences, University of Glasgow), and primary
cultures of rat neonatal cardiomyocytes were prepared by Sarah Goodfellow, Fiona Cairns
and Louise Derblay. Myocytes were kindly provided plated on to 6-well tissue culture
dishes that had been coated with a 1% (w/v) gelatin (Sigma) solution, in Dulbecco’s
modified Eagle’s medium/medium 199 (DMEM/M199 at a ratio o f 4:1 v/v) supplemented
with 10% (v/v) horse serum (HS), 5% (v/v) FBS, 100 units/ml penicillin and 100 gg/ml
streptomycin (all Sigma). Cells were plated at a density of approximately 10^  cells per
m m \ After 24 hours, confluent myocytes had begun to beat spontaneously. At this time,
cells were washed in DMEM/M199 (4:1) supplemented with 4% (v/v) HS, 100 units/ml
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penicillin and 100 gg/ml streptomycin (maintenance medium), then maintained in this 
medium until use (usually 24 hours).
For experiments, cardiomyocytes were either serum-starved in DMEM/M199 (4:1) 
supplemented with 100 units/ml penicillin and 100 gg/ml streptomycin or grown in the 
same medium with 10% (v/v) FBS for 4 or 16 hours, in the presence of vehicle (DMSO), 
rapamycin (100 nM) or LY294002 (50 pM).
2.2 Preparation of total cellular RNA
Total cellular RNA was isolated from cells when approximately 80% confluent using TRI 
reagent (Sigma), a solution of guanidine thiocyanate and phenol, in accordance with the 
manufacturer’s instructions. Media was aspirated off cells grown in 10cm tissue culture 
dishes. Cells from each dish were harvested by scraping in 1ml of TRI reagent per dish 
and transferred to a sterile eppendorf tube. Cells were left to stand for 5 minutes at room 
temperature to ensure complete dissociation of nucleoprotein complexes. Chloroform (0.2 
ml) was then added to each tube and the samples vortexed for 15 seconds. The samples 
were then allowed to stand for a further 15 minutes at room temperature prior to being 
centrifuged at 13, OOOg for 15 minutes at 4°C. This resulted in separation of the samples 
into three phases: a lower red organic phase (containing protein), a middle white interphase 
(containing precipitated DNA) and an upper colourless aqueous phase (containing RNA). 
The aqueous phase was carefully removed, ensuring no contamination from the remaining 
phases, and transferred to fresh eppendorf tubes. Isopropanol (500 pi) was added to each 
of these tubes containing the aqueous RNA and thoroughly mixed by repeated inverting. 
Following 5 - 1 0  minutes incubation at room temperature to allow maximal precipitation 
of RNA, samples were centrifuged at 13, OOOg for 10 minutes at 4°C. The supernatant was 
then removed and the remaining RNA pellet was washed with 1ml of 75% (v/v) ethanol 
made up with diethylpyrocarbonate (DEPC)-treated dHiO (0.1% (v/v) DEPC, thoroughly 
mixed into solution, left overnight at room temperature and then autoclaved to inactivate 
the remaining DEPC). The samples were vortexed briefly, subsequently microcentrifuged 
at 7, 500g for 5 minutes at 4°C and the supernatant aspirated off. Residual supernatant was 
removed with a P20 pipette following pulse microcentrifugation. Appropriate volumes of 
DEPC-dHzO, in the range of 10 -  30 pi, were added to the RNA pellets and the samples 
were heated in a 65°C water bath for 10 -  15 minutes to facilitate resuspension of the 
RNA. The samples were stored at -70°C.
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2.3 Quantification of nucleic acids
Nucleic acid concentrations were estimated by spectrophotometry at A260/A280 (WPA 
lightwave S2000, WPA Cambridge), where an OD of 1 at 260 nm corresponds to 50 pg/ml 
of double-stranded DNA and 40 pg/ml of single-stranded DNA and RNA (Sambrook et al, 
1989). RNA concentration was determined by UV spectrophotometry at A26o/A2go* 
Readings were zeroed with the solution in which samples had been diluted. The following 
formulae were used;
RNA concentration (pg/ml) = absorbance at 260nm x 40 x dilution factor.
DNA concentration (pg/ml) -  absorbance at 260nm x 50 x dilution factor.
The ratio of A260/A280 provided an estimate of nucleic acid purity. Values between 1.8 and 
2.0 indicated preparations of acceptable purity.
2.4 Northern blot analysis of total cellular RNA
Typically RNA samples of 10 -  30 pg were used in analysis, made up to a total volume of 
10 pi with DEPC-dH20. 10 pi of 2 x RNA sample buffer (1 x MOPS comprised of 
solutions made up with DEPC-dH20, (20 mM MOPS pH 7.0, 8 mM sodium acetate, 1 mM 
EDTA pH 8.0), 4.4 M formaldehyde, 54% (v/v) formamide) was added to each sample 
prior to heating at 65°C for 15 minutes to denature the RNA secondary structure. The 
samples were immediately transferred to ice to prevent any renaturation, and centrifuged 
for 5 seconds to deposit all the fluid at the bottom of the tube. A further 2 pi of 1 mg/ml 
ethidium bromide and 2 pi of 10 x RNA loading buffer (50% (v/v) glycerol, 1 mM EDTA 
pH 8.0, 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol FF) were added to 
each sample. Following a 30 minute pre-run at 40 V of a denaturing gel (1% (w/v) 
agarose, 2.2 M formaldehyde, 1 x MOPS) in 1 x MOPS, samples were loaded and run for 
approximately 5 hours at 40V in order to electrophoretically separate the different species 
of RNA according to size. The gel was visualised under a UV transilluminator in order to 
confirm separation and photographed. It was then washed for 20 minutes in 20 x SSC 
buffer (3 M NaCl, 0.3 M sodium citrate pH 7.0) prior to capillary transfer, as described by 
Maniatis et aL (Maniatis et aL, 1982).
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The transfer procedure required the prepared gel to be placed, inverted, on a bridge of 
Whatman 3MM chromatography paper supported on a glass plate and suspended over a 
reservoir of 20 x SSC buffer. An appropriate size of Hybond N nylon membrane 
optimised for nucleic acid transfer (Amersham) was pre-soaked in 20 x SSC and 
positioned over the gel, followed by a further two layers of pre-soaked Whatman paper; at 
each stage of layering, care was taken to ensure removal of air bubbles. This arrangement 
was surmounted with a stack of paper towels and an appropriate weight in order to allow 
efficient capillary action. During transfer, the migration of the RNA from the gel to the 
nylon membrane is facilitated by the passive movement of the transfer solution through the 
gel. Plastic wi'ap was used to prevent direct contact between the paper towels and the 
Whatman bridge; this ensured movement of the buffer was only through the gel. In order 
to achieve high-transfer efficiency, the capillary action was allowed to proceed overnight. 
Following transfer, the RNA was fixed to the membrane by UV-crosslinking at 1200 pJ.
Radiolabelled DNA probes complementary in sequence to a particular RNA of interest 
were used to locate it on the membrane. The B2 gene probe was a 240bp EcoKl-Pstl 
fragment from pTB14 (White et aL, 1989), and the acidic ribosomal phosphoprotein PO 
(ARPP PO) probe, a 1 kb EcoKL-HindUl fragment from the mouse cDNA (Hurford et aL, 
1997). The probes were labelled using a Megaprime DNA labelling system (Amersham) 
according to the random oligonucleotide priming method of Feinberg and Vogelstein 
(Feinberg and Vogelstein, 1984). 25 ng of purified DNA template was denatured by 
heating at 95°C for 5 minutes in the presence of random hexamer oligonucleotide 
sequences and the appropriate volume of DEPC-dHiO. DNA synthesis is primed by the 
hexamer oligonucleotides which are able to anneal to the DNA during slow cooling to 
room temperature. 10 pi of reaction buffer (from Amersham kit; containing dATP, dGTP, 
dTTP in Tris-HCl pH 7.5, p-mercaptoethanol and MgCli), 2 pi (2 U) DNA polymerase I 
Klenow fragment and 50 pCi of [a-^^P] dCTP (1 OmCi/ml, 3000Ci/mmoI) were added to 
initiate labelling. This reaction was allowed to proceed for 1 hour at 37°C before the 
labelled DNA was denatured by heating at 100°C for 5 minutes, and chilled at 4°C until 
the nylon membrane with bound RNA had been pre-hybridised.
While the probe was being prepared, the nitrocellulose was pre-hybridised by rotation in a
hybridisation oven at 45°C for 45 minutes in 25 ml of hybridisation buffer (0.2 M sodium
phosphate buffer pH 7.2, 1 mM EDTA, 1% (w/v) BSA, 7% (w/v) sodium dodecyl sulphate
(SDS), 45% (v/v) formamide in DEPC- dHaO). The radiolabelled probe was then added to
25ml of fresh hybridisation buffer with rotation at 45°C overnight. The nylon membrane
was then washed with rotation in wash buffer (40 mM sodium phosphate buffer pH 7.2, 1
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mM EDTA, 1% (w/v) SDS in DEPC-dHaO) at room temperature for 5 minutes and then 
twice for 15 minutes at 65 °C in order to remove non-specifically bound radioactivity 
before being exposed to autoradiography film overnight at ™70“C. Membranes were 
stripped by incubating in boiling water for 5 minutes and pre-hybridised again prior to 
being re-probed. Quantification of the RNA was achieved using densitometry (TotalLab 
v l . l l )
2,5 Reverse transcriptase -  polymerase chain reaction (RT-PCR)
2.5.1 Preparation of cDNAs
cDNAs were prepared using 3 pg of RNA (Ipg/pl). 2 pi of hexanucleotide mix (Roche) 
diluted 1:10 with DEPC- dH20 was mixed with 19 pi of DEPC- dHiO. Primer annealing 
was carried out at 80°C and allowed to proceed for 10 minutes before transferral to ice. 8 
pi of 5 X First Strand Buffer (Invitrogen), 4 pi of 0.1 M dithiothreitol (DTT), 2 pi of 10 
mM dNTP mix (prepared in DEPC- dH20) and 1 pi (200U) of Superscript II Reverse 
Transcriptase (Invitrogen) was added to initiate reverse transcription, which was performed 
for 1 hour at 42°C before the reaction was stopped by heating at 70°C for 15 minutes.
2.5.2 Polymerase chain reaction (PCR)
PCRs were carried out using a Uvigene FTGENE2U (UVITEC Ltd). 2 pi of cDNA was 
amplified with 20 pmol of relevant primers under various cycling parameters (Table 2.1). 
Reaction mixtures also contained 0.5U of Taq polymerase (Promega), 1 X Taq DNA 
polymerase buffer (Promega), 1.5 mM MgCk, 1 pCi of [a-^^P] dCTP (Amersham), and 0.2 
mM of each dNTP, made up with nuclease-free water to a 20 pi final volume.
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Table 2,1: Primers and cycling parameters
Transcript Primers Size of 
Product
Cycle
number
Program 
(Dénaturation; 
Cycling; Final 
Extension)
ARPP PO 5 ’-GC ACTGGAAGTCC AACTACTTC-3 ’ 
5 ’-TG AGGTCCTCCTTGGTGAACAC-3 ’
265 bp 18- 22 95°C for 2 min 
95°C for 1 min 
58°C for 30 s 
72°C for 1 min 
72°C for 3 min
B2 5 ’-GGGGCTGGAGAGATGGCT-3 ’ 
5’-CCATGTGGTTGCTGGGAT-3’
120bp 15-18 95°C for 3 min 
95°C for 30 s 
58^C for30s 
72°C for 30 s 
72°C for 5 min
GAPDH 5’-TCCACCACCCTGTTGCTGTA-3’
5’-ACCACAGTCCATGCCATCAC-3
452 bp 18-22 95°C for 3 min 
95°C for 30 s 
58°C for30s 
72°C for 30 s 
72°C for 5 min
snRNA
U6
5 ’-GCTCGCTTCGGCAGCACATATAC-3 ’ 
5’-TATCGAACGCTTCACGAATTTGCG-3’
96 bp 18-20 95 °C for 3 min 
95°C for 1 min 
60°C for 30 s 
72°C for 1 min 
72°C for 5 min
Mafl 5’~GCAGTTCTGCCAGGAGGGCCA-3 ’ 
5 ’-CTCCATGGTGCTGGTCTCCTC-3 ’
613 bp 25-30 95°C for 2 min 
95°C for 30 s 
60°C for 30 s 
72°C for 1 min 
72°C for 5 min
tRNA'-'" 5’-GTCAGGATGGCCGAGTGGTGTAAGGC
GCC-3’
5’-CCACGCCTCCATACGGAGACCAGACC
C-3’
88 bp 25-30 95°C for 3 min 
95°C for 30 s 
68°C for 30 s 
72°C for 30 s 
72°C for 5 min
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Table 2.1 Primers and cycling parameters continued
Transcript Primers Size of 
Product
Cycle
number
Program 
(Dénaturation; 
Cycling; Final 
Extension)
tRNA'y' 5 ’ - AGG ACTTGGCTTCCTCC ATT-3 ’
5 ’ -GACCTA AGG ATGTCCGC AAA-3 ’
84 bp 25-30 95°C for 3 min 
95°C for Imin 
65°C for 30 s 
72°C for 15 s 
72°C for 5 min
5SrRNA 5 ’-GGC ATACCACCCTGAACGC-3 
5 ’-CAGCACCCGGTATTCCCAGG-3
107 bp 18-23 94°C for 3 min 
95°C for 30 s 
58°C for 30 s 
72°C for 1 min 
72°C forlO min
7SK 5 ’ -CG ATCTGGTTGCG AC ATCTG-3 ’ 
5 ’-CGTTCTCCTACAAATGGAC-3 ’
247bp 25-30 95°C for 3 min 
95°C for 30 s 
57°C for 30 s 
ITQ, for 30 s 
72°C forlO min
Reaction products were resolved on 7% (v/v) polyacrylamide sequencing gels containing 7 
M urea and 0.5 x TBE (45 mM Tris-HCl, 45 mM boric acid, 0.625 mM EDTA pH 8.0). 
Gels were pre-run for 30 minutes at 40 W in 0.5 x TBE and 2 pi of each sample was loaded 
after being boiled at 95°C for 2 minutes and quenched on ice. Electrophoresis was carried 
out for a further 1 hour at 40 W and the gel subsequently vacuum-dried at 80°C for 1 hour 
before being exposed to autoradiography film in order to detect the radiolabelled products. 
Quantification of results was achieved by densitometry (TotalLab v l.l  1).
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2.6 Preparation of whole cell extracts
Whole cell extracts were prepared from cells grown in 10cm tissue culture dishes to 
facilitate scraping and were harvested at approximately 80% confluency. Preparation was 
performed on ice as rapidly as possible and all solutions and tubes were kept ice-cold. 
Cells were washed twice with 5 ml of PBS before being scraped with a plastic spatula into 
5 ml of ice-cold PBS. Cells were collected in 50ml Falcon tubes and pelleted by slow 
centrifugation at 1 lOOg for 8 minutes at 4°C. A small volume of fresh ice-cold PBS was 
used to resuspend the cell pellets and allow the cells to be transferred to eppendorf tubes. 
These were then microcentrifuged briefly at 4°C to re-pellet the cells and the PBS 
removed. The volumes of cell pellets were then measured by comparison with pre­
measured volumes o f water. Optimal microextraction requires pellets to be between 50 -  
150 pi, giving approximately 0.5 -  3 x 10  ^cells; larger pellets were subdivided. An equal 
volume of freshly made pre-cooled microextraction buffer (450 niM NaCl, 50 mM NaF, 20 
mM Hepes pH 7.8, 25% (v/v) glycerol, 1 mM DTT, 0.5 mM phenylmethylsulphonyl 
fluoride (PMSF), 0.2 mM EDTA, 40 pg/ml bestatin, 1 pg/ml trypsin inhibitor, 0.7 pg/ml 
pepstatin, 0.5 pg/ml aprotinin, 0.5 pg/ml leupeptin) was added to the cells and, following 
resuspension, the cells were immediately snap-frozen on dry ice. Cells were then placed in 
a 30°C water bath until just thawed before being immediately returned to dry-ice. This 
freeze-thaw procedure was performed a total of 3 times to ensure optimal cell lysis, with 
cells then being micro centrifuged at 7, OOOg for 7 minutes at 4°C after the third thaw. The 
supernatant was carefully decanted into a fresh tube, leaving behind the cell debris, and 
then promptly aliquotted and snap frozen. These whole cell extracts were then stored at 
-80°C.
2.7 Measuring protein concentration
The protein concentration of samples was determined using Bradford’s reagent (Biorad).
Quantification of the colour reaction produced upon mixing 1ml of diluted reagent (1:4 in
distilled water) with a volume of sample containing protein in the range o f -1 -12 pg gave
an accurate indication of protein concentration. A Bradford assay standard curve was
constructed by measuring the absorbance of bovine serum albumin (BSA) standards at 595
mn in a UV spectrophotometer, as absorbance in response to increasing amounts of protein
under these conditions is approximately linear. Three sample dilutions were measured and
averaged, so as to provide a more accurate measurement of protein concentration.
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2.8 Immunoprécipitation
Antibodies for immunoprécipitation experiments were coupled to protein A-sepharose 
beads (Pharmacia) or HA-tagged proteins were bound directly to monoclonal anti-HA- 
agarose conjugate (Sigma). 30 pi of packed beads was used per sample. Beads were 
washed twice with 200 pi TBS (2.5 mM Tris-HCl pH 7.6, 15 mM NaCl), centrifuged at 6, 
OOOg, and the supernatant removed prior to incubation with the appropriate antibody on a 
shaker for 1 hr at 4°C. The beads were then washed twice with 300 pi of TBS to ensure 
removal of unbound antibody.
For co-immunoprecipitation reactions, typically 500 pg of cell extract (made up to a total 
volume of 500 pi with TBS) and/or 5 -10 pi of in vitro translated protein was incubated 
with the prepared protein A-Sepharose beads covalently linked to the antibody of interest 
at 4°C for 3 hours on a rotating wheel with 0.25 pM phenymethylsulfonylfluoride (PMSF). 
The beads were gently pelleted by pulse microcentrifugation and the supernatants carefully 
removed. The beads were then washed with TBS and pulse- centrifuged so that the 
supernatant could be removed. This was repeated 4 times before the bound material was 
released by the addition of an equal volume of 2 x protein sample buffer (125 mM Tris- 
HCl pH 6.8, 1% (w/v) SDS, 10% (v/v) P-mercaptoethanol, 20% (v/v) glycerol, 0.25% 
(w/v) bromophenol blue), and analysed by SDS-PAGE and either Western Blotting or 
autoradiography.
2.9 SDS-polyacrylamide gel electrophoresis (PAGE) analysis
2.9.1. Separation of proteins by SDS-PAGE
Proteins were resolved on denaturing polyacrylamide gels according to molecular weight 
by electrophoresis. Typically, 7.8% (v/v) polyacrylamide resolving minigels (375 mM 
Tris-HCl pH 8.8, 0.1% (w/v) SDS) were used with a stacking layer comprised of 4% (v/v) 
polyacrylamide gel (125 mM Tris-HCl pH 6.8, 0.1% (w/v) SDS) based on the 
discontinuous buffer system described by Laemmli (Laemmli, 1970). Samples were boiled 
for 2 minutes in 1 x protein sample buffer (62.5 mM Tris-HCl pH 6.8, 0.5% (w/v) SDS,
5% (v/v) P-mercaptoethanol, 10% (v/v) glycerol, 0.125% (w/v) bromophenol blue) prior to
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loading. Electrophoresis was performed in 1 x SDS running buffer (0.1% (w/v) SDS, 76.8 
mM glycine, 10 mM Tris-HCl, pH 8.3) at an initial voltage of 80 V while the bromophenol 
dye front moved through the stacking gel and a subsequent voltage of 120 V after reaching 
the resolving gel. Electrophoresis was allowed to proceed until the dye front had reached 
the bottom of the gel, approximately 1 -  1.5 hours.
2.9.2 Western blot analysis
Electrophoretic transfer of proteins resolved by SDS-PAGE to 0.2 pM pore nitrocellulose 
membrane (Biorad) was achieved using the BioRad Mini Trans-Blot Electrophoretic 
Transfer Cell system. Transfer was carried out in 1 x transfer buffer (76.8 mM glycine, 
10 mM Tris-HCl pH 8.3, 16.5% (v/v) methanol) at 50 V for 2 hours. Following transfer, 
the membrane was blocked in milk buffer (2.5 mM Tris-HCl pH 7.6, 15 mM NaCl, 0.2% 
(v/v) Tween-20, 4% (w/v) skimmed milk powder) (Marvel) for 1 hour at room 
temperature. Membranes were incubated with primary antibodies (typically a 1:1000 
dilution in milk buffer) overnight at 4^C (see Table 2.2 for list of antibodies). Excess 
primary antibody was removed by washing the blot 3 times for 5 minutes in fresh milk 
buffer before incubating for 1 hour at room temperature with the appropriate horseradish 
peroxidase-conjugated secondary antibody (1:1000 dilution in milk buffer) (DAKO). To 
ensure removal of excess secondary antibody, the blot was washed in ftesh milk buffer, 3 
times for 10 minutes. After one further 5 minute wash using 1 x TBS (2.5 mM Tris-HCl 
pH 7.6, 15 mM NaCl), the blot was developed using the enhanced chemiluminescence 
method (ECL™, Amersham Pharmacia).
2.9.3 Western signal detection
HRP-conjugated (horseradish peroxidase) secondary antibodies were used to detect signals 
on Western blots. Horseradish peroxidase activity can be detected using either 
chemiluminescence or DAB substrates. Chemiluminescence detection, using the ECL"^  ^
Western Blotting analysis system (Amersham Pharmacia), was performed by adding equal 
volumes of reagent 1 and reagent 2 to the filter, incubating at room temperature for 1 
minute, and then exposing the blot, covered in Saran Wrap, to ECL film (Amersham 
Pharmacia) for different lengths of time before developing using the X-OMAT film 
processor.
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2.9.4 Coomassie staining of SDS-PAGE gels
When required, after SDS-PAGE, the gels were stained using Coomassie Brilliant Blue (5 
% (v/v) glacial acetic acid, 45 % (v/v) methanol and 0.25 g/1 Coomassie Brilliant Blue R 
which was filtered through Whatman No.l filter paper). The gel was submerged in stain for 
approximately 1 hour before rinsing and destaining in the same acetic acid/methanol/HzO 
mixture, without Coomassie dye. The destaining solution was changed frequently until the 
bands on the protein gel appeared sharp and the background on the gel clear, this typically 
took 3 hours.
2.9.5 Peptide design and Mafl antibody synthesis
The rabbit polyclonal anti-Mafl antibodies were directed against peptides corresponding to 
amino acids 136-148 (YDFSTARSHEFSREPS) and 265-281 (GGEGRAEETSTMEEDR). 
which were conserved between the human and mouse sequences. Peptides were 
synthesised and antibodies raised by Eurogentec. They were supplied after purification by 
peptide affinity chromatography.
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2.9.6 Primary antibodies 
Table 2,2: Primary antibodies
Protein Antibody Type Company
Actin C ll Polyclonal Santa Cruz Biotechnology
Brfl 1284 Serum In house
Cyclin D1 SC-450 Monoclonal Santa Cruz Biotechnology
Cyclin E SC-20684 Polyclonal Upstate
c-MYC 9E10 Polyclonal Santa Cruz Biotechnology
RB C15 Monoclonal Santa Cruz Biotechnology
phospho-RB 44-576 Polyclonal Biosource International
S6K1 C-18 Polyclonal Santa Cruz Biotechnology
phosphO“S6 K l 9202 Polyclonal Cell signalling Technology
4EBP-1 R-113 Polyclonal Santa Cruz Biotechnology
TFIIIC 63 N-15 Polyclonal Santa Cruz Biotechnology
TFIIIC 90 1898 Polyclonal In house
TFIIIC 102 3238 Polyclonal In house
TFIIIC 110 4286-4 Polyclonal In house
TFIIIC 220 Ab-7 Polyclonal In house
p l 6 C-20 Polyclonal Santa Cruz Biotechnology
TBP mTBP-6 Monoclonal In house
TBP 58C9 Monoclonal Santa Cruz Biotechnology
BDP 1 2663 Polyclonal In house
TAF i48 C19 Polyclonal Santa Cruz Biotechnology
p44/42 ERK 9102 Polyclonal Cell Signalling Technology
Phospho- ERK E10 9101 Monoclonal Cell Signalling Technology
Mafl SK-2667 Polyclonal Eurogentec
BN51 113 Serum Gift from G. Ittman
RPC155 1900 Polyclonal In House
TFIIB C-18 Polyclonal Santa Cruz Biotechnology
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2.10 Storage, propagation and preparation of plasmid DNA
2.10.1 Plasmid selection
The plasmids used in this study contained the ampicillin resistance gene encoding p- 
lactamase and so were selected for by the presence of 1 0 0  pg/ml ampicillin when grown on 
L-Agar or in L-Broth. This antibiotic was made as a 100 mg/ml stock solution (w/v) in 
50% (v/v) H2O, 50% (v/v) ethanol and stored at -20°C.
2.10.2 Storage of bacterial cultures
1 ml of bacterial culture was added to 40% (v/v) glycerol solution (in H2O) before being 
frozen in liquid nitrogen. Frozen stocks were stored at -80°C.
2.10.3 Transformation of competent cells
E.coli XL-1 Blue supercompetent cells (Stratagene) were transformed for plasmid storage 
and propagation. Cells, which were stored at —80°C and highly temperature sensitive, 
were thawed on ice to prevent loss of transformation ability. 0 .4  pi of P-mercaptoethanol, 
which enhances transformation efficiency, was added to the 50 pi of cells that were 
required per transformation reaction to give a final concentration of 25 mM, Typically 10 
-  20 ng of plasmid DNA was then gently mixed into the chilled cells. The contents were 
gently tapped occasionally during a 30 minute incubation on ice, before being heat shocked 
at 42°C for exactly 45 seconds and then transferred to ice for a further 2 minutes. Cells 
were incubated at 37°C for 1 hour on an orbital shaker (225 -  250 rpm) following the 
addition of 450 pi of preheated (42°C) SOC medium (LB broth, 0.04% (w/v) glucose, 10 
mM MgSO^, 10 mM MgCl2). Typically 10 pi and 100 pi of the transformation mixture 
was then plated on LB agar (2% (w/v) LB, 2% (w/v) agar) plates containing 50 pg/ml 
ampicillin (Amp) and the plates were incubated at 37°C overnight to allow growth and 
colony-formation of the transformed cells.
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2.10.4 Preparation of plasmid DNA
For large scale plasmid DNA preparation, a single isolated bacterial colony was selected 
from a freshly-streaked plate and used to inoculate 5ml of LB medium containing the 
selective antibiotic (100 pg/ml ampicillin). This was allowed to incubate with vigorous 
shaking at 37°C for ~ 6  hours to form a mini-culture and was subsequently used to 
inoculate 250ml of LB medium containing 100 pg/ml ampicillin. Following an overnight 
incubation at 37°C on an orbital shaker (~300rpm), cells were harvested by centrifugation 
at 6 , OOOg for 15 minutes at 4°C and plasmid DNA retrieved using the Qiagen Plasmid 
Maxi Kit.
The bacterial pellet was resuspended in 10 ml of Buffer PI (50 mM Tris-HCl pH 8.0, 10 
mM EDTA, 100 pg/ml RNase A) and then gently but thoroughly mixed with 10 ml of 
Buffer P2 (200 mM NaOH, 1% (w/v) SDS) to initiate an alkaline lysis reaction. This 
reaction was allowed to proceed for 5 minutes at room temperature before neutralising the 
lysate by the addition of 10ml of chilled Buffer P3 (3 M potassium acetate, pH 5.5), which 
subsequently resulted in formation of a precipitate of potassium dodecyl sulphate. The 
SDS-denatured proteins and chromosomal DNA were co-precipitated with the detergent, 
whilst the plasmid DNA remained in solution due to a lack of close protein associations. 
Precipitation was enlianced by a 20 minute incubation on ice and the precipitate pelleted 
by centrifugation at 20, OOOg for 30 minutes at 4°C. The supernatant containing plasmid 
DNA was promptly removed and applied to a Qiagen-tip 500 column, pre-equilibrated 
with 10 ml of Buffer QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol, 
0.15% (v/v) Triton X-100). Gravity flow allowed the supernatant to pass through the 
anion-exchange resin to which plasmid DNA is able to bind tightly. The resin was then 
washed twice with 30 ml of Buffer QC (1 M NaCl, 50 mM MOPS pH 7.0, 15% (v/v) 
isopropanol) and the purified plasmid DNA was subsequently eluted with 15 ml of Buffer 
QF (1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15% (v/v) isopropanol) and precipitated with
10.5 ml (0.7 volume) of room-temperature isopropanol. This was immediately followed 
with a 15, OOOg centrifugation at 4°C for 30 minutes. The plasmid DNA pellet was then 
washed with 70% (v/v) ethanol, dried at room-temperature for 5 -  10 minutes and 
resuspended in an appropriate volume of sterile water or TE.
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2.11 Restriction digests and DNA analysis
2.11.1 Restriction digests
Restriction digests were typically performed in 20pl volume and contained 1 pg DNA, 1 pi 
enzyme, 2  pi enzyme buffer appropriate to the restriction enzyme being used, and were 
made up to the final volume with H2O. All enzymes and buffers were supplied by 
Promega. DNAs were digested with enzymes for 1 hour at 37°C. When double digestion 
was required the reaction was initiated with the enzyme with the lower strength buffer and 
after heat inactivation (at 65°C for 20 minutes) an appropriate amount of salt was added 
before addition of the second enzyme. When this was not feasible due to very different 
buffers required for each enzyme, purification of the first digestion product was performed 
using the Qiagen PCR Purification Kit and according to the manufacturers’ instructions. 
Amounts of DNA in a restriction digest varied between 1-3 pg for plasmid DNA and 3-5 
pg for genomic DNA.
Digests were mixed with 6 x Agarose Gel DNA Loading Buffer (0.25% (w/v) 
Bromophenol Blue, 0.25% (w/v) Xylene Cyanol, 30% (v/v) glycerol), analysed on 1% 
(w/v) agarose gels containing ethidium bromide (Sigma) and visualised on an ultraviolet 
light box. The concentrations of nucleic acid solutions were determined 
spectrophotometrically using a quartz cuvette.
A260 of 1 = 5 0  pg/ml dsDNA
2.11.2 Ethanol precipitation of DNA
When it was necessary to concentrate or clean DNA, ethanol precipitation was carried out. 
0.1 volume 3 M sodium acetate, pH 5.3, was added to samples followed by 2.5 volumes of 
ethanol. The sample was kept at -20°C for at least 30 min to allow precipitation to occur. 
The DNA was then pelleted by centrifugation at 4°C for 30 min at 15, 000 g. The pellet 
was washed with 70% (v/v) ethanol and allowed to dry thoroughly before being 
resuspended in an appropriate volume of dH2 0  (Sambrook et al, 1989).
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2.11.3 Agarose gel electrophoresis of DNA
DNAs were separated in 1 % (w/v) agarose in Ix TAB (40 mM Tris-acetate, 1 mM EDTA 
pH 8.0) eontaining 0.1 pg/ml EtBr as described previously (Sambrook and Russell, 2001), 
using Ix TAB as the electrophoresis buffer. Sizes were compared to a 1 kb ladder (Gibco- 
BRL). Prior to loading, 6  x loading dye (0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol, 30% (v/v) glycerol in water) was added to the samples to a final Ix 
concentration of loading dye in the sample.
2.11.4 Purification of DNA from gels
DNA bands were excised from the gel using a clean scalpel blade and the DNA extracted 
using the Qiagen Gel Extraction Kit according to the manufacturers’ instructions. DNA 
was typically eluted in 30 pi of pre-warmed buffer EB (Qiagen) or HgO.
2.11.5 DNA ligations
For cloning inserts into vectors, plasmid DNA containing the vector and the insert were 
digested with appropriate restriction enzymes, as described in Section 2.11.1. For 
directional cloning of inserts, two different enzymes were used to restrict the vector and the 
insert, which permits cloning of the insert into the vector in a predicted and directional 
manner. After the restriction digest, both vector and insert were electrophoresed on a 1% 
(w/v) agarose gel and the DNA bands excised from the gel and gel-purified (see Section 
2.11.4).
For the ligation reaction, a molecular ratio of 3:1 insert:vector was used and typically 50- 
100 ng of vector. Ligation reactions were carried out with 2 pi lOx T4 ligase buffer (Gibco 
BRL), with 1 pi (1 U) of T4 ligase (Gibco BRL) in a final volume of 20 pi with sterile 
water. The ligation was carried out overnight at 14°C. For transformation of XL 1-Blue, 1 
pi and 4 pi of the ligase reaction was used.
2.12 Subdoning of Mafl into pCDNA3HA
A cDNA encoding Mus Mus cuius Mafl (MmMafl .His) was a gift from Olivier Lefebvre
(CEA/Saclay, France). Primers were designed to add an Xbal site on to the 3’ end of the
gene (5’-GCGATCTAGACAAATACAGATCACTGGGAC-3’). An additional primer
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which incorporated the BamRl site already present on the gene was also designed (5’- 
TTCCACGGATCCATGAAGCTATTGGAGAAC-3’). The mammalian expression vector 
pCDNASHA was digested with the restriction enzymes BamYil and Xbal and 
MmMafl .His was ligated into the polylinker of this vector.
2.13 Production of recombinant Mafl
Recombinant Mafl was prepared by Danuta Oficjalska (CEA/Saclay, France). The Homo 
sapiens (Hs) Mafl gene was cloned into the pFastBac vector from the Bac-to-Bac 
Baculovirus Expression System (Invitrogen) using BamRl and Sail restriction sites. The 
recombinant protein has 6  His tags at its C-terminal and was obtained by expression in 
insect cells infected by baculovirus. HsMafl .His was then affinity purified using a Poros 
MC20 (Boeringer Mannheim) Cobalt-chelate affinity column, and was eluted using 50 mM 
Imidazole. The HsMafl .His was 95% pure and was used at a eoncentration of 2 pg/pl. A 
fraction that was obtained from control purification of HsMafl with no His tag was used as 
control buffer for the HsMafl .His experiments.
2.14 Chromatin Immunoprécipitation (ChIP)
Formaldehyde was added directly to plates of cells containing media to a final 
concentration of 1% (v/v). They were then incubated at 37°C for 10 minutes. Glycine was 
added to a final concentration of 0.125 M to stop the cross-linking. The plates were then 
transferred to ice, and scraped in the media, transferred to Falcon tubes, and centrifuged at 
1500 rpm for 5 minutes at 4°C. The cells were then washed twice by resuspension in 40 ml 
chilled PBS and pelleted by centrifugation at 1, 500 g. The supernatant was then decanted 
off and the cells were incubated on ice for 30 minutes in 40 ml of high salt buffer (0.5% 
(v/v) NP-40/PBS, 1 M NaCl). Cells were then re-centrifuged and washed with 0.5% (v/v) 
NP-40/PBS. This was followed by hypotonic disruption for 30 minutes on ice with 40 ml 
of low salt buffer (0.1% (v/v) NP-40, 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.1 MNaCl). 
The samples were then centrifuged at 1, 500 g at 4°C, the supernatant decanted off, and the 
pellets resuspended in 1 ml of low salt buffer. Nuclei were obtained by passing the sample 
through a 26 gauge needle three times. The samples were re-centrifuged and the nuclei 
resuspended in 2.7 ml of low salt buffer and lysed with 300pl sarkosyl. The samples were 
then transferred to a sucrose solution containing 40 ml low salt buffer/100 mM sucrose,
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and centrifuged at 4000g for 10 minutes at 4°C. The supernantant was then discarded and 
the pellet resuspended in 3 ml of 1 x TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA). The 
process was then repeated. The pellet containing the genomic DNA was finally 
resuspended in 2 ml of 1 x TE and sheared by sonication (Branson sonifier, 10x10  second 
intervals at 40% duty cycle).
Sonicated material was adjusted with 1/10 volume of 11 x NET (1.65 M NaCl, 5.5 mM 
EDTA, 5.5% (v/v) NP-40, 550 mM Tris-HCl pH 7.4). Samples were centrifuged at 13, 000 
g for 5 minutes at room temperature and aliquots of the supernantant were put into 
eppendorfs. The volume of the sample used in the subsequent immunoprécipitation 
depended on the number of antibodies used. 10 % of each sample was stored at 4°C to use 
as input control. 4 pg (-25pi ) of antibody was added to each tube and they were 
incubated overnight at 4°C. Protein A-Sepharose beads (Pharmacia) were prepared by 
washing in 1 x NET buffer and centrifuging at 6 , 000 g for 30 seconds at room 
temperature. This was repeated and after the supernatant was removed a further 500 pi of 1 
X NET buffer was used to resuspend the protein-A beads. 100 pi of the protein A/ NET 
suspension was added to each tube and these were left rotating for 1-2 hours at 4°C. The 
negative control was incubated with beads alone. The samples were re-suspended in 1 ml 
of RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1 % (w/v) SDS, 0.5% (w/v) 
deoxycholate, 1% (v/v) NP-40) and loaded onto a Polyprep column (Biorad). The columns 
were washed twice in 10 ml of RIPA buffer, twice in 10 ml o f LiCl buffer (10 mM Tris- 
HCl, 250 mM LiCl, 0.5% (v/v) NP-40, 0.5% (w/v) deoxycholate, 1 mM EDTA pH 8.0) and 
twice in 10 ml of TE. Once all the remaining TE had eluted the columns were stoppered 
and 200 pi of 1 x TE/1% (w/v) SDS was used to re-suspend the beads in the columns. The 
eluant was collected in a 1.5 ml tube and then rotated for 10 minutes at room temperature 
before being centrifuged at 8 , 000 g for 1 minute at room temperature. The supernatant was 
transferred to a fresh tube, and the process was repeated until a further supernatant was 
collected, and unified with the first supernantant. 1 /1 0  volume of the initial 
immunoprecipitated sample was pipetted into a fresh eppendorf and made up to 400 pi 
with 1 X TE/1% (w/v) SDS, before adding 5 pi of proteinase K (lOmg/ml). Inputs taken 
prior to immunoprécipitation were made up in the same way as the samples and all tubes 
were then incubated overnight at 42°C to degrade proteins and antibodies. DNA was 
extracted twice using PhOH/CHCI3/IA A, and ethanol precipitated. The
immunoprecipitated DNA was then re-suspended in 40 pi of 1 x TE and quantified by 
PCR.
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2.15 Pol III in vitro transcription assay
In vitro transcription of class III genes was reconstituted using 20 pg of HeLa nuclear 
extracts (Computer Cell Culture Center, Mons, Belgium) to provide the basal pol III 
transcription components. This was supplemented with the addition of 250 ng of plasmid 
DNA to supply a specific pol III template and reactions were carried out in a 25 pi volume 
with a final concentration of 12 mM HEPES pH 7.9, 60 mM KCl, 7.2 mM MgCL, 0.28 
mM EDTA, 1.2 mM DTT, 10% (v/v) glycerol, 1 mM creatine phosphate, 0.5 mM each of 
rATP, rCTP and rGTP and 10 pCi [a-^^P] UTP (400mCi/mmol) (Amersham). 
Transcription components were assembled on ice and the reaction was performed at 30‘^ C 
for 1 hour. Transcription was terminated by the addition of 250 pi of 1 M ammonium 
acetate/0.1% (w/v) SDS eontaining 20 pg of yeast tRNA which acts as a carrier for the 
synthesised RNA. Phenol-chloroform extraction of the samples was performed to remove 
protein and DNA by adding 250 pi of a 25:24:1 ratio solution of PhOH/CHClg/IAA. The 
samples were vortexed, microcentrifuged at 13, OOOg for 5 minutes and 200 pi of the upper 
aqueous layer was then transferred to a fresh eppendorf tube containing 750 pi of 96% 
ethanol in order to precipitate the RNA. The samples were thoroughly mixed by repeated 
inversion, left at -20°C overnight before being microcentrifuged at 13,000g for 30 minutes 
to pellet the preeipitated RNA. The supernatant was carefully removed and 750 pi of 70% 
(v/v) ethanol was added to each sample to wash the pellet. This was also carefully 
removed to avoid dislodging the pellet and the samples were heated at 50°C for 5 -  10 
minutes to dry. 4 pi of formamide loading buffer (98% (v/v) formamide, 10 mM EDTA 
pH 8.0, 0.025% (w/v) bromophenol blue, 0.025% (w/v) xylene cyanol FF) was added to 
each sample, which was then vortexed for 1 hour to ensure the RNA was fully re­
dissolved. 1.5 pi of each sample was loaded on a pre-run 7% (v/v) polyacrylamide 
sequencing gel containing 7 M urea and 0.5 x TBE after being boiled at 95°C for 2 minutes 
and quenched on ice. Electrophoresis was performed at 40 W for 1 hour in 0.5 x TBE 
before being dried and exposed to autoradiography film in order to detect the radiolabelled 
transcripts. Quantification of results was achieved by densitometry (TotalLab vl . l l ) .
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2.15.1 Plasmid templates used in in vitro transcription assays
The plasmid templates used for in vitro transcription assays were as follows: pVAi is a 
221 bp Sall-Ball fragment of adenovirus 2 DNA containing the VAi gene subcloned into 
pUC18 (Dean and Berk, 1988); pLeu is a 240bp EcoRl-Hindlll fragment of human 
genomic DNA carrying a tRNA^^" gene, subeloned into pA TI53 (McLaren and Goddard, 
1986); PHu5S3.1 is a 638bp BarnRl-Sacl fragment of human genomic DNA containing a 
5S rRNA gene, subcloned into pBluescript SK+; pTB14 is a 200bp Bglll fragment 
containing a B2 gene from upstream of the mouse (BALB/c) D^ class I MHC gene 
subcloned into pUC18; the pol I template was pHrP2 (Lescure et aL, 1994), which has an 
800 bp Sau2A  fragment of the human rRNA promoter, from -411 to +378, subcloned into 
RawHl-linearised pUC9; p7L30.1 contains a HindlU-EcoRl fragment carrying a human 
7SL gene subeloned into pUC13 (Ullu and Weiner, 1985); 7SK-PAT/153 contains a 
HindUl-Aspll^ fragment containing human 7SK sequences from -250 to +1, subcloned 
into pUC8 (Kleinert et a l, 1990).
2.15.2 Peptide substrate inhibitors used in in vitro transcription assays
The peptide substrate inhibitors used for in vitro transcription were PKB substrate peptide 
inliibitor GRPRTSSFAEG (Biomol) or PKA phospho-acceptor peptide LRRASLG 
(Upstate).
2.15.3 Preparation of fractions used in \n vitro transcription assays
PC-B is the 0.1 to 0.35 M KCl step fraction from a phosphocellulose column, and contains 
both TFIIIB and pol III (Segall et al., 1980). PC-C is the 0.35 to 0.6M KCl step fraction 
ftom a phosphocellulose column and contains both TFIIIC and pol III (Segall et a l, 1980). 
The CHep-1.0 fraction was generated as described previously (White et a l, 1995b) by 
loading PC-C onto a heparin-sepharose CL-6 B in BC buffer (25 mM Tris-HCl, pH 7.9, 
10% (v/v) glycerol, 10 mM p-mercaptoethanol) plus 100 mM KCl (BC-lOO). The column 
was washed with BC-280 and eluted with BC-1000 to produce the CHep-1.0 fraction
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containing TFIIIC. The A25 (0.15) fraction containing TFIIIB was generated as described 
previously (White et al., 1995b) by applying PC-B to an A25 DEAE-Sephadex column in 
buffer A (20 mM HEPES-KOH pH 7.9, 20% (v/v) glycerol, 5 mM MgCl%, 3 mM DTT, 0.2 
mM PMSF) plus 50 mM (NH4)2S0 4 . After extensive washing with this buffer, the A25 
(0.15) fraction containing TFIIIB was eluted in buffer A plus 150 mM (NH4)2S0 4 . These 
fractions were provided by Prof. Robert J. White.
2.16 Electrophoretic Mobility Shift Assay (EMSA)
2.16.1 Preparation of the Probe
TFIIIC2 DNA-binding activity was determined by EMSAs which were carried out using a 
y-^^P labelled oligonucleotide containing a B-block consensus (5’-AGAGGTCCTGAGTT- 
CAAATCCCAG-3’ (RJW l; 10 ng/pl) annealed to the complementary strand (RJW2; 10 
ng/pl). For use in EMSAs, oligonucleotides were 5’ end-labelled using T4 polynucelotide 
kinase (PNK). 4 pi (40 ng) of RJWl was assembled on ice with 1 pi (10 U) of PNK 
(Promega) in 1 x PNK buffer (Promega). 20 pCi of [y-^^P] dATP (10 mCi/ml) and the 
appropriate volume of nuclease-free water were then added to give a total volume of 10  pi. 
The reaction was allowed to proceed for 1 hour at 37°C, before being stopped by heating at 
65“C for 10 minutes. The PNK enzyme was then phenol chloroform-extracted by adding 
50 pi of PhOH/ CHCI3/IA A (25:24:1), followed by vortexing and microcentrifugation at 
13, 000 g for 5 minutes. The aqueous layer was transferred to a fresh eppendorf tube and 5 
pi of 3 M sodium acetate and 125 pi of 96% ethanol added. After a 30 minute incubation 
on dry ice, the precipitated oligonucleotide was pelleted by microcentrifugation at 13, 000 
g for 10 minutes. The supernatant was removed and the pellet washed by sequential 
addition and removal of 100 pi of 70% (v/v) ethanol to ensure removal of unincorporated 
label. The pellet was then dried by heating at 47“C for 10 minutes before being re­
dissolved by incubation at 30°C for 30 minutes in 20 pi of TE buffer (final concentration 2 
ng/ pi). This was followed by heating in a hot block at 90°C for 2 minutes in the presence 
of unlabelled complementary oligonucleotide (RJW2), which was added in 2.5-fold excess 
to ensure that all the labelled oligonucleotide was annealed. The hot block was then turned 
off and the sample cooled slowly overnight. It was then stored at 4°C until ready for use, at 
which point it was diluted to 0.5ng/ pi with TE.
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2.16.2 EMSA Assay
Each binding reaction was performed in a total volume of 10 pi, with an optimal salt 
concentration of 60 mM KCl, and contained 1 pg of poly(dl.dC) (2 pi), 100 ng of non­
specific or specific competitor oligonucleotide (2 pi), typically 2-4 pi of cell extract and 
Ing of labelled probe (2 pi). A pre-incubation of 15 minutes at 30°C was carried out prior 
to addition of the probe, followed by a further 15 minutes at 30°C. Analysis of the 
formation of protein-DNA complexes was achieved by electrophoresis of samples on a 4% 
(v/v) non-denaturing polyacrylamide gel. The gel was pre-run in 1 x TAE buffer at 150 V 
for 1 hour at 4°C, and samples were run for 1.5 hours in the same conditions. The gel was 
then dried and exposed to autoradiography film overnight at -80°C.
2.17 Primer Extension
Expression levels of the transfected pol III template VAi (0.25 pg) and the GFP gene (0.25 
pg), which was co-transfected as an internal control for transfection efficiency, were 
analysed by primer extension. VA, (5’-CACGCGGGCGGTAACCGCATG-3’) or GFP 
(5’-CGTCGCCGTCCAGCTCGACCAG-3’) oligonucleotides were end-labelled
using T4 polynucleotide kinase (PNK). For each primer extension reaetion, 10 pg of total 
RNA (made up to 10 pi with DEPC- dH2 0 ) were incubated at 80°C for 10 minutes with 9 
pi of First Strand Buffer (Invitrogen) and 1 pi of the relevant labelled probe to act as a 
primer. Samples were immediately transferred to a hot block for further 2 hours 
incubation, 30 pi of an elongation mix (23 pi DEPC-dHzO, 0.5 pi DEPC- dH2 0 , 1 M DTT, 
5 pi 5 mM dNTP mix (5 mM in DEPC- dH2 0 ), 0.5 pi 4 mg/ml actinomycin D, 0.5 pi (100 
U) of Superscript II Reverse Transcriptase (Invitrogen)), was then added to the samples to 
initiate reverse transcription and the reaction was allowed to proceed for 1 hour at 42^C. 
Reaction products were ethanol precipitated overnight, as described in section 2.11.2. 
Pellets were resuspended in 4 pi of formamide loading buffer (98% (v/v) formamide, 10 
mM EDTA pH 8.0, 0.025% (w/v) bromophenol blue, 0.025% (w/v) xylene cyanol FF) was 
added to each sample, which was then vortexed for 1 hour to ensure the RNA was fully re­
dissolved. 1.5 pi of each sample was loaded on a pre-run 7% (v/v) polyacrylamide 
sequencing gel containing 7 M urea and 0.5 x TBE (45 mM Tris-HCl, 45 mM boric acid, 
0.625 mM EDTA pH 8.0), after being boiled at 95°C for 2 minutes and quenched on ice. 
Electrophoresis was performed at 40 W for 1 hour in 0.5 x TBE, before being dried and 
exposed to autoradiography film in order to detect the radiolabelled transcripts. 
Quantification of results was aehieved by densitometry (TotalLab vl . l  1).
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2.18 Random polymerase assay
Random polymerisation assays were based on a method deseribed by Roeder (Roeder, 
1974). Reactions were performed in a total volume of 50 pi with a final concentration of 6 
mM HEPES pH 7.9, 30 mM KCl, 3.6 mM MgCh, 6 mM Tris-HCl pH7.9, 200 pM EDTA,
7.5 mM ammonium sulphate, 800 pM mangenese chloride, 600 pM rATP, rCTP and 
rGTP, 50 pM UTP, 0.6 mM DTT and 5% (v/v) glycerol. This was supplemented with 5 pg 
of poly(dA-dT) to provide a non-specific template, 20 pg BSA, 10 pCi [a-^^P] UTP 
(400Ci/mmol) and 10 pg of whole cell extract prepared from cells treated with and without 
rapamycin (lOOnM) for 4 hours. For inhibition of pol II activity, a-amanitin (diluted in 
DEPC- dH2 0 ) was added to give a final concentration of 1 pg/ml or of 100 pg/ml for 
inhibition of both pol II and pol III activities. Reactions were performed at 30°C for 20 
minutes and were stopped by transferral to 2 cm^ Whatman DE5 paper discs, which were 
then subjected to serial 5 minute washes: 6 washes in 0.5 M Na2HP0 4 , twice in dH2 0 , 
twice in 96% ethanol and finally once in ether. Discs were then dried at room temperature 
for a few minutes and transferred to scintillation vials containing 5 ml of Optiflow 
scintillation fluid (Fisons chemicals). Levels of incorporated radioactivity were then 
measured in a scintillation counter counting ^^P for 5 minutes. Pol III activity was 
calculated by subtracting the polymerisation obtained in the presence of 1 0 0  pg of a- 
amanitin per ml (due to pol I) from that obtained in the presence of 1 pg of a-amanitin per 
ml (due to pol III and pol I).
2.19 In vitro kinase assay
Recombinant Mafl (HsMafl .His) (2pg) was bound to n P  beads (20 pi) which had been 
washed twice in 300 pi TBS. These were incubated for 10 minutes at 30®C in the presence 
of control buffer or with 50 pi of whole cell extract taken from cells treated with either 
vehicle (DMSO), or rapamycin (lOOnM) for 4 hours. The samples were incubated for 15 
minutes at 30°C in a master mix containing 20 mM Tris-HCl pH7.4, 20 pM ATP, 10 mM 
MgCL, 1 mM DTT and 5 pCi of [y-^^P] ATP. Immunoprecipitates were then washed 
once with 300 pi TBS/0.1 % (v/v) Triton X-100 and then washed a further twice in 300 pi 
TBS with microfuging at 13, 000 g for 1 minute between each wash. The bead-bound 
samples were then re-suspended in 2 x protein sample buffer (125 mM Tris-HCl pH 6 .8 , 
1% (w/v) SDS, 10% (v/v) p-mercaptoethanol, 2 0 % (v/v) glycerol, 0.25% (w/v) 
bromophenol blue), and analysed by SDS-PAGE. The amount of ^^ P incorporated into 
HsMafl .His was assessed by autoradiography.
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2.20 Targeting of endogenous M afl using siRNA
2.20.1 siRNA design
Four Mafl target sequences were selected. Beginning with the AUG start codon, the length 
of the Mafl gene was scanned for sequences beginning with AA and the adjacent 19 
nucleotides 3’ of AA were noted. These 33 potential siRNA target sites were compared to 
the mouse genome database (using the BLAST alignment tool) and targets with significant 
homology to other genes were eliminated in this way. Since the length of the target was 
21mer, a complete homology match score was 42 (21 X 2). Four sequences that appeared 
to be specific to the gene of interest were chosen for siRNA design.
Table 2.3: siRNA oligonucleotides
Target Sequence 
(Gene Position)
Antisense siRNA 
oligonucleotide template
Sense siRNA 
oligonucleotide template
5’-AAGATGGCGGG 
AGATGAT AAA-3’ 
(103)
5’-AAGATGGCGGGAGA
TGATAAACCTGTCTC-3’
5’-AATTTATCATCTCC
CGCC ATCCCTGTCTC-3 ’
5’-AAGTCATGAAT
TCAGCCGAGA-3’
(342)
5’-AAGTCATGAATTCAG
CCGAGACCCTGTCTC-3 ’
5’-AATCTCGGCTGAATT 
CATGACCCTGTCTC-3 ’
5’-AAATGCAGTCA 
ACTGCAGCCT -3’ 
(384)
5’-AAATGCAGTCAACTG 
C AGCCTCCTGTCTC-3 ’
5 ’-AAAGGCTGCAGTTG 
ACTGCATCCTGTCTC-3 ’
5’-AACTGCAGCCT 
GTTTTCAGCT -3’ 
(394)
5 ’-AACTGCAGCCTGTTT 
TC AGCTCCTGTCTC-3 ’
5’-AAAGCTGAAAACAG 
GCTGC ACCTGTCTC-3 ’
DNA oligonucleotide sequences for each target were designed using the ‘‘siRNA Template 
Design Tool for the Silencer siRNA Construction Kit”, This was achieved by entering the 
Mafl mRNA target sequence beginning with AA into 
http://ambion.com/techlib/misc/silencer_siRNA_template.html. This tool determines the 
final 29mer DNA sequences of the sense and antisense siRNA oligonucleotide templates 
by adding a CCTGTCCTC sequence which is complementary to the T7 promoter primer, 
to the 3’end of each oligonucleotide. Transeription of the antisense strand oligonucleotide 
generates RNA that is fully complementary to the mRNA target sequence. Transcription of
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the sense strand template generates a 3’ terminal UU that is not complementary to the 
antisense strand of the siRNA. It is unknown whether this non-complementary 
dinucleotide is important for the activity of siRNAs.
2.20.2 siRNA preparation
Two 29-mer DNA oligonucleotides for each of the four selected Mafl siRNAs were 
synthesised using the sense and antisense siRNA oligonucleotide template sequences 
(Genosys), and made up to 200 pM in nuclease-free water. In separate reactions, 2 pi of 
either the sense or anti sense siRNA oligonucleotide templates were hybridised to 2 pi of 
T7 promoter primer in the presence of 6  pi of DNA hybridisation buffer (all reagents are 
from Ambion). The mixture was heated to 70®C for 5 minutes and left at room temperature 
for 5 minutes. The hybridised oligonucleotides were then added to a mixture containing 2 
pi of 10 X Klenow Reaction Buffer, 2 pi of 10 x dNTP Mix, 4 pi of Nuclease-Free water 
and 2 pi of Exo-Klenow, and gently mixed, followed by slow vortexing and brief 
centrifuging in order to collect the mixture at the bottom of the tube. The mixture was then 
incubated at 37®C for 30 minutes to allow the 3’ ends of the hybridised oligonucleotides to 
be extended by Klenow fragment of DNA polymerase to create double-stranded siRNA 
transcription templates.
The sense and antisense siRNA templates were transcribed by T7 RNA polymerase in a 
reaction containing 2pl of either sense or antisense template, 4 pi Nuclease-Free water, 10 
pi 2 X NTP Mix, 2 pi 10 X T7 Reaction Buffer and 2 pi T7 Enzyme Mix. These 
transcription reactions were incubated for 2 hours at 37‘’C after brief vortexing, and 
centrifuging to allow collection of the reaction mixture at the bottom of the tube. The 
resulting RNA transcripts were hybridised to create dsRNA by combining the sense and 
antisense transcription reactions at 37°C in an overnight incubation. The leader sequences 
and the DNA template were removed by digesting the dsRNA with a single-strand specific 
ribonuclease and a deoxyribonuclease. The dsRNA (made by in vitro transcription) was 
gently mixed with 6  pi Digestion Buffer, 48.5 pi Nuclease-Free water, 3 pi RNase, 2.5 pi 
DNase and incubated for 2 hrs at 37°C. 400 pi of siRNA Binding Buffer was added to the 
nuclease digestion reaction prior to incubation for 2-5 minutes at room temperature. Filter 
Cartridges were prepared by pre-wetting with 100 pi of siRNA Wash Buffer and 2 ml 
collection tubes were attached. To bind the siRNA, the premixed siRNA nuclease digestion 
reaction and the siRNA Binding Buffer were added to the Filter Cartridge and spun at 10, 
OOOg in a microeentrifuge tube for 1 minute. The flow-through was discarded and the filter
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was washed twice with 500 pi of siRNA Wash Buffer to remove excess nucleotides, short 
oligomers, proteins and salts from the reaction. A new 2 ml tube was attached for each 
wash. 100 pi of Nuclease-free water (preheated to 75°C) was added to each Filter Cartridge 
and incubated for 2 minutes at room temperature. The Filter Cartridge was then spun at 12, 
OOOg for 2 minutes to collect the purified siRNA. The end product is a double stranded 21- 
mer siRNA with 3’ terminal uridine dimers which was stored at -80°C prior to transfection 
into A31 cells.
The RNA coneentrations (pg/ml) of the siRNAs were quantified by measuring the 
absorbance at 260nm (see section 2.3), and the molar concentration determined using the 
formula:
uM = Concentration in us/ml 
14
2.21 Transient transfection
2.21.1 Transient transfection of Brfl and Mafl
A31 and CCL39 cells were transfected using the Lipofectamine reagent (Life Technologies 
Inc.) The transient transfection with lipofectamine required cells to plated out at 1 x 10  ^
cells/well on 6  well plates or 10 cm dishes, 24 hours prior to transfection, resulting in a 
confluency of -75%  at the time of transfection. Two wells of a 6  well plate were 
transfected per treatment. Master-mixes for each set of wells were made. The first of these 
comprised the appropriate plasmid DNA (2 pg) and 0.12 ml of OptiMEM (Gibco) 
(volumes per well). In a separate tube, 0.12 ml OptiMEM and 8 pi lipofectamine were 
mixed (volumes per well), and these were transferred into the tube containing the plasmid 
with OptiMEM. The two were mixed by pipetting up and down and the tube was incubated 
for 45 minutes in the dark at room temperature. During the incubation period, each 6  well 
plate to be transfected was washed with 1 ml of OptiMEM per well, and then 0.76 ml of 
OptiMEM was added per well and the plates incubated at 37°C. After the incubation 
period, 1 ml of the Lipofectamine-DNA-OptiMEM mix was overlaid dropwise into each 
well. The plates were gently rocked back and forth to evenly distribute the complexes and 
then were left for 3 hours at 37°C in an incubator. The Lipofectamine-DNA mix was then 
removed by aspiration from each well and replaced with 3 mis of fresh medium. Cells were 
incubated for a further 48 hours to allow expression of the transfected DNA, with media
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being renewed again after 24 hours. Cells were then harvested and total RNA or protein 
extracted for analysis.
10  cm dishes were transfected using the same method as the 6 -well plates, although, 
volumes were adjusted. Cells were transfected with 10 pg of plasmid DNA and master- 
mixes for each plate comprised the appropriate plasmid DNA and 0.828 ml of OptiMEM 
per dish, which was mixed with 0.828 mis OptiMEM and 30 pi Lipofectamine per dish. 
The DNA-OptiMEM and OptiMEM-Lipofectamine mixes were incubated as before for 45 
minutes in the dark at room temperature. During this time 10 cm plates were washed with 
6  mis of OptiMEM and 5.6 mis of OptiMEM was added until the end of the 45 minute 
incubation time. At this point, 1.6 mis of the Lipofectamine-DNA-OptiMEM mix was 
added to each plate. Media on plates containing transfected cells was replaced after 3 
hours, and again after 24 hours. RNA or protein was extraeted 48 hours post-transfection.
2.21.2 Transfection of siRNAs
A31 cells were plated at 1 x 1 0  ^ cells/well on 6  well plates and grown for 24 hours in 
media containing DMEM supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 
U/ml penicillin and 100 pg/ml streptomycin. Cells were transfected when 70% confluent, 
with the cocktail of siRNAs described in section 2.20 at a final concentration of 50 nM. 
SilencerlM  scrambled GAPDH siRNA and SilencerTM  GAPDH siRNA were also 
transfected, all at 50 nM final concentration. Two wells per 6  well plate were used per 
treatment. The same volumes for transient transfections were used as described in section 
2.21.1, except that 50 nM of siRNA was used where DNA had previously been transfected 
and 4 pi of the transfection reagent siPORT (Ambion) was used per well. The siPORT- 
RNA-OptiMEM mix was removed after 4 hours and replaced with fresh media. RNA was 
extracted 48 hours post-transfection.
2.21.3 Transfection of plasmid templates for primer extensions
Asynclu'onously growing A31 fibroblasts cultured in DMEM supplemented with 10% (v/v) 
FBS, 2  mM L-glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin were transfected 
for 48 hours with a total of 2 pg of DNA per well of a 6  well plate. This was made up of 
0.5 pg of the plasmids pVAl and pGFP (Promega), each at 0.25pg, plus one of the
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following plasmid templates; pCDNA3-Brfl, which encodes wt Brfl (Sutcliffe et a l, 
2000), pCDNA3-PKB (Burgering and Coffer, 1995), pCDNA3-PKB kd (Burgering and 
Coffer, 1995), pCDNA3-Ap85 (Kara et al., 1994), pCDNA3-mTOR D2338A which 
encodes kinase-dead mTOR (Brunn et a l, 1997), pCDNA3-mTOR which encodes wild 
type mTOR (Brunn et a l, 1997) or pCDNA3-S6KED3E, which is constitutively active and 
partially rapamycin-resistant, containing the point mutations T389E, S411D, S418D, 
T421E and S424D (Pearson et a l, 1995). During the final 16 hours of transfection, the 
cells were either maintained in the same medium, or in a medium containing 0 .5 % (v/v) 
serum. For the final 4 hours, either vehicle (DMSO) or rapamycin (lOOnm) was added. 
VAI and GFP levels were assayed by primer extension.
2.22 Phosphate labelling in vivo
Labelling was carried out with 0.5 mCi/ml [^^P] orthophosphate for 3 hours in phosphate- 
free DMEM (Gibco). After incubation, cells were washed twice in 5 mis of ice-cold PBS 
and then solubilised in 0.25 ml of lysis buffer (50mM HEPES pH 7.5, 5 mM EDTA, 10 
mM NaF, 150 mM NaCl, 25% (v/v) glycerol, 0.5% (v/v) Triton X-100, 0.5 mM PMSF, 0.5 
pg/ml leupeptin, 0.7 pg/ml pepstatin, 0.5 pg/ml aprotinin, 40 pg/ml bestatin, 1 mM sodium 
vanadate and 50 mM p-glycerophosphate) and left on ice for 15 minutes. Samples were 
then passed through a 26G needle three times before centrifuging at 13, OOOg for 10 
minutes at 4°C to pellet the cell debris. An aliquot of the supernatant was then used in a 
Bradford Protein Assay to determine protein concentration and 500 pg of protein was used 
in subsequent immunoprécipitations.
2.23 In vitro transcription-translation
Proteins were synthesised in vitro using the Single Tube Protein System 3 (STP3)-T7 kit 
(Novagen) following the manufacturer’s protocol. Reactions were assembled on ice. 8 pi 
of STP3 T7 Transcription Mix was added to 1 pg plasmid DNA to a final reaction volume 
of 10 pi made up with nuclease-free water. These were incubated at 30°C for 20 minutes. 
Translation was carried out by adding 30 pi of STP3 Translation Mix and 4 pi (40 pCi) 
^^S-labelled Cys/Met or 2  pi of unlabelled Methionine (625 pM), made up to a final 
reaction volume of 50 pi with nuclease-free water. Reactions were gently mixed and 
incubated at 30°C for 1 hour. 5 - 10 pi of each sample was analysed via separation by SDS-
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PAGE. The gel was then incubated with 20 mis of amplify (Amersham) for 2 hours, 
coomassie stained and destained and was dried and visualised by autoradiography.The 
plasmids used for in vitro transcription-translation were: pCDNASHA.Brfl;
pCDN A3 HA. Mafl and pCITESTP3 (luciferase), which all contained the T7 promoter.
2.24 Recombinant M afl immunoprécipitations
10 pi of ^S]-Methionine-labelled M afl, luciferase, or Brfl were prepared as described in 
section 2.23, using in vitro transcription and translation with reticulocyte lysate. Each in 
vitro translated protein was incubated with Ni^^ for 1 hour at 4"’C in 500 pi of TBS. These 
pre-cleared samples were then microfuged at 13, OOOg for 1 minute and the supernatant 
removed. The supernatant containing the in vitro translated protein was then incubated 
with 2 pg recombinant Mafl (pre-bound to Ni^ "" for 1 hour at 4"’C) for 30 minutes in 
incubation buffer (TBS, 1 mM DTT, 0.25 pM PMSF, 40 pg/ml bestatin, 1 pg/ml trypsin 
inhibitor, 0.7 pg/ml pepstatin, 0.5 pg/ml aprotinin, 0.5 pg/ml leupeptin). The bound 
proteins were then washed once with TBS and 0.1 % (v/v) Triton X-100 and the 
supernatants were removed after microfugation at 13, OOOg for 1 minute. This was 
followed by a further three washes with TBS. Bound material was separated by SDS- 
PAGE and incubated with Amplify (Amersham) for 2 hours at room temperature before 
coomassie staining and de-staining and being dried and exposed to autoradiography.
2.25 Pull-down assays
2.25.1 M afl puU-downs
10 pi of Methionine-labelled Brfl was prepared as described in section 2.23, using in vitro
transcription and translation with reticulocyte lysate and unlabelled methionine. 500 pi of
TBS and 30 pi of anti-HA-agarose beads (Sigma) were added to Brfl protein and this HA
immunoprécipitation was carried out for 1 hour at 4°C. The supernatant was removed after
microfugation at 13, OOOg for 1 minute. 10 pi of [^^S]-Methionine-labelled Mafl,
luciferase, or Brfl prepared as described in section 2.23, was added to the HA-beads with
500 pi incubation buffer (TBS, 1 mM DTT, 0.25 pM PMSF, 40 pg/ml bestatin, 1 pg/ml
trypsin inhibitor, 0.7 pg/ml pepstatin, 0.5 pg/ml aprotinin, 0.5 pg/ml leupeptin), and this
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was left to incubate for 30 minutes at 4°C. The bound proteins were then washed once 
with TBS and 0.1 % (v/v) Triton X-100 and the supernatants were removed after 
microfugation at 13, OOOg for 1 minute. This was followed by a further three washes with 
TBS. Bound material was separated by SDS-PAGE and incubated with Amplify 
(Amersham) for 2  hours at room temperature before coomassie staining and de-staining 
and being dried and exposed to autoradiography.
2.25,2 GST pull- downs
Glutathione ^'-transferase (GST) fusion proteins were expressed in bacteria and purified on 
glutathione-agarose beads (Sigma) by Jemiifer Fairley, Niall Kenneth and Louise Derblay. 
GST fusion proteins were stored at -80°C for use in pull-down experiments. GST -Z n 
contains residues 1-93 of Brfl, GST-Hl contains residues 281-397 of Brfl and GST-H2 
contains residues 393-513 of Brfl. Equal amounts of immobilised GST (previously 
prepared according to manufacturers’ instructions) and GST-Zn, GST-Hl and GST-H2 
(estimated by Coomassie staining) were used in the reactions. 25 pi of packed glutathione 
beads bearing GST-Zn, GST-Hl and GST-H2 or GST alone were incubated with 5-10 pi 
of ^^S-labelled recombinant Mafl (which had been pre-cleared for 2 hours with 
Glutathione agarose) in 500 pi of TBS. Samples were incubated on a rotating wheel for 30 
minutes at 4°C. Beads were then washed in 300 pi of TBS, 0.25mM NaCl, 0.5 % (v/v) 
Triton X-100 followed by microfuging at 12, OOOg for 1 minute. This was followed by a 
further 4 washes with TBS. Bound material was separated by SDS-PAGE and incubated 
with Amplify (Amersham) for 2 hours at room temperature before coomassie staining and 
de-staining and being dried and exposed to autoradiography.
2.26 Statistical analysis
Data are presented as the mean plus or minus the standard error. Statistical significance 
was determined by the Student’s r-test (paired two samples for means; two-tails) using 
Microsoft Excel. P values of <0.05 were considered significant.
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Chapter 3
The mTOR and PI3K Pathways 
Regulate Pol III Transcription
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3.1 Introduction
3.1.1 The mTOR signalling pathway
The proteins TORI, T0R2 and FPRl were first identified in Saccharomyces cerevisiae in 
a screen for mutants that could confer resistance to the anti-proliferative effects of the 
macrolide antibiotic rapamycin. FKBP12 (FK506 -binding protein of 12kDa; encoded by 
the FPRl gene) is a direct cellular receptor of the drug rapamycin, and is an abundant, and 
ubiquitously expressed, petidyl-prolyl cis/trans isomerase that may function in protein 
folding (Schreiber, 1991; Harding et a l,  1989). Whilst the FPRl mutant is recessive, the 
TOR mutants are dominantly acting point mutations, which map to a region of TOR, 
namely the FKBP12-rapamycin binding (FRB) domain. Upon exposure to rapamycin these 
TOR mutants cannot bind, nor be inhibited by, the rapamycin-FKBP 12 complex, resulting 
in proliferation in the presence of rapamycin (Stan et a l,  1994; Chen et a l, 1995). The 
presence of FKBP12, not its activity, is required for the toxic, anti-proliferative action of 
rapamycin in yeast. This is demonstrated by the fact that deletion of all four FKBP12 genes 
in S. cerevisiae is not lethal, the yeast remain viable and exhibit resistance to the toxic 
effects of rapamycin (Heitman et ah, 1991; Koltin et al., 1991).
The mammalian TOR (mTOR) protein is a 289 kDa Ser/Thr kinase orthologue of yeast Tor 
1 and Tor 2. TOR is highly conserved from yeast to mammals; human, mouse and rat TOR 
proteins share 95% identity at the amino acid level (Heitman et al., 1991; Oldham et al., 
2000; Long et al., 2002). TOR homologues have also been identified in plants 
(Arabidopsis thaliana), worms {Caenorhabiditis elegans) and flies {Drosophila 
melanogaster) (Menand et al., 2002; Long et al., 2002; Oldham et al., 2000; Zhang et ah,
2000). mTOR is a member of the phosphoinositide 3-kinase related kinases (PIKKs), 
which comprise a family of high molecular mass signalling proteins that play central roles
in the control of cell growth, gene expression and genome surveillance and repair in
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eukaryotic cells. Mammalian cells express six PIKK family members, including; ataxia- 
telangiectasia mutated (ATM) and ATM- and Rad3- related (ATR) kinases, DNA -  
dependent protein kinase (DNA-PK), suppressor of morphogenesis in genitalia-1 (SMG-1), 
and transformation/ transcription domain-associated protein (TRAAP). A bioinformatics- 
based analysis suggests that the amino-terminal domains of mTOR, ATM and ATR are 
composed almost entirely of Huntington, elongation factor 3, A subunit of protein 
phosphatase 2A, and TORI (HEAT) repeats. Remarkably, the PIKK amino termini appear 
to contain 40-54 HEAT repeats (Perry and Kleckner, 2003) and this terminal half appears 
to be the site of critical protein-protein interactions.
The structural motif that defines the PIKKs as members of a common kinase superfamily is 
the catalytic domain. As the family name indicates, this domain shows significant 
homology to the catalytic domains of the phosphoinositide-3-kinases (PI3K). The sequence 
homology is particularly high with respect to the amino acid residues involved in the ATP- 
binding site of the PIKK catalytic domain (Hunter, 1995). However, in spite of this 
homology to the PI3K catalytic domain, all of the PIKKs for which biochemical 
information is available have been shown to use proteins, rather than lipids, as 
phosphoacceptors for the y-phosphate of ATP (Brunn et al, 1997; Burnett et ah, 1998; 
Isotani et al., 1999). The catalytic domains of the PIKKs are flanked by two loosely 
conserved stretches of amino acids termed FAT and FATC domains (Bosotti et al., 2000), 
The exact function of the FAT region is unclear, but mutagenesis and deletion studies 
performed with mTOR and ATR indicate that the integrity of the FATC domain is critical 
for the kinase activity of these otherwise intact polypeptides (Abraham, 2004).
Four of the five PIKKs that express kinase activities show strong preference for the 
phosphorylation of Ser/Thr followed by a glutamine (Gin) residue. Consequently, ATM, 
ATR, DNA-PK and hSMG-1 are known as “ S/T-Q-directed” PIKKs and are particularly
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common in proteins involved in checkpoint signalling and DNA repair, relevant examples 
being BRCAl, M DCl, hChkl (Abraham, 2004). In contrast, mTOR, shows no preference 
for the Ser/Thr-Gln motif, and studies to date have no elear consensus site for Ser-Thr 
phosphorylation by the mTOR kinase domain. It has been suggested that inTOR’s lack of 
preference for S/T-Q sites, may prevent mTOR inappropriately phosphorylating 
downstream targets of the genome surveillance/repair pathways (Abraham, 2004).
There is much controversy over the sub-cellular location of mTOR. Whilst an early report 
indicated much of the protein was associated with microsomes (Withers et al., 1998), 
subsequent work suggested most of it was associated with the mitochondria (Desai et ah,
2002). Other reports have found much of the mTOR to be nuclear (Zang et al., 2002). It is 
not clear whether these differences arise from the fact that different techniques were 
employed or whether its location does vary under different conditions.
3.1.2 PI3K
PI3K function is important for a wide variety of cellular processes including cell growth, 
cell cycle progression and proliferation, cell survival and cell migration (Manning et a l,
2002). Many of the downstream changes in cell physiology leading from activation of 
PI3K are the result of so far unknown signalling events. In response to a wide variety of 
extracellular stimuli, PI3K phosphorylates the lipid phosphatidylinositol-4, 5-bis- 
phosphate (PIP2) at the 3’-OH position to generate the second messenger 
phosphatidylinositol-3, 4, 5-trisphosphate (PIP3) (see Figure 3.1). PIP3 then recruits 
proteins containing pleckstrin homology (PH) domains, such as PDKl and the Ser/Thr 
kinase PKB, to the plasma membrane where they can be fully activated (Rameh and 
Cantley, 1999; Katso e ta l ,  2001; Cantley, 2002).
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Fig. 3.1 : mTOR integrates signals from nutrients and growth factors leading to 
cell growth (adapted from Jacinto and Hall, 2003)
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Fig, 3,1 : mTOR integrates signals from nutrients and growth factors leading 
to cell growth (adapted from Jacinto and Hall, 2003)
Growth factor stimulation activates phosphatidylinositol 3-kinase (PI3K) which 
phosphorylates phosphatidylinositol-4-5-bisphosphate (PtdIns(4,5)P2) (PIP^) at 
position 3 to generate PtdIns(3,4,5)P3 (PIP3). The lipid phosphatase PTEN 
antagonises PI3K action by converting PIP3 back to PIP2. The protein kinases PKB 
and 3-phosphoinositide-dependent protein kinase-1 (PDKl) are recruited to the 
membrane and bind PIP3 through their pleckstrin homology (PH) domains. 
Membrane-bound PKB is activated, leading to the phosphorylation of TSC2 and 
inactivation of the TSC complex- formed by TSCl and TSC2. This thereby relieves 
the inhibitory constraint on the mammalian target of rapamycin (mTOR) and allows 
activation the mTOR complex, which consists of mTOR bound to raptor and 
mLST8 . mTOR promotes hierarchical phosphorylation of the translational activator 
S6 K and the translation inhibitor 4E-BP either directly or indirectly by inhibition of 
protein phosphatase A (PP2A). Phosphorylation o f S6 K and 4E-BP promotes 
translation, via the ribosomal protein S6  and the eukaryotic initiation factor 4 E 
(eIF4E), respectively. Nutrients phosphorylate and inactivate TSC2 which acts as a 
negative regulator of the small GTP-binding protein Rheb. It is thought that TSC2 
functions as a Rheb-GAP, shifting the equilibrium to inactive Rheb-GDP. Under 
low energy conditions, mTOR is inhibited as the AMP/ATP ratio rises. LKBl is a 
tumour suppressor which phosphorylates and activates AMPK under such 
conditions. AMPK then phosphorylates TSC2 to enhance the tumour suppressor 
function resulting in inhibition of mTOR.
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Both mTOR and PBK-dependent signals co-ordinately control the translational effectors 
S6K1 and 4E-BP1. Initial studies showing phosphorylation of S6K1 and 4E-BP1 were 
sensitive to inhibition by both rapamycin and wortmannin, placed PI3K and mTOR in a 
linear signalling pathway (Gingras, 2001; Martin, 2002). However, this simplistic view 
was challenged when a rapamycin-resistant mutant of S6K1 remained sensitive to 
inhibition by wortmannin, indicating that PI3K controls S6K1 activation via an mTOR- 
independent mechanism (Cheatham et al 1995; Weng et a l, 1995; Dennis et a l, 1996). 
More recent developments revealing upstream regulators of mTOR suggest a model 
whereby PI3K lies both upstream of and parallel to mTOR with both branches converging 
on common downstream targets (Manning and Cantley, 2003).
Overexpression of an activated form of PKB in HEK293 cells promotes 4E-BP1 
phosphorylation in the absence of growth factors and in a wortmannin-resistant and 
rapamycin-sensitive manner (Gingras et a l, 1998). Furthermore, overexpression of a 
dominant negative form of PKB impairs insulin-mediated phosphorylation of 4E-BP1 
(Gingras et a l,  1998). These findings unequivocally place PKB upstream of mTOR and 
are also consistent with several studies in Drosophila, where overexpression of 
Drosophila PKB (dPKB) increases organ and cell size (Verdu et a l,  1999) and a non- 
phosphorylatable form of Drosophila 4E-BP suppresses this phenotype (Miron et a l,
2001), whereas loss of dPKB reduces cell and body size (Scanga et a l, 2001). Recent 
knockdown experiments using RNAi in Drosophila S2 tissue culture cells also provide 
evidence that PKB is a positive regulator of mTOR (Lizcano et a l ,  2003; Miron et a l,
2003). Studies in mice lacking two of the three PKB family members provide the first 
genetic evidence that PKB functions upstream of mTOR in mammalian cells (Peng et al,
2003). However, the upstream positive regulatory role of PKB in mTOR activation has 
been questioned, as S6K1 phosphorylation does not always correlate with PKB activity in 
both mammalian cells and in Drosophila (Dufner et a l,  1999; Radimerski et a l, 2002). A
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major breakthrough in the understanding of how growth factors and PKB regulate mTOR 
activity was the discovery that TSCl (Tuberous sclerosis complex 1, also known as 
hamartin) and TSC2 (Tuberous sclerosis complex 2, also known as tuberin) are upstream 
regulators o f mTOR (Gao and Pan, 2001; Potter et a l,  2001; Tapon et a l, 2001; 
Radimerski et a l, 2002; Inoki et a l, 2002; Gao et a l, 2002; Tee et a l,  2002; Tee et a l, 
2003a). Several pieces of information suggested that the TSC 1/2 complex was somehow 
required for mTOR to sense nutritional sufficiency. This was preceded by genetic and 
biochemical studies which found that the small G protein, Rheb (Ras homolog enriched in 
brain), was a direct target of TSC2, and that TSC2 functions as a GAP (GTPase-activating 
protein) to inhibit Rheb activity and thus inhibit its ability to stimulate the mTOR 
signalling pathway (Castro et a l, 2003; Garami et a l, 2003; Inoki et al, 2003; Saucedo et 
a l, 2003; Tee et a l, 2003b; Zhang et a l, 2003). Thus, it appears that the TSC complex is a 
negative regulator of mTOR. When membrane-bound PKB is activated this leads to the 
phosphorylation and inactivation of the TSC complex, which thereby relieves the 
inhibitory constraint on mTOR.
3.1.3 Nutrient sensing by mTOR
In S, cerevisiae, TOR is sensitive to changes in amino acid, nitrogen, and glucose levels. 
Furthermore, inliibition of TOR with rapamycin or by TOR gene deletion triggers a stress 
response program that strongly resembles the nutrient starvation phenotype (Barbet et a l, 
1996; Thomas and Hall, 1997). These observations provided the first indication that TOR 
signalling coordinates nutrient availability with cell growth and proliferation (Schmelzle 
and Hall, 2000). It is apparent that the nutrient sensing function of TOR is evolutionarily 
conserved since the TOR signalling pathway has been found to couple nutrient availability 
with cell growth in S. cerevisiae, D. melanogaster and mammalian cells (Raught et a l, 
2001; Rohde et a l, 2001; Crespo and Hall, 2002; Schmelzle and Hall, 2000). A major role
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of the mTOR pathway in mammalian cells is to co-ordinate the synthesis of ribosomal 
proteins with the levels of available amino acids. This is accomplished by controlling the 
translational regulator S6K1. The S6  protein is a component of the small (40S) subunit of 
eukaryotic ribosomes, and is phosphorylated by S6K1 in response to a wide variety of 
extracellular signals (Fingar and Blenis, 2004). This drives translation of 5TO P (terminal 
oligopyrimidine) mRNA-encoding proteins, such as c-myc, early response genes, cyclins 
and ribosomal elongation factors (Jefferies et al., 1994, 1997; Terada et al., 1994; 
Sonenberg and Gingras, 1998). Up-regulation of 5’-TOP mRNA translation will enhance 
the eellular levels of ribosomes and other components required for translation, thus 
favouring higher rates of protein synthesis and cell growth and /or proliferation. Striking 
data from targeted genetic knock-outs of S6 K in fruit flies (where there is only one S6 K 
gene) demonstrated a key role for this enzyme in both cell and organismal growth 
(Montagne et al., 1999). Knockout flies were much smaller than wild-type flies, an effect 
that was due to reduced cell size rather than diminished cell number. Similar but more 
modest effects were observed when one of the S6 K genes was knocked out in mice (Shima 
et al., 1998). These data show that the S6  kinase, and thus mTOR signalling, plays a key 
role in growth control.
Given that both ribosome biogenesis and general protein synthesis require ample amino 
acids, it makes physiological sense for mTOR signalling and S6 K activity to be positively 
regulated by amino acid supply. Consistent with this hypothesis, activity and 
phosphorylation of the mTOR substrates S6K1 and 4E-BP1 deereases in amino acid- 
and/or glucose-free medium and is stimulated upon their re-addition (Hara et ah, 1998; 
Fox et al., 1998; Gingras et al., 2001; Inoki et al., 2003a; Kim et al., 2002). Furthermore, a 
rapamycin-resistant allele of S6K1 caused eells to be unresponsive to amino acid depletion 
(Hara et al., 1998), suggesting that mTOR is key to this sensing mechanism.
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Recent studies have elucidated some of the molecular mechanisms of mTOR regulation in 
response to nutrients and growth factors, in mammalian cells (summarised in Fig. 3.1). 
Reports that mTOR was found in complexes of around 2MDa, indicate that these 
complexes contain a number of mTOR-interacting proteins. Two such proteins have 
recently been identified: these are the scaffold protein Raptor (regulatory-associated 
protein of mTOR) (150kDa; homologous to the TOR partner KOGl in yeast) (Kim et al., 
2002; Hara et a l,  2002; Loewith et a l, 2002) and the protein G|3L (36kDa; homologous to 
the TOR-binding protein LST8 in yeast) (Loewith et ah, 2002, Kim et a l, 2002). Since 
reduction of Raptor or GpL expression with siRNA reduces the phosphorylation of S6K1 
on a rapamycin-sensitive site, it seems clear that these proteins play an important role in 
mTOR action (Kim et a l, 2003). In fact, TOR was reported to interact with Raptor to 
transduce nutrient signals to downstream translational machinery in mammals (Kim et a l, 
2002; Hara et a l, 2002). Raptor associates in a near stochiometric ratio with mTOR to 
form a complex that functions as a nutrient sensor (Kim et a l,  2002) and it has been 
proposed that Raptor acts as a scaffold to bridge mTOR with its putative phosphorylation 
targets (Abraham, 2002; Kim et al., 2002; Hara et a l, 2002).
5’ Cap-dependent translation, which accounts for 85% of total translation, requires mTOR 
activation. Nevertheless , mTOR activity requires not only TSC inactivation by PI3K/PKB 
(Inoki et a l,  2003a; Manning et al, 2002; Potter et al, 2002), but also appropriate ATP and 
nutrient levels (Dennis et a l,  2001; Fang et a l, 2001). As protein synthesis not only 
consumes amino acids but also requires large amounts of metabolic energy, it was perhaps 
not surprising to discover that energy supply modulates the activity of components 
required for protein synthesis. One way in which mTOR may sense cellular energy levels 
is through AMP-activated protein kinase (AMPK); a kinase which is activated during 
states of low cellular energy (high AMP: ATP ratio). The result of AMPK activation is two 
fold; to reduce ATP expenditure by inhibiting key enzymes of biosynthetic pathways and
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to increase the ATP supply by activating enzymes that produce ATP (reviewed in Hardie 
and Hawley, 2001). AMPK can modulate mTOR function by phosphorylating TSC2, 
which negatively regulates mTOR (Inoki et a l,  2003b). TSC2- knockout studies have 
shown that upon ATP depletion, the mTOR reporter proteins S6K1 and 4E-BP1 are not 
dephosphorylated, and that these cells are more susceptible to apoptosis due to glucose 
deprivation (Inoki et al., 2003b). Hence, it is likely that direct sensing of ATP levels by 
mTOR, as suggested in earlier studies (Dennis et a l, 2001), does not occur but rather that 
the AMP/ATP ratio regulates mTOR indirectly through activation of AMPK. It has been 
concluded that the energy- and stress-sensing mechanism (via AMPK) and the peptide 
growth factors and mitogen-stimulated pathway (through PI3K) bifurcate on TSC2 above 
mTOR (Fingar and Blenis, 2004).
3.1.4 Transcriptional control by mTOR
In addition to TOR’s well established role in the control of translation initiation, TOR 
proteins play a dynamic role in controlling transcription in response to nutrient signals. 
Transcriptional profiling of cells treated with rapamycin or starved of various nutrients 
have revealed that TOR controls expression of broad groups of genes with roles in protein, 
lipid, and nucleic acid metabolism (Cardenas et a l, 1999; Hardwick et a l, 1999; Peng et 
a l, 2002; Shamji et a l,  2000). In yeast, TOR regulates expression of specific classes of 
starvation response genes by sequestration of transcription factors such as GLN3/GAT1 
(regulated by nitrogen), MSN2/MSN4 (carbon) and RTG1/RTG3 (glutamine) (Beck and 
Hall, 1999; Komelli et a l,  2000).
Inhibition of TOR also results in the rapid repression of genes involved in ribosome 
biogenesis, including tRNAs and rRNAs transcribed by pol I and pol III as well as 
ribosomal proteins expressed by pol II (Cardenas et a l, 1999; Mahajan, 1994; Powers and
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Walter, 1999; Zaragoza et a i, 1998). Studies in S. cerevisiae found that when active yeast 
extracts with a conditional tor 2 mutant strain were shifted to the non-permissive 
temperature in vitro, pol III transcription was blocked (Zaragoza et al., 1998), suggesting a 
direct effect of TOR on the pol III system. These studies implicated the TFIIIB factor Brfl 
as a target for control; however, the mechanism by which mTOR regulates pol III 
transcription in mammals remains to be determined.
As discussed previously, the high specificity of rapamycin for mTOR allows use of this 
drug to delineate the down-stream effects of the mTOR signalling cascade. Therefore, 
rapamycin was used to investigate if the mTOR pathway was controlling pol III 
transcription. The PI3K inhibitor LY294002 was also used in this mammalian cell system 
to verify if (any) effects on pol III transcription were due to pathways upstream of mTOR.
3.2 Results
3.2.1 The mTOR signalling pathway regulates pol III transcription
Initial experiments were carried out to show how quickly pol III transcript levels change 
when quiesced fibroblasts were stimulated with serum. An immediate rise in pol III 
transcription occurs within minutes of serum addition to growth arrested fibroblasts 
(Figure 3.2A, upper panel), where pol III transcripts derived from the B2 middle repetitive 
gene family were compared to levels of a pol II transcript ARPP PO. In fact there is a 3.7- 
fold increase in levels of the B2 transcripts within 10 minutes of serum addition (Fig. 
3.2B). This effect is specific, since levels of the pol II transcript ARPP PO do not respond 
to serum (Figure 3.2A lower panel). A useful property of the pol III transcript B2 is its 
short half-life so that it provides a reliable indication of transcriptional output. It was found
that B2 expression increases proportionally with time of serum stimulation, until the 720
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Figure 3.2: Serum induces pol III transcription.
(A) Northern blot of total RNA (20gg) extracted from A31 mouse fibroblast cells 
cultured in 0.5% serum for 24 hrs (lane 1) and then stimulated with 10 % serum for 
the times indicated (lanes 2-8). The upper panel shows the blot probed with a B2 
gene; the lower panel shows the same blot that has been stripped and re-probed with 
the ARPP PO gene.
(B) The B2 signals from (A) were quantified by densitometry and normalised against 
the ARPP PO signal. The graph shows the mean and standard deviations from three 
independent experiments; values obtained for cells grown in medium containing 
0.5% serum for 12 hrs (lane 1) were set as 1 and other values were calculated as a 
fold increase.
denotes statistically significant difference from 0 min, at p < 0.05
minute (12hr) time point, at which point B2 expression increases dramatically. This 
significant increase is in agreement with a finding that near maximal B2 expression is 
reached by 12 hrs in these cells, shortly before S phase entry, as determined by flow 
cytometry (Scott et al., 2001).
In mammalian cells, growth factors and cytokines not only regulate nutrient uptake but 
also activate signalling pathways that act in parallel or in concert with nutrients (Hay and 
Sonenberg, 2004). Given the complex mix of mitogens that are present in serum, the full 
response of pol III activation is likely to involve multiple signalling pathways that may 
feed into several components of the pol III machinery. However, initial studies in 
S. cerevisiae implicated the TOR signalling pathway as a regulator of pol III transcription 
in response to nutrient availability (Zaragoza et a l, 1998). In light of this evidence, we 
investigated whether the mTOR pathway could regulate pol III transcription in mammalian 
cells.
When quiescent fibroblasts were stimulated with serum for 16hrs there was an 8 -fold 
increase in B2 transcript abundance (Fig 3.3, upper panel). Serum-stimulated levels of pol 
III transcription could be markedly reduced by the addition of either the mTOR inhibitor 
rapamycin or the PI3K inhibitor LY294002. In contrast, neither compound had any 
significant effect on basal B2 expression in serum-deprived cells. Interestingly, addition of 
both rapamycin and LY294002 together in the presence o f serum repressed pol III 
transcription more than either drug alone, although the effect on the levels of the B2 
transcript was not additive. The effect is specific since neither drug affected levels of the 
pol II transcript ARPP PO. Quantification of these results showed that rapamycin treatment 
reduced the pol III response to serum by approximately 35% +/- 13%, whilst LY294002 
treatment reduced it by 45% +/- 13%. Moreover, the combination of both rapamycin and
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F/gwre 5J :  Blocking the mTOR and FI3K signalling cascade reduces serum- 
stimulated pol III transcription in mammalian cells
(A) Northern blot of total RNA (20|ig) extracted from A31 mouse fibroblast cells 
cultured in 0.5% serum for 24hrs (lanes 1, 3, 5, 7) or in medium containing 10% 
serum (lanes 2, 4, 6 , 8 ) and treated for 16hrs with vehicle (lanes 1 and 2), 
rapamycin (lOOnM; lanes 3, 4, 7, 8 ) or LY294002 (50pM; lanes 5, 6 , 7, 8). The 
upper panel shows the blot probed with a B2 gene; the lower panel shows the 
same blot that has been stripped and re-probed with the ARPP PO gene (blot shows 
two replicates numbered as one lane).
(B) The B2 signals from (A) were quantified by densitometry and normalised 
against the ARPP PO signal. The graph shows the means +/- the standard error of 
the mean for two replicates; values obtained for cells serum-stimulated for 16 hrs 
(lane 2 ) were set as 1 0 0  and other values were calculated as a percentage of this.
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LY294002 resulted in more than a 65% reduction in pol III transcription, as compared to 
serum-stimulated fibroblasts.
A further way to determine the effects of rapamycin on pol III transcription was to use 
primer extension analysis. For this pCDNAg was transfected into cells along with a VAl 
pol III reporter construct and GFP as a control. Following 32hrs transfection, rapamycin or 
vehicle was added for a further 16hrs in the presence and absence of serum. VAl 
transcription is stimulated upon addition of serum for 16hrs (Fig. 3.4A, lane 3) and this 
effect can be blocked in the presence of rapamycin (Fig. 3.4A, lane 4). Levels of the pol II 
reporter GFP remained constant in each condition (Fig 3.4A, lower panel).
Whilst it was clear that blocking the mTOR and PI3K pathways using inhibitors decreased 
pol III transcription, it was interesting to further determine if pol III transcription could be 
specifically altered by using constitutively active or dominant negative components of 
these pathways. For this purpose, vectors encoding active and kinase dead PKB (Burgering 
and Coffer, 1995), dominant-negative p85 subunit of PI3K (Hara et al., 1994), or wild-type 
and a catalytically inactive mTOR Asp2338Ala mutant that abrogates phospho-transferase 
activity (Brunn et ah, 1997), were transiently transfected into fibroblast cells, along with 
the adenoviral VAl gene and a pol II control GFP gene. VAl and GFP RNA levels were 
assayed by primer extension. Brfl has previously been found to be limiting for pol III 
transcription in these cells; this was used as a positive control to induce pol III activity 
(Felton-Edkins et al., 2003a). Transfection of Brfl into cells indeed causes a significant 
induction of VAl transcription by pol III, as previously reported (Felton-Edkins et ah, 
2003a). Transfection of these cells with either the wild-type mTOR or PKB stimulated the 
transcription of the pol III reporter VAl, as compared to those cells which were transfected 
with vector alone (Fig 3.4, upper panel). In contrast, transfection of kinase dead PKB or 
catalytically inactive mTOR resulted in similar levels of pol III transcription as the control
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Figure 3.4: Manipulation of the mTOR and PI3K pathway affects pol III activity
(A) Asynchronously growing A31 fibroblasts were transfected with pVAl (0.25pg; 
all lanes), pGFP (0.25pg; all lanes), pCDNA3 (l.Spg; all lanes). Lanes 3 and 4 were 
serum-stimulated (10% FBS) and lanes 2 and 4 were rapamycin-treated (lOOnM) for 
4 hrs. VAl (upper panel) and GFP levels (lower panel) were assayed by primer 
extension as shown. This result is representative of three independent experiments.
(B) Asynchronously growing A31 fibroblasts were transfected with pVAl (0.25pg; 
all lanes), pGFP (0.25pg; all lanes), pCDNA3 (1.5pg; lane 1), pCDNA3-Brfl (l.Spg; 
lane 2), pCDNA3-PKB (l.Spg; lane 3), pCDNA3-PKB kd (1.5pg; lane 4), pCDNA3- 
Ap85 (l.Spg; lane 5), pCDNA3-mTOR D2338A (l.Spg; lane 6), and pCDNA3- 
mT0R(1.5pg; lane 7). VAl (upper panel) and GFP levels (lower panel) were assayed 
by primer extension as shown. This result is representative of two independent 
experiments.
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vector, whereas dominant- negative PI3K reduced pol III transcription below control 
levels. The pol II reporter GFP was used to check transfection efficiency and this remains 
virtually unchanged (Fig. 3.4).
Having established that long term exposure to either rapamycin or LY294002 reduces 
serum-induced activity, and that components of the mTOR and PI3K pathway could 
specifically activate pol III transcription, it was important to assess the time frame of 
inhibition. Since blocking this pathway with rapamycin or LY294002 has previously been 
found to cause a G1 arrest (Wiederrecht et a l, 1995; Zhang et a l, 2000), I determined 
whether the effects of these compounds were due to blocking entry to S phase.
Total RNA was extracted from cells in culture at various time points following rapamycin 
treatment, and Northern analysis was performed. As shown in Figure 3.5A, there is a 
pronounced decrease in the level of the pol III transcript B2 within 2 hrs of rapamycin 
treatment as compared to untreated cells, this decrease was quantified as being a 3 5 % 
reduction after normalisation to the ARPP PO control transcript (Fig 3.5B). Pol III 
inhibition is optimal between 4 and 6  hrs of rapamycin treatment, at which point levels of 
B2 have been reduced to around 50% of cells treated with vehicle only. These inhibitory 
effects of pol III transcription are specific, as the pol II transcript ARPP PO remained 
unchanged throughout (Fig. 3.5A, lower panel).
Having established the apparent involvement of the mTOR and PI3K pathways in the 
serum response of pol III transcription, it was important to check that the downstream 
effectors of mTOR were blocked during the rapamycin and LY294002 drug treatments. 
This was accomplished by checking the phosphorylation status of a well known 
translational effector of the mTOR pathway, namely S6K1, which belongs to the ribosomal 
protein S6  kinases. One of the ways mTOR has previously been found to regulate protein
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Figure 3.5: Blocking the mTOR signalling cascade reduces pol III transcription
(A) Northern blot of total RNA (20pg) from A31 mouse fibroblast cells cultured in 
10% serum and vehicle treated (lane 1) or treated with rapamycin (lOOnM) for the 
times indicated (lanes 2-6). The upper panel shows the blot probed with a B2 gene; 
the lower panel shows the same blot that has been stripped and re-probed with the 
ARPP PO gene.
(B) The B2 signals from (A) were quantified by densitometry and normalised against 
the ARPP PO signal. The graph shows the mean and standard deviations from three 
independent experiments; values obtained for cells grown in serum plus vehicle for 
12 hrs (lane 1) were set as 100 and other values were calculated as a percentage of 
this.
(C) Protein (50pg) extracted in parallel to the experiment described in (A) was 
resolved by SDS-PAGE and then analysed by western blotting with antibodies 
against S6K1 phosphorylated at Thr389 (upper panel), and total S6K1 (lower panel). 
These blots are representative of at least three independent experiments.
(D) 15pg of whole cell extract was prepared from A31 fibroblast cells grown in 
either 10% serum and vehicle (lane 1) or 10% serum and rapamycin (lOOnM) for the 
times indicated (lanes 2-5). Samples were transcribed in an in vitro transcription 
assay using the templates (250ng) of VAl (upper panel) or B2 (lower panel). These 
results are representative of three independent experiments.
* denotes statistically significant difference from control, at p < 0.05
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synthesis is by the phosphorylation and activation of S6K1. Phosphorylation of S6K1 is 
prevented by treating cells with rapamycin in vivo (Brunn et al., 1997; Burnett et al., 
1998). Western analysis show that the phosphorylation of S6K1 was also ablated at all 
time points in the present study during exposure of cells to rapamycin, as compared with 
vehicle-treated cells (Fig 3.5C, upper panel) and that this effect was not due to a reduction 
in levels of total S6K1 (Fig 3.5C, lower panel). In order to further investigate whether the 
mTOR pathway controls pol III transcription, protein cell extracts were made at the same 
time as the RNA extractions and were used in an in vitro transcription assay. Extracts of 
fibroblasts treated for just 2hrs with rapamycin transcribe B2 and VAl genes significantly 
less than vehicle alone (Fig 3.5D). This is in agreement with Northern analysis of pol III 
transcript levels (Fig 3.5A).
The effect of LY294002 on pol III transcription was also determined over time. Total 
RNA was extracted from cells in culture at various time points during LY294002 treatment 
and Northern analysis performed. Within 2hrs there is a significant reduction in the level of 
the pol III transcript B2 (Fig. 3.6A/B), which is further reduced by 6hrs to 40% for the 
remainder of the time course. Since PI3K lies upstream of mTOR, then blocking this 
enzyme is also known to reduce S6K1 phosphorylation (Wiederrecht et al., 1995). The 
effect on the phosphorylation status of S6K1 was confirmed in this study when the FI3K 
pathway was blocked with LY294002. Once again, the S6K1 protein phosphorylated at 
Thr 389, was undetectable in those cell extracts which had been treated with LY294002, 
whereas total levels of S6K1 remained unchanged throughout the experiment (Fig. 3.6C). 
Western analyses shown in Fig. 3.5 and 3.6 show clearly that both the mTOR and PI3K 
pathways are inhibited under these conditions.
To verify if blocking the mTOR and PI3K pathways affected the RNA transcript levels of 
different pol III promoter types, RT-PCR was performed on total RNA extracted from both
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Figure 3.6: Blocking the PI3K pathways reduces pol III transcription
(A) Northern blot of total RNA (20|ig) from A31 mouse fibroblast cells cultured 
in 10% serum and vehicle treated (lane 1) or treated with LY294002 (SOpM) for 
the times indicated (lanes 2-6). The upper panel shows the blot probed with a B2 
gene; the lower panel shows the same blot that has been stripped and re-probed 
with the ARPP PO gene.
(B) The B2 signals from (A) were quantified by densitometry and normalised 
against the ARPP PO signal. The graph shows the mean and standard deviations 
from three independent experiments; values obtained for cells grown in serum 
and vehicle for 12  hrs (lane 1) were set as 1 0 0  and other values were calculated as 
a percentage of this. These blots are representative o f at least three independent 
experiments.
(C) Protein (50pg) extracted in parallel to the experiment described in (A) was 
resolved by SDS-PAGE and then immunoblotted and analysed by western blotting 
with antibodies against and S6K1 phosphorylated at Thr389 (upper panel) and total 
S6K1 (lower panel). This blot is representative of at least three independent 
experiments.
* denotes statistically significant difference from control, at p < 0.05
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rapamycin and LY294002-treated cells. A substantial decrease was observed for both 
tRNA^^“ and tRNA^^’^ RT-PCR products following treatment with rapamycin or LY294002 
for 6  and 12 lirs (Fig. 3.7). Similarly, levels of 5S rRNA were significantly inhibited by 
both rapamycin and LY294002 during the same time course. In contrast to the type 1 (5S 
rRNA) and type II (tRNA) promoter products, the level of the type III promoter product 
U6  was not altered when cells were treated with rapamycin or LY294002 (Fig. 3.7). These 
effects were specific as there was no change in the level of the class II gene ARPP PO 
mRNA (Fig. 3.7). This data suggest that the production of most pol III transcripts in vivo is 
sensitive to the inhibition of the mTOR and PI3K pathways.
To confirm that this pathway influences pol III transcription, the effect of blocking the 
cascade was determined in vitro. Since a peptide substrate inhibitor of PKB is 
commercially available, I looked at the effect of this in an in vitro pol III transcription 
assay. It was found that VAl transcription was reduced in a dose-dependent manner up to 
90% by the substrate peptide containing the PKB consensus phospho-acceptor site (Fig. 
3.8, upper panel). The inhibitory response was specific, since a protein kinase A (PKA) 
substrate peptide had minimal effect (Fig 3.8, lower panel). This data suggests that the 
signalling pathway leading to mTOR can contribute significantly to the level of pol III 
transcription in vitro.
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Figure 3.7: Blocking the mTOR and PI3K pathways reduces pol III 
transcript levels of type I and type II promoters.
A31 fibroblast cells growing in 10% serum were treated with vehicle (lanes 1
and 4), rapamycin (lOOnM; lanes 2 and 3) or LY294002 (SOpM; lanes 5 and 6),
for the times indicated. RNA was extracted and cDNAs were generated using
reverse transcription. These cDNAs were PCR amplified by using primers
specific for ARPP PO (upper panel), tRNA^“ (second panel), tRNA^^r (third
panel), 5S rRNA (fourth panel), and U6 (lower panel). These results are
representative of two independent experiments.
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Figure 3.8\ Pol III transcription is blocked specifically by a peptide substrate 
inhibitor of PKB
In vitro transcription was carried out using 20pg of HeLa nuclear extract and a 
VAl template (250ng) after pre-incubation with buffer (lane 1), or with 10, 20, 30, 
40pg of PKB substrate peptide inhibitor (upper panel, lanes 2-5, respectively) or 
with 10, 20, 30, 40pg of PKA phospho-acceptor peptide (lower panel, lanes 2-5, 
respectively). This result is representative of three independent experiments.
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3.2.2 Blocking the mTOR signalling cascade does not affect the levels of 
TFIIIB or TFIIIC and doesn’t affect the abundance or activity of pol III.
Several studies have shown that one of the molecular mechanisms for raising pol III output 
in transformed cells occurs via the overexpression of pol III transcription factors (White, 
2004a). A potential mechanism by which the inhibition of the mTOR or PI3K pathways 
reduced pol III activity was via decreased abundance of the pol III transcription factors. To 
assess this hypothesis, levels of the pol III transcription factors TFIIIB and TFIIIC were 
monitored by Western blotting. Extracts from cells treated over time with rapamycin were 
subjected to SDS-PAGE analysis and immunoblotting with antibodies specific to 
components of TFIIIB (Fig. 3.9A) or TFIIIC (Fig. 3.9B); actin was used as a loading 
control in each case. Protein levels remain virtually unchanged; suggesting that changes in 
the abundance of these proteins was not the mechanism by which pol III transcription was 
downregulated in response to mTOR inhibition. Protein levels of two of the subunits of pol 
III; RPC 155 and RPC53 were also measured during rapamycin treatment and were found 
to be unchanged (Fig. 3.10A). Therefore, a change in the abundance of pol Ill-specific 
transcription factors is unlikely to be responsible for de-regulating pol III output during 
rapamycin treatment. To determine the activity of the pol III enzyme, we measured its 
ability to catalyse randomly initiated RNA synthesis independently of transcription 
factors, using a poly (dA-dT) template. Two matched pairs of extracts were tested. No 
consistent difference in the level of random polymerisation by pol 111 was observed 
between extracts prepared from cells incubated in vehicle-treated or rapamycin-treated 
conditions (Fig 3.1 OB).
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Figure 3.9 : Decrease in Pol III transcription in rapamycin-treated cells is not 
due to reduced TFIIIB or TFIIIC levels.
(A) Extracts of cells (50|ig) treated with (lOOnM) rapamycin for the times indicated 
were resolved by SDS-PAGE and analysed by western blotting with antibodies 
against the TFIIIB subunits Bdpl (upper panel), Brfl (second panel) and TBP 
(third panel), or in (B) with antibodies against the TFIIIC subunits TFIIIC220 
(upper panel), TFIIICllO (second panel), TFIIIC 102 (third panel), TFIIIC90 
(fourth panel) and TFIIIC63 (fifth panel). Actin was used as loading control in each 
case (A; fourth panel and B; sixth panel). These blots are representative of at least 
three independent experiments.
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Figure 3.10 ; Rapamycin treatment does not alter pol III abundance or 
activity.
(A) Extracts of cells cultured in 10% serum were incubated with vehicle for 12 hrs 
(lane 1) or rapamycin (lOOnM; lanes 2-6) over the times indicated. Samples were 
subjected to SDS-PAGE analysis and immunoblotted with antibodies against 
RPC-155 (upper panel) , or RPC 53 (lower panel). These blots are representative 
of two independent experiments.
(B) Extracts of cells cultured in 10% serum plus vehicle for 12 hrs or rapamycin 
(lOOnM) for 4hrs or 12hrs, were used to measure their ability to catalyse randomly 
initiated RNA synthesis, using a poly (dA-dT) template. Results from two 
independent experiments are shown with the vehicle treated value set to 100 in 
each case.
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To determine whether the PI3K and mTOR pathways converge and/or act on different 
downstream targets, the protein levels of the multi-subunit complexes TFIIIB (Fig 3.11 A), 
TFIIIC (Fig. 3.1 IB) and pol III (Fig. 3.12A) were investigated during a time course of 
LY294002 treatment in fibroblast cells. No changes in abundance were noted at any time 
point, verifying that protein levels of the transcription factors TFIIIB and TFIIIC and the 
enzyme pol III remain unaffected when either the mTOR or PI3K pathways are blocked. 
The activity of pol III was assessed during exposure to LY294002 and was found to have 
the same levels of activity in both vehicle-treated and LY294002-treated extracts (Fig. 
3.12B).
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Figure 3.11 : Decrease in pol III transcription in LY294002-treated cells is 
not due to reduced TFIIIB or TFIIIC levels
(A) Cell extracts (50pg) treated with (50 p,M) LY294002 for the times indicated 
were resolved by SDS-PAGE and analysed by western blotting with antibodies 
against the TFIIIB subunits Bdpl (upper panel), Brfl (second panel) and TBP 
(third panel), or in (B) with antibodies against the TFIIIC subunits TFIIIC220 
(upper panel) TFIIICllO (second panel), TFIIIC 102 (third panel) TFIIIC90 
(fourth panel) and TFIIIC63 (fifth panel). Actin was used as loading control in 
each case (A; fourth panel and B; sixth panel). Blots are representative of at 
least three independent experiments.
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Figure 3.12; LY294002 treatment does not alter pol III abundance or
activity
(A) Extracts of cells cultured in 10% serum were incubated with vehicle for 
12hrs (lane 1) or LY294002 (50pM; lanes 2-6) over the times indicated. Samples 
were subjected to SDS-PAGE analysis and immunoblotting with antibodies to 
RPC 155 (upper panel) or RPC 53 (lower panel). Blots are representative of two 
independent experiments.
(B) Extracts of cells cultured in 10% serum plus vehicle for 12 hrs or LY294002 
(50pM) for 4hrs or 12hrs, were used to measure their ability to catalyse 
randomly initiated RNA synthesis, using a poly (dA-dT) template. Results from 
two independent experiments are shown with the vehicle treated value set to 100 
in each case.
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3.2.3 Pol III transcription is sensitive to amino acid availability
It has previously been shown that transfer of cultured mammalian cells from standard 
growth medium into amino acid-free medium leads to rapid dephosphorylation of both 
S6K1 and 4E-BP1 (Hara et aL, 1998). This indicates that mTOR is involved in an amino 
acid sensory pathway which co-ordinates protein synthesis with amino acid availability 
(Proud, 2002). The knowledge that the mTOR pathway regulates protein synthesis with 
amino acid availability, together with the experimental data so far, which show that mTOR 
regulates pol III activity (indirectly controlling the cell’s protein biosynthetic capacity), led 
to the hypothesis that the mTOR pathway could be involved in the regulation of pol III 
transcription in response to amino acid availability.
Total RNA was extracted from cells grown in culture for various times in the presence or 
absence of amino acids, and northern analysis was performed. Within 2hrs of amino acid 
deprivation there is a 20 % reduction in the level of the pol III transcript B2 (Fig. 
3.13A/B), which is further reduced by 61us to 60% of control cells. The effect is specific 
since levels of the pol II transcript ARPP PO remained constant (Fig. 3.13A). Protein cell 
extracts were also prepared from fibroblasts deprived of amino acids for various times. 
Subsequent SDS-PAGE analysis and immunoblotting shows that the phosphorylation of 
mTOR effectors S6K1 and 4E-BP1, are blocked at each time point (Fig. 3.11C), 
confirming previous studies (Hara et aL, 1998). 4E-BP1 exists as a number of species with 
different mobilities on SDS-PAGE due to differences in phosphorylation, with the fastest 
mobility form being the hypo-phosphorylated (a) form. It can be seen that the under- 
phosphorylated form is only present in extracts from cells which had been cultured in the 
amino acid-free medium (Fig, 3.13C, lower panel).
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Figure 5.13 \ Signalling through mTOR is blocked in the absence of amino 
acids
(A) Total RNA (20pg) was extracted from fibroblasts cultured in DMEM 
containing 10% dFBS (lane 1), or in BBSS containing 10% dFBS (lanes 2-4) for 
the times indicated. Northern analysis was performed and the upper panel shows 
the blot probed with a B2 gene; the lower panel shows the same blot that has been 
stripped and re-probed with the ARPP PO gene.
(B) Levels o f the B2 transcript were quantified by densitometry and normalised 
against the ARPP PO signal. The graph shows the mean and standard deviations 
from three independent experiments; values obtained for cells grown in DMEM + 
10% dFBS were set as 100 and other values were calculated as a percentage of 
this.
(C) Extracts (50pg) were prepared from cells grown in culture as in (A) and 
western analysis performed with antibodies against S6K1 phosphorylated at 
Thr389 (upper-panel), S6K1 (middle panel) and 4E-BP1 (lower panel) over the 
time points indicated. Blots are representative of at least three independent 
experiments.
* denotes statistically significant difference from control, at p < 0.05
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The effect of addition of amino acids to nutrient-deprived fibroblasts was also investigated. 
Overnight serum starvation was followed by amino acid starvation (except lanel) for 1 hr 
and then different media treatments for 2hrs. Withdrawal of amino acids from serum- 
starved cells did not effect pol III transcription in A31 cells (Fig. 3.14, compare lanes 1 and 
2 ), yet addition o f essential amino acids to amino acid starved cells produced a stimulation 
of B2 levels (1.5-fold; Fig. 3.14B, lanes 3 and 4) either by addition of DMEM or 1 x amino 
acids. Exposure of amino acid-starved cells to dialysed serum yielded an increase in pol III 
transcription, albeit incomplete (2-fold; Fig. 3.14B, lane 5), suggesting autophagy may 
play a role in salvaging amino acids in cells. However, the addition of amino acids 
together with dialysed serum produces the greatest pol III response (3-fold; Fig. 3.14B, 
lanes 6  and 7 ).
To determine whether changes occurred to the key components of the pol III 
transcriptional apparatus, in response to amino acid deprivation, the effect of this on levels 
of TFIIIB and TFIIIC subunits was investigated. Western blot analysis shows no change in 
the levels of Bdpl, Brfl and TBP up to 6 hi's of amino acid deprivation (Fig. 3.15A). 
Similarly, no change in the abundance of the TFIIIC subunits; TFIIIC220, TFIIIC 110, 
TFIIIC 102, TFIIIC90 or TFIIIC63 is detected (Fig. 3.15B) when these cells were deprived 
of amino acids, suggesting that this repression of pol III transcription is not due to limited 
availability of these transcription factors. These preliminary experiments show that pol III 
transcription is sensitive to the availability of amino acids.
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Fig 3.14 : Pol III transcription is up regulated in response to amino acids
(A) Serum starved A31 fibroblasts were amino acid starved for 1 hr (lanes 2-7), then 
DMEM (lanes 3 and 7), a 1 X stock of amino acids (Lanes 4 and 6 ), or no amino 
acid stock (lanes 1, 2,  3 , 5  and 7) was added and the cells were incubated with 
(lanes 5,6 and 7) or without (lanes 1 - 4 )  10% dFBS for 2 hrs. Total RNA was 
extracted and Northern analysis performed using the B2 and ARPP PO probes.
(B) Analysis and representation of transcript levels from three independent 
experiments, +/-standard deviation. Where lane 1 is designated 1 and other values 
are calculated as a fold increase o f this.
* denotes statistically significant difference from control, at p < 0.05
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Figure 3.15 : Decrease in pol III transcription in amino acid deprived cells 
is not due to reduced TFIIIB, TFIIIC or pol III levels.
(A) Extracts (50pg) prepared from cells cultured in either DMEM containing 
10% dFBS (lanes 1, 3 and 5) or 1 X PBS containing 10% dFBS ( lanes 2, 4 
and 6) were resolved by SDS-PAGE and analysed by western blotting with 
antibodies against the TFIIIB subunits; Bdpl (upper panel), Brfl (second 
panel) and TBP (third panel) or in (B) with antibodies against the TFIIIC 
subunits; TFIIIC220 (upper panel) TFIIICllO (second panel),TFIIICI02 
(third panel) TFIIIC90 (fourth panel) and TFIIIC63 (fifth panel) over the time 
points indicated. Actin was used as a loading control in each case (A; fourth 
panel, B; sixth panel). Blots are representative of at least three independent 
experiments.
(C) Extracts (50pg) were prepared from cells cultured in either DMEM 
containing 10% dFBS (lanes 1, 3 and 5) or 1 X PBS containing 10% dFBS ( 
lanes 2, 4 and 6) for the times indicated. Samples were subjected to SDS- 
PAGE analysis and immunoblotted with antibodies to RPC 155 (upper panel) 
or RPC 53 (lower panel). Blots are representative of two independent 
experiments.
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3.3 Discussion
These data suggest that serum induces an immediate increase in pol III transcription that is 
regulated, in part, by the mTOR and PI3K signalling cascades. Specific inhibitors of the 
mTOR and PI3K pathways can reduce pol III transcription within 2 lirs. Inactivation of the 
mTOR pathway induces a down-regulation in the levels of 5S rRNA and tRNA transcripts 
as demonstrated by RT- PCR. Primer extension analysis showed that increased signalling 
through the PI3K and mTOR pathways can increase pol III transcription. Conversely, 
direct inhibition of the mTOR and PI3K pathways, using a peptide substrate inhibitor 
shows a concentration-dependent decrease in pol III activity. Signalling through mTOR 
and PI3K contributes to pol III transcription in asynchronous cells and these effects occur 
without effect on the abundance of the pol III transcription factors TFIIIB or TFIIIC. 
Furthermore, we find that pol III transcription is sensitive to amino acid availability and 
that serum-starved fibroblasts respond to addition of amino acids by quickly up-regulating 
pol III transcription.
Increased protein synthesis is one of the major anabolic events required for the growth 
response (Kozma and Thomas, 2002). Since the output of pol I is concerned exclusively 
with protein synthesis and much of the output of pol III (tRNA and 5S rRNA) is required 
for the same purpose, it has been found that the two systems are usually co-ordinately 
regulated (White, 2004b). Interestingly, a functional TOR pathway is required for the co­
ordinate regulation of transcription by both pol I and pol III. This was demonstrated by the 
fact that synthesis of pre-rRNA by pol I and tRNA and 5S rRNA by pol III (Majahan, 
1994; Zaragoza et aL, 1998; Powers and Walter, 1999) can be inhibited by rapamycin. 
Recent studies in mammalian cells have identified putative targets of repression by 
rapamycin in the pol I system (Hannan et aL, 2003; Mayer et aï., 2004), however, 
relatively little is published about the regulation of pol III by the mTOR pathway.
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Evidence is provided here that pol III transcription is under the control of the mTOR 
signalling pathway, which is in agreement with previous work in mammals and yeast 
(Majahan, 1994; Zaragoza et aL, 1998; Powers and Walter, 1999). This along with data 
from pol I regulation (Stefanovsky et aL, 2001, Zhao et aL, 2003; James and Zomerdijk, 
2004) demonstrates further the existence of a direct link between growth factor signalling 
and ribosome biogenesis in mammals.
Other kinases have been found to regulate pol III transcription. Specifically, a link between 
a rapid growth factor signalling pathway and the regulation of pol III transcription was 
recently reported by Felton-Edkins and co-workers. This demonstrated that ERK mitogen- 
activated protein kinases stimulate the assembly of pol III transcription complexes in 
mammals (Felton-Edkins et aL, 2003a). Specifically, control of pol III activity was found 
to be through the direct binding and phosphorylation of a subunit of TFIIIB (discussed 
further in Chapter four) (Felton-Edkins et al, 2003a). Previous reports had also shown that 
the highly conserved protein kinase CK2 regulates pol III transcription via an interaction 
with TFIIIB. In S. cerevisiae CK2 was found to phosphorylate the TBP component of 
TFIIIB in vitro whereas all three human TFIIIB subunits could be phosphorylated directly 
by CK2 in vitro (Ghavidel and Schultz, 1997; Ghavidel et aL, 1999; Johnston et aL, 2002). 
Since CK2 is known to form part of the Wnt signalling pathway in Drosophila and 
mammals (Song et aL, 2000; Willert et aL, 1997) and is required for the proliferation of 
yeast, worm and mammalian cells (Ghavidel and Shultz, 2001), then these earlier reports 
provide evidence of the regulation of pol III transcription by a growth signalling pathway.
Northern analysis showed that substantial inhibition of pol III transcription occurred when 
serum-starved cells were exposed to LY294002 or rapamycin overnight (Fig. 3.3). 
However, LY294002 treatment reduced B2 transcript levels 10% more than rapamycin 
treatment. This further reduction of pol III transcription may occur via the inhibition of
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another signalling pathway by LY294002, as it is known that PI3K lies upstream of a 
number of signalling pathways including the MAPK ERK pathway. Interestingly, 
LY294002 has also been reported to block CK2 activity (Davies et aL, 2000) so the 
negative effects on pol III transcription may occur due to inliibition of CK2, a known 
positive regulator of pol III (Ghavidel and Schultz, 1997; Ghavidel et aL, 1999; Johnston et 
aL, 2002). When cells were exposed to a combination of LY294002 and rapamycin there 
was a further reduction in the levels of B2 pol III transcript, relative to when either drug 
was added alone. The effect is not additive, but the combination of drugs show a more 
complete inhibition of pol III transcription than inhibition o f either the PI3K and mTOR 
pathway alone.
Whilst the Northern and in vitro transcription data both indicate that the mTOR pathway 
controls pol III transcription, the inhibition of pol III appears to have occurred much more 
quickly in the in vitro transcription assay. The Northern analysis ascertains the levels of B2 
at the time the cells are harvested. Whilst B2 provides a reliable indication of 
transcriptional output due to its short half-life, the RNAs inevitably will be present after 
inhibition of pol III has occurred. In contrast, an in vitro transcription assay allows the 
direct activity o f the transcription machinery to be determined in the extracts at a specific 
time point on a naked template. As the two methods assay different aspects of pol III 
regulation, this may explain the difference in the time frame of rapamycin inhibition.
RT-PCR analysis showed that substantial decreases in tRNA^^" and tRNA^ *^^  occurred after 
exposure to rapamycin or LY294002 for only 6 hrs (Fig 3.7). Since these primers hybridise 
to the introns within unprocessed tRNA precursors, then these short-lived primary 
transcripts are spliced very rapidly. Consequently, their levels provide a reliable indication 
of ongoing transcription in a cell (Winter et aL, 2000); indicating that type II promoters are 
sensitive to rapamycin and LY294002 treatment. It was interesting to note that whilst
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inhibition of the mTOR and PI3K pathways decreased the RNA levels of both type I (5S 
rRNA) and type II (tRNA) pol III promoters, levels of the type III promoter (U6 ), 
remained unchanged throughout the time course (Fig. 3.7). As type III promoters do not 
utilise the TFIIIB component Brfl for promoter recognition or the same form of TFIIIC as 
the other promoter types, this may implicate Brfl or TFIIIC as targets of the PI3K and/or 
mTOR pathways.
PKB has been placed unequivocally upstream of mTOR as a result of several studies in 
Drosophila (Gingras et al, 1998; Verdu et a l,  1999; Scanga et al. 2001; Lizcano et al, 
2003; Miron et al, 2003) and in mice (Peng et al, 2003). PKB has emerged as a critical 
mediator of mTOR activity. This is demonstrated by the fact that growth factors inactivate 
TSCl/2 through the activation of PKB resulting in TSC2 phosphorylation in both 
mammalian and Drosophila cells (Dan et al, 2002; Inoki et al, 2002; Manning et al, 2002; 
Potter et al., 2002). This inactivation is considered a critical step in the phosphorylation of 
S6K1 and 4E-BP1. When a competitive substrate inhibitor of PKB was used in an in vitro 
transcription assay it reduced VAl transcription in a dose-dependent manner (Fig. 3.8). 
Without PKB phosphorylation, TSC2 is no longer phosphorylated, so no inhibition of the 
TSC tumour suppressor complex occurs and mTOR signalling cannot be potentiated. 
Therefore, this result suggests that active mTOR is required for pol III transcription.
It was possible that the inhibition of pol III transcription which occurred when the mTOR 
and PI3K pathways were blocked was due to a change in transcription factor abundance. 
Previous reports have demonstrated that pol III transcription factor levels do change under 
certain circumstances, for example fibroblasts transformed with polyomavirus or simian 
virus 40 have abnormally active pol III activity and over-express Bdpl at both the mRNA 
and protein level (Felton-Edkins and White, 2002), and elevated TBP levels have been 
found in colon tumours (Johnson et aL, 2003). However, the results presented here show
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that inhibition of the mTOR and PI3K pathways does not result in changes in the 
abundance of the pol III transcription factors TFIIIB or TFIIIC (Fig 3.9 and 3.11). 
Potentially, changes in the activity of one or several of these components could have 
occurred through post-translational modifications; therefore, further investigation into this 
control could involve looking at the phosphorylation status of TFIIIB and TFIIIC, as it has 
been shown that these factors require phosphorylation to be activated (Hoeffler et al, 1998, 
Felton-Edkins et al., 2003a).
Transcription by pol III inevitably requires the presence and activity of the polymerase, 
therefore, the levels of two of the pol III subunits and the activity of the enzyme were 
analysed in cells which had been treated with rapamycin or LY294002. The abundance of 
the pol III subunits does not vary when the mTOR or PI3K pathways are blocked (Fig. 
3.10A and Fig. 3.12A); therefore it is unlikely that lack of pol III is responsible for de­
regulating pol III output in response to rapamycin or LY294002 treatment. Although we 
were unable to determine levels of all pol III subunits, from the available evidence changes 
in these are also unlikely to explain these results. Just as the abundance of subunits does 
not alter, neither does the activity of the polymerase in cells where the mTOR or PI3K 
pathways have been blocked (Fig. 3.1 OB and Fig. 3.12B). Despite the finding that the 
activity o f the polymerase does not change, its ability to transcribe pol III products does 
(Fig. 3.5-3.8). Therefore, this result provides further support to the hypothesis that 
regulation of the pol III transcription by the mTOR and FI3K pathways may occur through 
changes in the activity of the pol III transcription factors.
It has long been known that nutrients, especially branched chain amino acids, can regulate 
rates of protein synthesis in animal cells. However, more recently it has become clear that 
they can do so directly (i.e. the effect is not mediated by hormones such as insulin) and that 
this involves a signalling pathway implicated in controlling the cell cycle and cell size. The
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TOR signalling pathway has been found to couple nutrient availability with cell growth in 
S. cerevisiae, D. melanogaster and mammalian cells (Raught et aL, 2001; Rohde et aL, 
2001; Schmelzle and Hall, 2000). This control was determined through controlling the rate 
of translation in response to energy and amino acids (Rohde et aL, 2001). Furthermore, 
mammalian cells in culture exhibit an inhibition of overall protein synthesis with depletion 
of amino acids which is rapidly reversible upon addition of amino acids (Hara et aL, 1998). 
A31 mouse fibroblasts deprived of amino acids for 2, 4, and 6  hrs showed that the 
phosphorylation status of S6K1 and 4E-BP1 is affected by the absence of amino acids (Fig. 
3.13C ), confirming these previous studies. Additionally, we find that pol III transcription 
is sensitive to amino acid availability and a 20% decrease is observed within 2 hrs (Fig 
3.13B).
A major mechanism for degrading intracellular proteins in response to amino acid 
deprivation is autophagy. Autophagy is a major source of endogenous amino acids for 
gluconeogenesis and other critical pathways early in starvation (Shigemitsu et aL, 1999). A 
large increase in levels of B2 RNA occurred when dialysed serum was added back in the 
absence of amino acids (Fig. 3.14, lane 5); this effect could only be possible if autophagy 
had occurred, as the extracellular levels of amino acids have been depleted. By far the 
biggest increase in pol III transcription occurred when both serum and amino acids were 
added back together (Fig. 3.14, lane 6  and lane 7), indicating that the full response of pol 
III transcription to serum depends on both the availability of amino acids and serum. 
Insulin like growth factor-1 (IGF-1) induction of pol I transcription in HEK293 cells is 
dependent on PI3K activity and is modulated by mTOR, which coordinates pol I 
transcription with availability of amino acids (James and Zomerdijk, 2004).
To further investigate whether the response of pol III transcription to serum is dependent 
on the availability of amino acids, then an inhibitor of autophagy must be included in the
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experiment. To verify if amino acid stimulation is dependent on the activities of PI3K and 
mTOR, these inhibitors could be included in the amino acid add-back experiment. 
Although PI3K activity is still required for the activation of rapamycin-resistant mutants 
(Dennis et aL, 1996), this role of PI3K in the pol III response to amino acid availability 
was not investigated due to time constraints. As mTOR is widely regarded as an integrator 
of both the response to growth factors and the amino acid sensing mechanisms, a pathway 
involving this kinase may be involved in regulating pol III transcription in response to 
amino acid availability.
It can be concluded from the experimental data presented in this Chapter that pol III 
transcription is under the control of the PI3K and mTOR pathways. The following Chapter 
investigates the possible mechanisms by which the mTOR pathway (in particular), can 
achieve this control. Regulation of TFIIIB and TFIIIC via phosphorylation has already 
been identified as an important mechanism (Hoeffler et al, 1998, Felton-Edkins et aL, 
2003a), so this was further studied. RB, c-MYC and ERK will also be investigated to find 
if the mTOR pathway exerts its effect tlirough these known regulators of pol III 
transcription.
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Chapter 4
Investigation of the Mechanisms that 
Regulate Pol III Transcription via the
mTOR Pathway
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4.1 Introduction
4.1.1 Pol III regulation by RB
The data presented in Chapter 3 show that specific inhibitors of the mTOR and PÏ3K 
pathways reduce pol III transcription, and this occurs without influencing the abundance of 
TFIIIB, TFIIIC or pol III subunits, and without changes in the activity of pol IIL There are 
a number of known regulators of pol III transcription. This Chapter considers whether any 
of these may be influenced by blocking the mTOR signalling pathway or whether there 
may be an effect independent of the existing known mechanisms.
RB was the first tumour suppressor gene to be identified and characterised (Friend et aL, 
1986) and inactivation of RB is associated with a significant proportion of human cancers. 
These include; familial retinoblastoma, osteosarcomas, small-cell lung, cervical, prostate 
and breast carcinomas, and some forms of leukaemias (Sellers and Kaelin, 1997). Studies 
of the retinoblastoma gene have shown that its protein product acts to restrict cell 
proliferation, inhibit apoptosis and promote cell differentiation (Morris and Dyson, 2001). 
It does this by binding to and regulating a number of transcription factors (Morris and 
Dyson, 2001). One example of this control is the regulation of a pol Ill-specific factor 
TFIIIB. RB was originally found to repress pol III activity both in vitro and in vivo, as 
determined by in vitro transcription assays and transient transfection assays (White et aL, 
1996). It was discovered that the amino acids 379-928 of RB provide this activity and 
mutations in the pocket domain of RB inhibit the effect (Sutcliffe et aL, 1999). It is this 
portion of RB that was found to bind and inhibit the Brfl component of TFIIIB (Larminie 
et aL, 1997; Sutcliffe et aL, 2000). During the cell cycle maximum pol III activity occurs 
in late G1 when RB is phosphorylated and inactivated by cyclin-dependent kinases 
(Larminie et aL, 1997; Scott et aL, 2001). The importance of RB in regulating pol III
transcription is highlighted in RB-knockout mice which are substantially compromised in
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their ability to suppress pol III transcription when serum is withdrawn (Scott et aL, 2001). 
The RB-related pocket protein p i30 also binds TFIIIB during the GO and early G1 phases, 
contributing to its repression in serum-starved cells (Sutcliffe et aL, 1999; Scott et al., 
2001).
4.1.2 The MAP Kinase ERK pathway regulates pol I and III 
transcription
Whilst RB and p i30 undoubtedly play major roles in growth factor sensitivity of pol III 
transcription in mammalian cells, some stimulation of pol III transcription has been 
observed prior to the phosphorylation of RB (Johnson et aL, 1974; Mauck and Green, 
1974; Scott et aL, 2001; Felton-Edkins et aL, 2003a). This suggests that other regulatory 
mechanisms contribute to the mitogenic response. This immediate rise in pol III 
transcription, as discussed above, occurs within minutes of serum addition to growth- 
arrested fibroblasts (Felton-Edkins et aL, 2003a; Figure 3.2). Similar results have been 
reported in the regulation of pol I transcription in response to mitogenic stimuli. The pol I 
transcription factor UBF was found to be phosphorylated in response to growth factors by 
the MAP kinases ERKl and ERK2 (Stefanovsky et aL, 2001). The immediate early 
response of pol I transcription (Stefanovsky et aL, 2001) was found to coincide with an 
initial increase in pol III activity (Felton-Edkins et aL, 2003a; Scott et aL, 2001). A more 
recent report disputes that UBF is the target of ERK signalling and proposes that TIFIA is 
targeted by MAPK in vivo (Zhao et aL, 2003). Regardless of the pol I target, the co­
ordinate response of both pol I and pol III to increase production of rRNAs and tRNAs 
provides a key control point for the regulation of growth and hence proliferation. This is 
due to their critical role in determining ribosome production, where equimolar amounts of 
the ribosomal proteins 28S, 18S, 5.8S and 5S are required (Nomura, 1999; Warner, 1999; 
Brown et aL, 2000).
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Whilst the role of the ERK signalling pathway was determined in the pol I system, its role 
in the regulation of pol III transcription was not elucidated until recently. ERK was found 
to activate pol III transcription by binding and phosphorylating the Brfl subunit of TFIIIB 
(Felton-Edkins et al., 2003a). Subsequently, serum induction of pol III transcription can be 
compromised when substitutions of the ERK docking domain or phospho-acceptor sites in 
Brfl are made. ChIP analysis showed that treatment of cells with a specific inhibitor of 
MEK (the ERK activating kinase), impairs promoter occupancy of Brfl and pol III at 
tRNA and 5S rRNA genes. This finding suggests that the MAP Kinase signalling pathway 
is required for normal pre-initiation complex assembly on pol III templates, thus linking 
growth factor signalling with pol III activation.
4.1.3 Regulation of pol III transcription by c~Myc
The c-Myc gene was discovered as the cellular homologue of the retroviral v-myc gene 20 
years ago (Sheiness et al., 1978; Bishop, 1982). The Myc family members were 
subsequently considered to be proto-oncogenes, since alterations in their expression play 
an important, if not essential, role in the development of various animal and human 
tumours (Dang, 1999). The c-Myc protein contains a basic helix-loop-helix leucine-zipper 
transcription factor that can act as both a transcriptional activator and repressor (Grandori 
et aL, 2000). The role of Myc in transcription was made more obvious through the 
identification of a dimérisation partner called Max (Blackwood and Eisenman, 1991; 
Blackwood et aL, 1992). Max is the essential heterodimer partner of Myc proteins and 
together they are involved in regulating various biological activities including cell 
proliferation, apoptosis and differentiation (Amati et aL, 1992; Oster et aL, 2002).
c-Myc has been reported to regulate the expression of several pol Ill-specific genes 
(Gomez-Roman et aL, 2003). The pol III transcription factor TFIIIB is targeted by c-Myc,
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and this appears to be through protein-protein interactions rather than through direct DNA 
recognition by c-Myc (Gomez-Roman et aL, 2003). Chromatin immunoprécipitation 
assays revealed the presence of c-Myc at tRNA and 5S rRNA genes in untransformed 
fibroblasts, ovarian epithelial cells (Gomez-Roman et aL, 2003) and the transformed 
cervical cell line HeLa (Felton-Edkins et aL, 2003b). Transcription of tRNA and 5S rRNA 
genes can be induced when exogenous c-Myc is introduced into human diploid fibroblasts 
(Gomez-Roman et aL, 2003). Interestingly, specific depletion of endogenous c-Myc from 
HeLa cells using RNA interference (RNAi) results in a marked decrease in expression of 
tRNA and 5S rRNA (Felton-Edkins et aL, 2003b). The profound effect of c-Myc on pol III 
transcription in cells may provide an important component of its growth-promoting 
activity. This may occur by increasing protein synthesis through the targeting of the protein 
synthetic apparatus by c-Myc (Felton-Edkins et aL, 2003b). This hypothesis is consistent 
with studies that show c-Myc target genes include those involved in ribosome biogenesis 
(Oster et aL, 2002; O’Connell et aL, 2003), and the finding that c-Myc can regulate rRNA 
processing (Schlosser et aL, 2003).
In summary, the objectives of this Chapter were to examine the changes in pol III activity 
by proteins known to interact with this machinery in response to blocking the mTOR 
signalling cascade. This should establish whether this pathway regulates pol III via existing 
known mechanisms.
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4.2 Results
4.2.1. Blocking the mTOR and PI3K pathways affects pol III promoter 
occupancy
As discussed in Chapter 1, most genes transcribed by pol III require that TFIIIB is brought 
to the promoter by protein-protein interactions with TFIIIC; in turn, TFIIIB recruits pol III, 
placing it over the start site so that transcription can commence (Paule and White, 2000; 
Geiduschek and Kassavetis, 2001). Therefore, TFIIIB is required to bind both TFIIIC and 
pol III. It was possible that the mTOR and/or PI3K pathways regulate recruitment of pol III 
via targeted inhibition of one or more of the stages involved in pre-initiation complex 
formation. Therefore, promoter occupancy of pol III and its related factors was determined 
in rapamycin- and LY294002-treated cells, to find if blocking the mTOR and/or PI3K 
pathways affected complex assembly at pol III promoters.
Formaldehyde cross-linked soluble clii'omatin was prepared from asynchronously growing 
cells treated for 4 hrs with 50pM LY294002 (Fig. 4.1 A, lanes 1, 4, 7, 10, 13, 16 and 19), 
vehicle (Fig. 4.1 A, lanes 2, 5, 8 , 11, 14, 17 and 20) or lOOnM rapamycin (Fig. 4.1 A, lanes 
3, 6 , 9, 12, 15, 18 and 21). PCR analysis of precipitated DNA showed occupancy of 
TFIIICllO, Brfl and TBP is blocked on 5S rRNA promoters when mTOR or PI3K is 
inactivated. Furthermore, rapamycin and LY294002 decreased promoter-bound pol III. 
Chip analysis also shows that binding of TFIIIC 110, Brfl and TBP and pol III to tRNA^^ '^ 
genes is inhibited by blocking the mTOR and PI3K pathways (Fig. 4 .IB, lanes 5, 6 , 8 , 9, 
11, 12, 14 and 15) compared to vehicle-treated control cells (Fig. 4 .IB, lanes 4, 7, 10, and 
13). The Chip data for tRNA^^" were quantified and show significant decreases in the 
occupancy of TFIIIC, TFIIIB and pol III when the mTOR and PI3K pathways are blocked 
(Fig. 4.1C).
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A and B blocks are found in type II promoters (e.g. tRNAs) and are recognised by the 
multi-subunit complex TFIIIC, where B block binding is the major determinant of binding 
affinity (White, 2001). To test whether the DNA binding ability o f TFIIIC to these 
promoters was affected by rapamycin or LY294002 treatment, a band shift assay was 
performed. Microextracts were made from cells which had been grown in the presence of 
vehicle, rapamycin or LY294002 for 4hrs, Samples were then bound to a radio-labelled B 
block oligonucleotide in the presence of a competitor (Fig. 4. ID, lanes 2-4) or a non­
specific competitor (Fig. 4 .ID, lanes 5-7) whilst it migrated through a non-denaturing gel. 
TFIIIC proteins within the rapamycin and LY294002 extracts displayed increased DNA 
binding compared to the vehicle-treated extracts (Fig. 4 .ID). This increase was quantified 
as a 2-fold increase for LY294002-treated extracts, and a 3-fold increase for rapamycin- 
treated extracts (Fig. 4 .IE). A bandshift assay determines the DNA binding ability of a 
protein, whilst a ChIP measures promoter occupancy and is subject to competing 
influences such as chromatin structure and nucleosome positioning. TFIIIC could be 
passively released or actively displaced due to changes in the mTOR or PI3K pathway that 
result in changes in chromatin structure. Confirmation of such changes has been reported 
during inliibition o f the TOR pathway (Rohde and Cardenas, 2003). These data suggest 
that TOR signalling results in acétylation of histone H4 which alters chromatin 
conformation allowing active transcription of ribosomal proteins; upon rapamycin 
treatment, the clmomatin returns to a repressed state by recruitment of Rpd-Sin3 histone 
deacetylase (Rohde and Cardenas, 2003).
129
TFIIIC
Control Pol III 110 Brfl TBP
Input
1:100
Input
1:50
5S rRNA » # # # # *
1 2 3 4 5 6 7 8 9  101112 13 14 151617 18 19 20 2
B
Control
TFIIIC 
Pol III 110 Brfl TBP
Input
1:200
0)
.Si 2  .Si 2  • -  S ‘- 5
> 0 ^ ^ > P C  ^ > P C ^ > Q C  ^
.Si 2 - - 2"S R ^  "S C8 >4>  Pi ^  >  Qi
tR N A ^^“
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
130
c
I s
6  ^
I I
250 -
200 -c3 150
t 100
ISU3 50
0
tRNA promoter
□  Vehicle
■  Rapamycin
□  LY294002
A ntibody : TFIIICllO Brfl t b p pol III Control 
TFIIB
D
LY294002 : 
Rapamycin :
Vehicle:
Competitor Non-specific 
competitor
TFIIIC
Unbound
probe
Ia
£
3.5
3
U  _  2.5
giII 1.5
I I
Vehicle LY294002 Rapamycin
131
Figure 4.1: mTOR activity is required for pel III promoter occupancy
Asynchronous A31 mouse fibroblasts were treated for 4 hrs with vehicle (lanes 2,5, 8 , 
11, 14, 17 and 20 ), rapamycin (lOOnM; lanes 3, 6 , 9, 12, 15, 18, 21), or LY294002 
(50pM; 1, 4, 7, 10, 13,16 and 19). Association of TFIIICllO, B rfl, TBP and pol III 
subunit RPC 155 with 5S rRNA (A) genes or tRNA^®“ genes (B) was then determined 
by Chip analysis. This involved semi-quantitative PCR of equivalent DNA input 
amounts as determined by PCR on diluted input chromatin. Control ChlPs were carried 
out with TFIIB antibody. PCR reactions incorporated [a-^^P] dCTP and products were 
resolved on denaturing sequencing gels which were subjected to autoradiography. PCR 
products were quantified by densitometry (C). PCR products from three independent 
Chip experiments were quantified for tRNA^®“ genes; after normalisation to the input, 
the mean and standard error of the mean are shown for the drug treated/vehicle treated 
signals.
(D) Cell extracts (15pg) which had been vehicle-treated (lanes 4 and 7), rapamycin- 
treated (lOOnM; lanes 3 and 6 ) or LY294002-treated (50pM; lanes 2 and 5) for 4 hrs 
were used in a band-shift assay. Ing of radiolabelled B-block probe, and 1 pg of 
polydl-dC competitor was added to lanes 1-7. Lane 1 is a control and contained no 
extract. Lanes 2-4 contained 50ng of unlabelled B-block. Values shown in (E) are the 
average of 2  independent experiments +/- the standard error of the mean.
* denotes statistically significant difference from control, at p < 0.05.
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4.2.2. The mTOR pathway controls the interaction of TFIIIB and TFIIIC 
and the interaction of TFIIIB with pol III
TFIIIB is brought to most pol III promoters by protein-protein interactions with TFIIIC; in 
turn, TFIIIB recruits pol III placing it over the start site to allow transcription to commence 
(Paule and White, 2000). Therefore, TFIIIB binds to both TFIIIC and to pol III. To 
investigate whether the mTOR signalling pathway can influence the interaction between 
TFIIIB and TFIIIC, co-immunoprecipitations were carried out in Rati A cells which stably 
over-express pCDNA3HA.Brfl. In asynchronously growing cells, the Brfl component of 
TFIIIB stably associates with TFIIICllO (Fig 4.2 A, lane 1). Rapamycin treatment for 4 hrs 
prevents TFIIIC binding to TFIIIB (Fig 4.2A, lane 2). This was quantified as a 7.6 fold 
reduction in binding (Fig. 4.2B). This effect is specific since immunoprécipitations with 
control antibodies showed no interaction between HA.Brfl and 4E-BP1 (Fig 4.2A, lanes 3 
and 4). Since TFIIIB binds to both TFIIIC and to pol III we were interested to know 
whether the mTOR pathway also regulated the interaction between TFIIIB and pol III. 
RPC53 (a subunit specific to pol III) associates with the Brfl subunit of TFIIIB, in 
asynchronously growing cells (Fig 4.2B, lane 1). Rapamycin blocks the interaction 
between TFIIIB and pol III (Fig 4.2B, lane 2). The binding of TFIIIC and pol III to TFIIIB 
was specific since binding wasn’t observed when an irrelevant control antibody was used 
(Fig 4.2B, lanes 3 and 4). These data suggest an important role for mTOR signalling in the 
regulation of pol III transcription. Having established that rapamycin could inliibit pol III 
transcription via a block to complex assembly, our attention turned to the possible 
mechanism by which this was occuning.
133
A
R apam ycin:
IP: HA
+
10%  Input
H A .Brn=W
TFIIIC  1 1 0 -^
...
I f  'M # # w
J m s .1 2 3 4 5 6
"lOSkDa
"75kDa
-  lO S k D a
B
S î ’,‘ 
Ë  : »
S I -a  X  '■* 
n  '0.5
0
R apam ycin:
*
l J  j
c
R apam ycin: -
IP: H A
X
H A .B rflH >
10%  Input
klOSkDa 
' 75kDa
RPC53=t> — 50kDa
3
134
Figure 4.2 : Inhibition of mTOR compromises binding of TFIIIB to TFIIIC 
and the binding of TFIIIB to pol III
(A) Rati A cells (stably transfected with pCDNASHA.Brfl) were incubated for 
4hrs with vehicle (lanes 1 and 3) or rapamycin (lOOnM; lanes 2 and 4). Cell 
extracts (SOOpg) were immunoprecipitated with anti-HA antibody (lanes 1 and 2) 
or anti"4EBPl antibody as a control (C; lanes 3 and 4 ). Precipitates were resolved 
by SDS-PAGE and immunoblotted with anti-HA antibody (upper panel) or with 
anti-TFIIICllO ( lower panel). Lanes 5 and 6  show 10% input of the cell extracts. 
Results are representative of three independent experiments.
(B) The immunoprécipitations described in (A) was quantified by densitometry 
and values normalised to the input. The graph shows the mean +/- standard 
deviations fi*om three independent experiments. Values are arbitrary. 
* denotes statistically significant difference fi-om control, at p < 0.05
(C) RatlA cells (stably transfected with pCDNA3HA.Brfl) were incubated for 
4hrs with vehicle (lanes 1 and 3) or rapamycin (lOOnM; lanes 2 and 4). Cell 
extracts (500pg) were immunoprecipitated with anti-HA antibody (lanes 1 and 2) 
or anti-4EBPl antibody (c; lanes 3 and 4 ). Precipitates were resolved by SDS- 
PAGE and Western blotted with anti-HA antibody (upper panel) or with anti- 
RPC53 ( lower panel). Lanes 5 and 6  show 10% input of the cell extracts. Results 
are representative of two independent experiments.
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4.2.3. Amino acid and rapamycin-mediated effects on pol III 
transcription are independent of RB
There are several possible mechanisms by which the mTOR pathway could mediate the 
regulation of pol III transcription. One of these is through regulation of the tumour 
suppressor protein RB. RB is phosphorylated and de-phosphorylated in a cell-cycle 
dependent mamier and it is clear that these changes regulate its activity (Morris and Dyson, 
2001). It is known that pol III transcription is sensitive to the phosphorylation status of 
RB, and that TFIIIB interacts with the underphosphorylated form of pRB. In this way, RB 
represses TFIIIB activity and therefore, pol III transcription. Accordingly, TFIIIB is 
released as pRB becomes hyperphosphorylated by cyclin D- and cyclin E- dependent 
kinases at G l/S (Scott et a l, 2001). This de-repression allows TFIIIB to interact with 
TFIIIC2 at the promoter of class III genes, and recruit pol III to these templates (Sutcliffe 
et aL, 2000). There is conflicting evidence to support the effect of rapamycin on the 
phosphorylation of RB and this appears to be cell-type dependent (Chen et al., 1996; 
Muise-Helmericks et ah, 1998; Gaben et ah, 2004). Therefore, we determined in the 3T3 
cells used in this study, whether the effects of this drug on pol III transcription could be 
explained through changes in the phosphorylation status of RB. Extracts were prepared 
from cells incubated with lOOnM rapamycin over time. Little or no change was observed 
in the levels of RB phosphorylated at Ser795 until after Blirs incubation with the inhibitor, 
at which time phosphorylation of RB at this site is reduced (Fig. 4.3). This decrease is not 
due to a reduction in the total levels of RB (Fig. 4.3).
The sensitivity of pol III transcription to amino acid availability (previously described in
Chapter 3), is thought to involve a pathway comprising the TOR kinases. Therefore, it was
possible that this inhibition of pol III transcription that occurs in the absence of amino
acids (Fig. 3.13) was due to changes in the phosphorylation status of RB. Since the effect
of amino acid deprivation on the phosphorylation status of RB is unknown, protein extracts
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Figure 4.3 : Effect of rapamycin treatment on pol III transcription is
independent of RB at times when pol III transcription is reduced
Cell extracts (50 pg) were prepared from asynchronous A31 cells treated in the 
presence of vehicle for 12 hrs (lane 1) or for the various times indicated with 
rapamcyin (lOOnM). Samples were resolved by SDS-PAGE and analysed by 
western blotting with antibodies against total pRB (upper panel), pRB 
phosphorylated at serine 795 (second panel). Blots are representative of more than 
three independent experiments.
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were made from cells cultured in DMEM containing 10% dialysed serum (Fig. 4.4, lanes 1, 
3 and 5) or BBSS containing 10% dialysed serum (which contained no amino acids) (Fig. 
4.4, lanes 2, 4 and 6 ) over a time course. Western analysis shows that RB remained 
phosphorylated at Ser795 thi’oughout the time course, and total levels of RB remain are 
also constant (Fig. 4.4, upper two panels). This suggests that early effects of amino acid 
deprivation on pol III transcription are independent of RB.
The key event that regulates the Gl/S transition is the inactivation of RB via sequential 
phosphorylation by Cdk/cyclin complexes (Sherr, 1996). Regulation of Cdk activity, which 
is crucial for the orderly initiation and progression of the cell division cycle, involves 
modulation of the levels of cyclins and Cdk inhibitors (Morgan, 1995; Sherr and Roberts, 
1995). Subsequently, the levels of the G1 cyclins, cyclin D and cyclin E were investigated 
in amino acid-deprived cells. Western analysis shows that the levels of cyclin E proteins 
are unchanged when the mTOR pathway is blocked for up to 6  hrs; however, levels of 
cyclin D1 decrease after 4 his amino acid deprivation (Fig. 4.4, third and fourth panels). D- 
type cyclins (D l, D2, D3) are expressed sequentially and are induced in response to growth 
factor stimulation (Sherr, 1995). p i 6  is a specific inhibitor of cyclin Dl-dependent kinases 
and, as such, is termed a Cdk inhibitor (CKI). CKIs act stochiometrically, therefore, 
oscillations in their levels can have a profound effect on cell proliferation (Toyoshima and 
Hunter, 1994). Interestingly, western blotting for p i6  shows that its level does not alter 
with up to 6 hrs of amino acid deprivation, and blotting for actin shows that equal amounts 
of protein were in each lane (Fig. 4.4, fifth and sixth panel). Therefore, cyclin Dl 
regulation appears to be independent of p i 6 . The importance of cyclin Dl regulation in the 
amino acid sensitivity of pol III transcription is undetermined but does not appear to 
modulate RB phosphorylation at early time points.
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Figure 4.4 : Effects of amino acid deprivation on pol III transcription 
are independent of RB
Protein cell extracts (50 pg) were prepared from cells grown in DMEM 
containing 10% dialysed FBS (lanes 1, 3 and 5) or EBSS plus 10% dialysed 
FBS and without amino acids (lanes 2, 4 and 6). Samples were resolved by 
SDS-PAGE and analysed by Western blotting with antibodies against RB 
phosphorylated at serine 795 (upper panel), RB (second panel), cyclin E 
(third panel), cyclin Dl (fourth panel), p i6 (fifth panel), or actin (lower 
panel). Blots are representative of more than three independent experiments.
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4.2.4 Rapamycin and LY294002 inhibit pol III transcription independent 
of the effect on proliferation
Although the effects of rapamycin on pol III transcription appear to be independent o f an 
effect on the phosphorylation status of RB, it has previously been shown that this drug 
causes a G1 arrest (Abraham and Weiderrecht, 1996; Zhang et ah, 2000) and that 
expression of a rapamycin-resistant mutant of mTOR alleviates the effect of rapamycin on 
cell cycle progression (Hay and Sonenberg, 2004). We therefore wanted to confirm that the 
observed rapamycin effect is not due to an indirect consequence of regulation of cell cycle 
progression. The ability of rapamycin to inliibit pol III transcription was therefore 
examined in primary cultures of post-mitotic neonatal cardiomyocytes.
Upon stimulation with G q/G ll linked agonists such as phenylephrine (PE), endothelin-1 
(ET-1) and angiotensin II (Ang II), cardiomyocyte size increases, resulting in increased 
mass (growth) of the heart (Proud, 2004). Cardiomyocytes do not proliferate or undergo 
DNA synthesis in response to growth factor stimulation but instead undergo hypertrophic 
growth (Chien et al., 1991). Increased protein synthesis is a key feature of cardiac 
hypertrophy and probably underlies the increased cell and organ size observed under this 
condition (Hannan, 2003). Several signalling pathways have been implicated in cardiac 
hypertrophy including those involving PI3K (Wang et a l,  2001; Wang et a l, 2002; Tee et 
a l,  2003a).
Primary cultures of rat neonatal cardiomyocytes were cultured in 10% serum-containing
medium (Fig. 4.5A, lanes 3 and 4) or serum-free medium (Fig 4.5A, lanes 1 and 2), for
16hrs. Cells were then incubated in the presence (Fig. 4.5A, lanes 2 and 4) or absence of
rapamycin (lOOnM; Fig. 4.5A, lanes 1 and 3) for 16hrs and RNA was extracted. Northern
analysis was performed and shows that levels of the pol III transcript B2 increase upon
serum stimulation and this increase can be blocked by rapamycin treatment, whereas
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Figure 4.5: The effects of the mTOR and PI3K signalling pathways on pol III 
transcription are independent of cell cycle.
(A) Primary cultures of rat neonatal cardiomyocytes were grown in 10% PCS (lanes3 
and 4) or were serum-starved (lanes 1 and 2) for 16hrs. This was carried out in the 
presence of either vehicle (lanes 1 and 3), or rapamycin (lOOnm; lanes 2 and 4). RNA 
was extracted and Northern analysis was performed using the B2 probe (upper 
panel), the lower panel shows the same blot that has been stripped and re-probed with 
the ARPP PO gene. Experiment (A) was carried out by Fiona Cairns and is 
representative of more than three independent experiments.
(B) Primary cultures of rat neonatal cardiomyocytes were treated for 16hrs with 
serum to induce hypertrophic growth. The cells were also incubated with either 
vehicle (lanes land 4), LY294002 (50pM; lanes 2 and 5) or rapamycin (100nM;lanes 
3 and 6 ) for 4 hrs (lanes 1-3) or 16hrs (lanes 4-6). RNA was extracted and Northern 
analysis was performed using the B2 probe (upper panel), the lower panel shows the 
same blot that has been stripped and re-probed with ARPP PO.
(C) The B2 signals from vehicle, LY294002 and rapamycin treated cells as shown in 
(B) were quantified by densitometry and normalised against the ARPP PO signal. The 
graph shows means +/- the standard deviations from three independent experiments; 
values obtained for cells grown in serum for either 4 hrs or 16hrs were set as 100 and 
other values were calculated as a percentage of this.
* denotes statistically significant difference from control, at p < 0.05
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rapamycin treatment has only a slight reduction in the levels of B2 when cells are cultured 
in serum-free medium (Fig. 4.5 A). This effect is specific, since levels of the ARPP PO 
transcript are unchanged (Fig. 4.5A). To compare the effects of blocking the PI3K and 
mTOR pathway on pol III transcription during hypertrophy in cardiomyocytes, primary 
cultures of rat neonatal cardiomyocytes were serum-stimulated for 4hrs or 16hrs, with or 
without vehicle, rapamycin (lOOnM) or LY294002 (50gM) and RNA was extracted. 
Levels o f the pol III transcript B2 was reduced by 40% or 50% when exposed to rapamycin 
for 4hrs and 16hrs, respectively (Fig 4.5B and C). By 41irs, the drug LY294002 reduces 
levels of B2 by 70%, compared to untreated myocytes and this 70% reduction is 
maintained up to 16 hrs of LY294002 exposure (Fig 4.5B and C). Thus, the ability of 
mTOR to regulate pol III transcription is independent of its effects on cell cycle. This is 
consistent with the evidence that mTOR-dependent growth of fibroblasts continues despite 
a blockade of cell cycle progression (Fingar et a i, 2002).
4.2.5. Amino acid and rapamycin-mediated effects on pol III 
transcription are independent of ERK and c-Myc
Another known regulator of pol III transcription in serum-stimulated cells includes the 
ERK mitogen-activated protein kinase. Some reports have implicated a connection 
between the MAPK and mTOR signalling pathways (Wang et a l,  2001; Wang et al, 2002; 
Tee et al,, 2003a). In adult cardiomyocytes the GPCR agonists PE and ET-1 were shown to 
activate S6K1 and 2 and inactivate 4EBP1. These effects can be bloeked by inhibition of 
the ERK and mTOR pathways, but are independent of PI3K signalling (Wang et al., 2001; 
Wang et al., 2002). In addition, the phosphorylation and inactivation of TSC2 (an upstream 
regulator of mTOR) has also been shown to occur via a PI3K-independent mechanism that 
possibly involves MEK-regulated pathways (Tee et al., 2003a), which provides further 
support for comiections between MEK/ERK and mTOR signalling. Consequently, the
decrease in pol III activity observed during amino acid deprivation or rapamycin treatment 
is potentially due to inhibition of the ERK pathway. Recent work has shown that ERK in 
its active forms can interact with and phosphorylate the Brfl subunit of TFIIIB in vitro and 
in vivo, thus activating pol III transcription (Felton-Edkins et al,, 2003a). It is possible that 
treatment of cells with rapamycin or amino acid deprivation could be blocking ERK 
activation through cross talk of the mTOR and ERK pathways. To this end, the 
phosphorylation status of the p42 and p44 isoforms of ERK was measured during a 
rapamycin time course and the effect of amino acid deprivation was also investigated. 
Protein extracts were made from cells cultured in DMEM containing 10% serum and 
lOOnM rapamycin over a time course. Western analysis shows that there is no effect of 
rapamycin treatment on ERK phosphorylation for up to 12hrs, and that total levels of ERK 
remained unchanged (Fig 4.6A, first and second panels). Actin is used as a loading control 
to show equal protein levels throughout (Fig. 4.6A, lower panel). Similarly, protein 
extracts made from cells cultured in DMEM containing 10% dialysed serum (Fig. 4.6B, 
lanes 1, 3 and 5) or EBSS containing 10% dialysed serum (Fig. 4.6, lanes 2 , 4 and 6 ) over a 
time course. Amino acid deprivation does not affect the abundance or phosphorylation of 
ERK (Fig. 4.6).
The proto-oncogene c-Myc has also recently been discovered as a regulator of pol III 
transcription (Felton-Edkins et ah, 2003b; Gomez-Roman et al., 2003). c-Mye has the 
potent capacity to stimulate cell growth (Dang, 1999; Schmidt, 1999). Indeed, in some 
instances, c-Myc has been found to drive protein synthesis and growth independently of 
cell cycle progression (Schuhmacher et al., 1999; Kim et al., 2000). It follows that lack of 
c-Myc results in diminished growth and protein synthesis (Schmidt, 1999; Johnston et al., 
1999). In human cells, the translation of c-Myc is cap-dependent and is suppressed by 
rapamycin (Hosoi et al., 1998; Gera et al., 2003). The mechanism appears to be through a 
shift of c-Myc RNA from the polysomal fraction to the transiationally inactive pool (Gera
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Figure 4.6 : Effects of rapamycin treatment on pol III activity are independent 
of ERK signalling
(A) Protein cell extracts (50|ig) were prepared from cells grown in DMEM plus 
10% serum for 12hrs (lane 1) or for the various times indicated with rapamycin 
(lOOnM). Samples were resolved by SDS-PAGE and analysed by western blotting 
with antibodies against ERK 42 and 44kDa isoforms (upper panel) or total ERK 
(middle panel). Actin was used as a loading control (lower panel).Blots are 
representative of more than three independent experiments.
(B) Protein cell extracts (50 pg) were prepared from cells grown in DMEM and 
containing 10% dialysed FBS (lanes 1, 3 and 5) or EBSS plus 10% dialysed FBS 
(lanes 2, 4 and 6). Samples were resolved by SDS-PAGE and analysed by western 
blotting with antibodies to p42 and p44 isoforms of ERK (upper panel), or total 
ERK (second panel). Blots are representative of more than three independent 
experiments. 145
et ah, 2003). Since withdrawal of amino acids mimics rapamycin treatment, both 
rapamycin exposure and amino acid deprivation could potentially cause a decrease in 
levels of c-Myc.
Extracts of cells grown in the presence of rapamycin (lOOnM) were prepared for Western 
analysis. Protein levels of c-Myc are substantially decreased after 6 hrs exposure to 
rapamycin (Fig. 4.7A, upper panel). The effect is specific, since levels of actin are constant 
(Fig. 4.7, lower panel). Cells extracts grown in DMEM containing 10% dialysed serum 
(Fig. 4.7B, lanes 1 ,3 ,5  and 7) or EBSS containing 10% dialysed serum (Fig. 4.7B, lanes 2, 
4, 6  and 8 ) were harvested for protein. Subsequent immunoblotting shows levels of c-Myc 
decrease by 8 hrs in the absence of amino acids (Fig 4.7B upper panel). Thus, the effects of 
rapamycin on pol III transcription cannot be explained tluough changes in the abundance 
of c-Myc or phosphorylation of ERK.
4.2.6. Phosphorylation of TFIIIB and TFIIIC is due in part to the mTOR 
signalling pathway
Previous results have shown that inhibition of the mTOR pathway does not result in
changes in the abundance of the pol III transcription factors TFIIIB or TFIIIC (Fig. 3.9),
However, changes in the activity to one or several of these components could have
occurred through a post-translational modification, such as phosphorylation. In fact, it has
already been shown that TFIIIB and TFIIIC require phosphorylation to be activated
(Hoeffler et al., 1998, Felton-Edkins et al., 2003a). In addition, mutating an ERK
phosphorylation site on Brfl reduces serum-stimulated pol III transcription, indicating that
phosphorylation of this subunit is required for maximal activity (Felton-Edkins et ah,
2003a). Therefore, we investigated whether the phosphorylation status of TFIIIB and
TFIIIC changes in response to rapamycin treatment.
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Figure 4.7 : Effects of amino acid deprivation on pol III transcription are 
independent of c-Myc
(A) Protein cell extracts (50pg) were prepared from cells grown in DMEM 
containing 10% FBS, for 12hrs (lane 1) or for the various times indicated with 
rapamycin (lOOnM; lanes 2-6). Samples were resolved by SDS-PAGE and 
analysed by Western blotting with antibodies against c-Myc (upper panel) or actin 
(lower panel) as a loading control. Blots are representative of at least three 
independent experiments.
(B) Protein cell extracts (50 pg) were prepared from cells grown in DMEM and 
10% dialysed FBS (lanes 1, 3 and 5) or EBSS plus dialysed FBS (lanes 2, 4 and 6) 
were resolved by SDS-PAGE and analysed by Western blotting with antibodies 
for c-Myc (upper panel) or actin (lower panel). Blots are representative of at least 
three independent experiments.
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CCL39 fibroblasts were transfected for 48hrs with pCDNA3HA.Brfl and transferred to 
phosphate-free DMEM with 250pCi/ml [^^P] orthophosphate for 3hrs. This was carried out 
in asynchronously growing cells or those that were starved of serum for the final 16hrs of 
transfection. Extracts were immunoprecipitated using an HA antibody, run on SDS-PAGE 
gels and either subjected to autoradiogaphy or immunoblotted for HA. Phosphorylation of 
Brfl increased significantly in the presence of serum (Fig. 4.8A, upper panel); this effect 
was not due to decreased levels of Brfl in the serum-free media (Fig. 4.8A, lower panel). 
To establish whether the mTOR pathway blocks the phosphorylation of Brfl growing cells 
were labelled with [^^P] orthophosphate, similar to the previous experiment but this time in 
the presence or absence of rapamycin. Rapamycin was found to decrease the 
phosphorylation of Brfl by 30% (Fig. 4.8B and C). This effect is not due to changes in the 
abundance of the protein since overall levels of Brfl were not affected by rapamycin 
treatment (Fig. 4.8B, lower panel).
To investigate whether the TFIIIC subunit TFIIICllO was phosphorylated in response to 
serum, asynchronously growing cells were transferred to phosphate-free media, and 
incubated for 3hrs with [^^P] orthophosphate in the presence or absence of serum. Extracts 
were immunoprecipitated with an antibody for TFIIICllO, and after SDS-PAGE analysis 
either exposed to film or immunoblotted for TFIIICllO. Phosphorylation of TFIIICllO 
increased significantly in the presence of serum (Fig. 4.9A, upper panel) whilst 
immunoprecipitated levels of TFIIICllO were only slightly decreased in the serum-free 
media (Fig. 4.9A, lower panel). To test whether TFIIIC 110 phosphorylation was sensitive 
to rapamycin treatment, cells growing in a medium containing 1 0% serum were transfected 
with the construct pCDNA3HA.TFIIIC110. Cells were transferred to phosphate-free 
media 481irs later, and incubated for 3hrs with [^^P] orthophosphate in the presence or 
absence of rapamycin (lOOnM). Extracts were immunoprecipitated with HA antibody, run 
on SDS-PAGE gels and either subject to autoradiogaphy or immunoblotted for HA.
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Figure 4.8: Phosphorylation of B rfl is inhibited by blocking the mTOR 
pathway
(A) CCL39 cells transiently transfected with pCDNA3HA.Brflfor 48hrs, were 
labelled with p^P] orthophosphate for 3 hrs. Cells in lane 1 were transferred to 
semm-free medium for 24 hrs prior to labelling. Cell extracts were prepared and 
Brfl was immunoprecipitated with an anti-HA antibody, resolved by SDS-PAGE, 
and either visualised by autoradiography (upper panel), or transferred to PVDF 
membrane followed by Western blotting with HA antibody (lower panel). Results 
are representative o f more than three independent experiments.
(B) CCL39 cells growing in 10% serum were transiently transfected with 
pCDNA3-HA.Brfl (lOpg) and labelled 48 hrs later with p^P] orthophosphate for 3 
hrs in the absence (lane 1) or presence (lane 2) of rapamycin (lOOnM). Cell 
extracts were prepared and Brfl was immunoprecipitated with an anti-HA 
antibody, resolved by SDS-PAGE, and either visualised by autoradiography 
(upper panel) or transferred to PVDF membrane followed by western blotting with 
anti-HA (lower panel).
(C) The phospholabelling result described in (B) was quantified by densitometry 
and values normalised to the immunoprécipitation. The graph shows the mean +/- 
standard deviations from three independent experiments, where the untreated 
sample is 1 0 0 % and the rapamycin treatment is calculated as a percentage of the 
control.
* denotes statistically significant difference from control, at p < 0.05
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Phosphorylation of TFIIICllO significantly decreased during 3hrs rapamycin treatment 
(Fig. 4.9B, upper panel), whilst levels of immunoprecipitated TFIIIC 110 did not alter (Fig. 
4.9B, lower panel). This decrease was quantified as a 75% reduction in phosphorylation of 
TFIIICllO (Fig. 4.9C). The findings that both Brfl and the TFIIICllO subunit of TFIIIC 
were phosphorylated in response to serum, supports previous work in our laboratory (P. 
Scott, unpublished).
4,2.7. Regulation of pol III transcription by mTOR is due in part to 
signalling through S6K1
The implication that the mTOR pathway was involved in controlling the phosphorylation
status of TFIIIB and/or TFIIIC led to the search for an upstream kinase that could mediate
this. Recent evidence has reported that the pol I transcription factor UBF is regulated by an
mTOR pathway (Hamian et al., 2003). They showed that mTOR, via S6K1, can activate
rDNA transcription tlirough phosphorylation of UBF. With this in mind, the regulation of
pol III transcription by mTOR, via S6K1, was examined via primer extension. pCDNAa or
a constitutively active, rapamycin-insensitive mutant of S6 KI (S6KED3E) were
transfected into cells for 481ns along with a VAl pol III reporter construct and GFP as a
control. Cells were either left growing in serum or were transfen*ed to serum-free medium
for the final 16hrs of transfection. Vehicle or rapamycin were then added for a further 4hrs
in the presence and absence of serum. In the pCDNAs transfected cells, VAl transcription
is stimulated upon addition of serum (Fig. 4.10, compare lanes 1 and 3), and this effect can
be blocked by incubating the cells with rapamycin (Fig. 4.10, lane 4). Levels of the pol II
reporter GFP remained relatively stable in each condition (Fig. 4.10, lower panel). In
serum-starved S6KED3E-transfected cells, higher levels of VAl transcription by pol III
were shown (Fig. 4.10, compai'e lanes 1 and 5). However, there was a further increase in
pol III activity when S6KED3E-transfected cells were growing in serum (Fig. 4.10, lanes 5
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Figure 4.9: Phosphorylation of TFIIICllO is inhibited by blocking the mTOR 
pathway
(A) CCL39 cells were labelled with p^P] orthophosphate for 3 hrs. Cells in lane 1 
were transferred to serum-free medium for 24 hrs prior to labelling. Cell extracts were 
prepared and TFIIICllO was immunoprecipitated with an anti-TFIIICllO antibody, 
resolved by SDS-PAGE, and either visualised by autoradiography (upper panel), or 
transferred to PVDF membrane followed by Western blotting with anti-TFIIICllO 
(lower panel). Results are representative of more than three independent experiments.
(B) CCL39 cells growing in 10% serum were transiently transfected with pCDNA3- 
HA.TFIIIC 110 (lOpg) and labelled 48 hrs later with p^P] orthophosphate for 3 hrs in 
the absence (lane I) or presence (lane 2) of rapamycin (lOOnM). Cell extracts were 
prepared and TFIIIC 110 was immunoprecipitated with an anti-HA antibody, resolved 
by SDS-PAGE, and either visualised by autoradiography (upper panel) or transferred 
to PVDF membrane followed by western blotting with anti-HA (lower panel).
(C) The phospholabelling result described in (B) was quantified by densitometry and 
values normalised to the immunoprécipitation. The graph shows the mean +/- 
standard deviations from three independent experiments, where the untreated sample 
is 1 0 0 % and the rapamycin treatment is calculated as a percentage of the control.
* denotes statistically significant difference from control, at p < 0.05
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Figure 4.10 : Rapamycin inhibition of pol III activity may be partially mediated 
by S6K1 activity
Asynchronously growing A31 fibroblasts were transfected for 48hrs with pVAl 
(0.25pg; all lanes), pGFP (0.25|ig; all lanes), pCDNA3 (1.5pg; lanes 1- 4), pCDNA3- 
S6KED3E (l.Spg; lanes 5-8 ). During the final 16hrs of transfection, the cells were 
either maintained in the same medium (lanes 3, 4, 7 and 8), or in a medium 
containing 0.5% serum (lanes 1,2,5 and 6). For the final 4hrs either vehicle (lanes 1, 
3, 5 and 7) or rapamycin (lOOnm; lanes 2, 4, 6 and 8) was added. VAl (upper panel) 
and GFP levels (lower panel) were assayed by primer extension are shown. Results 
are representative of at least two independent experiments.
154
and 7). This effect is only reduced to basal levels in the presence of rapamycin (Fig. 4.10, 
compare lanes 6 , 7 and 8). These results suggest that regulation of pol HI transcription by 
mTOR is due in part to signalling tlirough S6K1.
4.3 Discussion
Pol III transcription is reduced when the mTOR signalling pathway is blocked. We have 
shown that transcription initiation complex assembly on pol III promoters is also reduced. 
This appears to be regulated at the level of both TFIIIB and TFIIIC recruitment, since both 
transcription factors are prevented from binding in the presence of the mTOR inhibitor 
rapamycin. Blocking mTOR activity also prevents TFIIIB binding to both pol III and to 
TFIIIC using co-immunoprecipitation studies. Since more is known about how TFIIIB is 
regulated in cells, the activities of known TFIIIB regulators were investigated in the 
current Chapter. This demonstrated that the effect of rapamycin on pol III transcription 
occurs prior to observing changes, if any, on the activation o f ERK and c-Myc, and the 
inactivation of the TFIIIB repressor RB. Although the precise mechanism of how mTOR 
links to these transcription factors was not identified, phosphorylation of both TFIIIB and 
TFIIIC was reduced when this pathway is blocked, providing the basis for future work 
considerations.
In order to investigate the role of the mTOR and PI3K pathways in controlling 
transcription by pol III, we explored the possibility that mTOR and/or PI3K downstream 
effectors were involved in the regulation of binding of pol III and its transcription factors 
to the promoters of pol Ill-transcribed genes. ChIP analysis showed that binding of TFIIIC, 
TFIIIB and pol III to tRNA^^" genes (type II promoter) is inhibited by rapamycin and 
LY294002 treatment (Fig. 4 .IB). These results suggest that both transcription factors could 
be targets of the mTOR and PI3K pathways. ChIP analysis also determined that binding of
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TFIIIC, TFIIIB and pol III to 5S rRNA genes is inliibited by blocking the mTOR or PI3K 
pathway (Fig. 4.1 A). The productive recruitment of TFIIIC to 5S rRNA promoters requires 
the presence of the gene-specific factor TFIIIA. TFIIIA serves as an adaptor, providing a 
platform that allows recruitment of TFIIIC onto 5S rRNA genes for which it has little 
affinity (White, 1996). Therefore, TFIIIA could be also be a target for the mTOR and PI3K 
pathways in this promoter type.
In other systems, a strong interaction between TFIIIC and tRNA genes was identified 
during nutrient deprivation (Roberts et al., 2003). Although mTOR was not implicated in 
this paper, the fact that mTOR activity is also down-regulated upon nutrient starvation 
(Hara et al., 1998; Kim et al., 2002) suggests a possible involvement of mTOR under such 
conditions in yeast when pol III is inactivated. In this Chapter, binding of TFIIIC to tRNA 
genes is blocked when mTOR activity is inliibited, suggesting that the regulation of TFIIIC 
binding to promoters is different in the two systems.
As described previously, transcription by pol III requires multiple general initiation factors 
that assemble on the promoter in an ordered fashion; recruitment of pol III to its promoters 
has been found to be primarily by interactions with TFIIIB (Schramm & Hernandez,
2002), however, TFIIIC attachment to the promoter region must precede this. Therefore, 
one explanation of the ChIP data is that by blocking the mTOR or PI3K pathways, 
modification of TFIIIC and/or TFIIIB can no longer occur. Two outcomes are then 
possible; the interaction of TFIIIC with the promoter is prevented, and/or the interaction 
between TFIIIC and TFIIIB is blocked. The bandshift data supports the idea that the DNA 
binding activity o f TFIIIC does not decrease after LY294002 or rapamycin-treatment; in 
fact, 2-fold and 3-fold increases, respectively, are found (Fig. 4 .IE). In contrast, the ChIP 
data shows TFIIIC is released from tRNA promoters. This can be explained by findings 
reported in Lasser et al. (1983), which show that although TFIIIC binds tightly on a tRNA
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gene, the stability of the DNA binding is dependent on the presence of TFIIIB, which has 
the ability to transform an otherwise unstable complex into a stable one (Lasser et al.^ 
1983). Thus, it is postulated that the inability of TFIIIB to occupy tRNA promoters after 
rapamycin and LY294002-treatment prevents the stabilisation of TFIIIC and leads to the 
release of TFIIIC, despite the fact that TFIIIC can bind the DNA.
The interactions of the pol III transcription factors were also investigated in response to 
rapamycin treatment. The association of TFIIIB with TFIIIC was ablated in the presence of 
rapamycin (Fig. 4.2), which suggests that the mTOR pathway controls this association. 
Other signalling pathways have been found to regulate the interaction between TFIIIB and 
TFIIIC, including the Wnt (Johnston et aL, 2002) and MAPK signalling pathways (Felton- 
Edkins et aL, 2003a). Phosphorylation and activation of TFIIIB by CK2 appears to be 
necessary for the interaction between TFIIIB and TFIIIC both in vitro and in vivo 
(Johnston et aL, 2002). More recent work demonstrated that the interaction of TFIIIB with 
TFIIIC is sensitive to ERK activity. Moreover, promoter occupancy by Brfl and pol III at 
endogenous tRNA and 5S rRNA genes decreases when cells are treated with the MEK 
inhibitor PD98059 (Felton-Edkins et aL, 2003a). In fact, both CK2 and ERK appear to play 
a role in the regulation of TFIIIB phosphorylation in serum-stimulated cells. Previous work 
has shown that TFIIIB and TFIIIC are phosphorylated in response to serum stimulated 
fibroblasts (Felton-Edkins et aL, 2003a; Scott et aL, unpublished); this finding was verified 
in the phospholabelling experiments seen in Fig. 4.8A and 4.9A. Interestingly, 
phosphorylation of both the Brfl component of TFIIIB and the TFIIIC 110 subunit of 
TFIIIC are reduced by 30% and 75%, respectively, after exposure of cells to rapamycin for 
4 hrs (Fig. 4.8B and 4.9B). Hence, the mTOR signalling pathway may also contribute to 
the phosphorylation status of these transcription factors.
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The mTOR pathway has also been found to link to other transcription factors. Recent 
studies in the pol I system have demonstrated that when the mTOR pathway is blocked, 
phosphorylation on certain sites of TIFIA can be enlianced, whilst others are reduced 
(Mayer et aL, 2004). This reduction in TIFIA phosphorylation may be due to blocking the 
downstream kinase activity o f the mTOR pathway via rapamycin treatment. However, 
enliancement of phosphorylation can be explained by the fact that mTOR controls the 
activity of PP2A, a phosphatase which is known to be inactivated by mTOR signalling 
(Peterson et aL, 1999). This finding was substantiated in the pol I system, where PP2A was 
found to regulate TIFIA in an mTOR-dependent manner (Mayer et aL, 2004). Upon 
rapamycin treatment, PP2A dephosphorylates and inactivates TIFIA in vivo, whereas 
inhibition of PP2A with calyculin A protects TIFIA from inactivation by rapamycin. 
Intriguingly, the same study showed that localisation of TIFIA altered in response to 
rapamycin treatment; blocking mTOR signalling caused a translocation of TIFIA from the 
nucleus to the cytoplasm (Mayer et aL, 2004). It remains possible that TFIIIB and TFIIIC, 
in addition to phosphorylation and activation by the mTOR pathway, undergo nucleo- 
cytoplasmic transport which is regulated reversibly by phosphorylation. Indeed, regulation 
of subcellular localisation of transcription factors has already been reported in response to 
TOR (Beck and Hall, 1999).
As well as contributing to the phosphorylation of TFIIIB and TFIIIC, the mTOR signalling 
pathway may also affect known regulators of pol III transcription such as ERK, c-Myc and 
RB. Hence, the observed effect of blocking mTOR could be explained by a change in 
activity of one of these proteins. In particular, analysis of the 5’UTR of the human cyclin 
D1 gene has revealed a tract of oligopyrimidines (TOP) proximal to the cap structure 
(Herber et aL, 1994). The mTOR pathway increases the translation of mRNAs containing 
such a tract and therefore cyclin D1 is considered rapamycin-sensitive (Jefferies et aL, 
1994; Terada et aL, 1994). The result of rapamycin treatment is therefore decreased
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translation of cyclin D l, resulting in decreased phosphorylation of RB (Hashemolhossein 
et aL, 1998), In the present study, rapamycin treatment of mammalian cells blocked the 
hyper-phosphorylation of RB; however, this inhibition only occurred after 12 hrs of 
rapamycin treatment (Fig. 4.3). The block to RB hyper-phosphorylation by rapamycin may 
be due to decreased levels of cyclin D l, as has been previously reported (Jefferies et aL, 
1994; Terada et aL, 1994), and could account for the reduction of pol III activity observed 
at the 12hr time point. There is however, a decrease in pol III activity that occurs prior to 
this when this signalling cascade is blocked (Fig. 3.5 and 3.6). These data suggest that 
effects on pol III activity via mTOR signalling are independent of RB.
Since mTOR is regarded as a sensor of amino acids, we also looked at the effect that amino 
acid deprivation has on the phosphorylation status of RB. RB phosphorylation is not 
blocked in cells which are cultured in amino acid-free medium for up to 6  hrs (Fig. 4.4). 
However, levels of cyclin Dl were inhibited after 4hrs amino acid deprivation (Fig. 4.4). 
The effect of mTOR on cell cycle progression is mediated at least in part, by increased 
translation of positive regulators of the cell cycle, such as cyclin Dl (Gera et aL, 2004). 
Moreover, pulse-chase experiments have determined that rapamycin treatment decreases 
the half-life of cyclin Dl (Hashemolhossein et aL, 1998), which may explain the decrease 
in cyclin D l levels. Since the abundance of p l 6 , a specific inliibitor of cyclin D l, is not 
altered by rapamycin treatment, the amino acid sensing pathway via mTOR may control 
the stability of cyclin D l. These data suggest that the reduction in pol III transcription in 
the absence of amino acids is independent of RB at early time points.
Since activation of the ERK signalling pathway is known to regulate pol III transcription 
(Felton-Edkins et aL, 2003a), it remained possible that mTOR and ERK pathways were 
involved in cross-talk, as has been previously reported (Wang et aL, 2001; Wang et aL, 
2002; Tee et aL, 2003a), and that rapamycin was blocking ERK activation. However,
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phospho-ERK was not affected by rapamycin treatment in these cells (Fig. 4.6 A), 
indicating that the inliibitory effects of rapamycin on pol III transcription were mediated by 
another mechanism. Similarly, amino acid deprivation over a time course of 6hrs did not 
affect phosphorylation of ERK (Fig 4.6B), indicating that the amino acid sensitivity of pol 
III transcription is independent of ERK signalling.
c-Myc has recently been reported as a regulator of pol III transcription (Gomez et aL,
2003). TFIIIB was reported as the target of c-Myc, and this appears to be through protein- 
protein interactions, rather than through direct DNA recognition by c-Myc. Since 
rapamycin has previously been reported to suppress the translation of c-Myc (Hosoi et aL, 
1998; West et aL, 1998; Gera et aL, 2004), this inhibition of pol III activity by rapamycin 
or by amino acid starvation could be via the degradation or down regulation of c-Myc. 
mTOR signalling via 4E-BP1 was found to relieve the translational repression imposed on 
c-myc mRNA by its structured 5’untranslated region (UTR). Therefore, rapamycin 
treatment is expected to block the phosphorylation of 4E-BP1 and abolish the translational 
component of the c-Myc response. This could account for the decrease in levels of c-Myc 
observed between 6 - Slirs of rapamycin exposure (Fig. 4.7A). Similarly, amino acid 
starvation is sensed by mTOR and results in the dephosphorylation of 4E-BP1 and thus a 
translational repression of c-Myc mRNA (Proud, 2002). The results indicate that levels of 
c-Myc are down regulated between 6  and 8hrs (Fig. 4.7 B). Whilst the decrease of c-Myc 
observed in both the rapamycin and amino acid starvation time courses could account for 
the reduction of pol III activity observed at this time, there is a decrease in pol III activity 
that occurs within 4 hrs of rapamycin treatment (Fig, 3.5 and 3.6). These data suggest that 
inhibition of pol III transcription by rapamycin and amino acid starvation are also 
independent of c-Myc at early time points.
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It is shown that expressing a constitutively active form of S6K (S6KED3E) can increase 
pol III transcription (Fig. 4.10), therefore, the effector of the mTOR pathway that regulates 
pol III may indeed be S6 K. This is particularly interesting since the pol I factor UBF was 
proposed to be regulated, at least in part, by S6K1 (Hannan et aL, 2003). Therefore, S6K1 
regulation of pol III transcription was investigated by studying the effect of S6KED3E 
mutant on pol III activity in serum-starved cells. In this way, this constitutively active 
construct could be considered in the absence of other cell signalling pathways. It was 
found that expression of active S6K1 is sufficient to induce VAl transcription by pol III. 
Thus, the ability of mTOR to regulate pol III transcription is mediated, at least in part, 
through S6K1.
To examine whether the effects of mTOR on pol III transcription might be the indirect 
consequence o f regulation of cell cycle progression, the ability of rapamycin to block pol 
III activity was tested in primary cultures of neonatal cardiomyoctes. Since these cells are 
non-dividing but can undergo hypertrophic growth then the effect of rapamycin on pol III 
transcription can be tested independently of effects on the cell cycle. Rapamycin treatment 
for either 4 lirs or 16hrs reduces pol III transcription by around 40% (Fig. 4.5B), A role for 
signalling through mTOR in cardiac hypertrophy has already been identified, as rapamycin 
blocks the increases in cardiomyocyte size induced by agonists such as PE and Ang II 
(Sadoshima and Izumo, 1995). The findings reported here imply that the aforementioned 
effect of rapamycin could be occurring through the inhibition of pol III transcription. 
Moreover, this evidence corroborates the findings that rapamycin inhibition of pol III 
transcription occurs independently of cell cycle effects (Fingar et aL, 2002). Strong 
inhibition of pol III that occurs upon exposure of cardiomyocytes to the PI3K inhibitor 
LY294002 may be explained by the fact that this kinase lies upstream of a number of 
signalling pathways including the Raf/ERK/MAP kinase pathway. Hence, the effect of this 
drug on pol III transcription may not be due solely to blocking mTOR. It is known that the
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hypertrophie response caused by agonists such as PE, ET-1 and Ang II can increase the 
proportion of Ras in its active GTP-liganded form (Sugden and Clerk, 2000), which in turn 
can activate signalling through both the Raf/ERK/MAP kinase and PI3K pathways. 
Therefore, both mTOR and ERK pathways may play an important role in the regulation of 
pol III transcription during cardiomyocyte hypertrophy.
In summary, the first two results Chapters have shown that pol III transcription is under the 
control of the PI3K and mTOR pathways; levels of pol III transcripts were reduced in vivo 
and pol III activity was reduced in vitro in response to inhibition of the pathways. 
Conversely, increased signalling tlirough the PI3K and mTOR pathways was found to 
increase pol III transcription. Investigation into the possible mechanisms by which the 
mTOR pathway can achieve this control showed that the mTOR pathway regulates 
phosphorylation of TFIIIB and TFIIIC. Additionally, when the mTOR pathway is blocked 
by rapamycin, the interactions between TFIIIB and TFIIIIC, and TFIIIB and pol III are 
ablated. This is supported by the finding that mTOR activity is required for normal 
promoter occupancy at pol III promoters. It is shown that inhibition of pol III transcription 
by rapamycin is independent of effects on the abundance of the pol III transcription factors 
TFIIIB and TFIIIC or indeed of pol III itself. Additionally, rapamycin-mediated inhibition 
is independent o f known regulators of pol III, that is, c-Myc, RB or ERK signalling. 
However, the inhibitory effect of rapamycin on pol III transcription is due in part to 
signalling through the translational effector S6K1.
It can be concluded from the experimental data presented in these Chapters that like the pol 
I system, the control of pol III transcription is under the regulation of the mTOR signalling 
pathway in mammalian cells. The importance of this is highlighted, when we consider that 
the majority of transformed and tumour cell types display abnormally elevated levels of the
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pol III products (Brown et a l, 2000) and that components of the mTOR signalling pathway 
have been identified as targets for oncogenic activation (Shamji et a l,  2003).
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Chapter 5
Involvement of Mafl in the Regulation 
of Mammalian Pol III Transcription
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5.1 Introduction
5.1.1 Discovery of Mafl; a regulator of pol III transcription
Transcription by pol III is tightly coupled with cell growth; increasing in response to serum 
and decreasing when nutrients or serum factors are limiting (Brown et ah, 2000). It is 
known that key aspects of this regulation involve RB, c-Myc and signalling through the 
ERK pathway. In addition, pol III transcription is regulated by a wide variety of conditions 
that perturb cellular processes or the environment of the cell (Zaragoza et ah, 1998; Powers 
and Walter, 1999; Ghavidel and Schultz, 2001; Li et ah, 2000), such as drug treatment, 
DNA damage and secretory pathway defects. These are sensed by different signalling 
pathways that converge on the transcription machinery to affect regulation (Upadhya et al., 
2002). The understanding of these signalling pathways, their mechanisms of 
transcriptional regulation and the ultimate targets of the transcription machinery were 
largely unknown until recently. Studies in yeast identified a structurally novel, and 
phylogenetically conserved protein, Mafl (Pluta et ah, 2001), as an essential and specific 
mediator of pol III regulation under a variety of conditions (Upadya et ah, 2002). Mafl 
was isolated and characterised in yeast based on the ability of m afl-1 mutants to decrease 
the efficiency of SUP 11 (tRNA^^*^ ) suppression and cause temperature-sensitive respiratory 
growth (Boguta et ah, 1997). Genetic methods were employed to identify trans-acting 
elements involved in tRNA biosynthesis which could convert a tRNA gene into a nonsense 
repressor. Phenotypic loss of suppression was then used to identify genes coding for the 
elements essential for tRNA biosynthetic activities. RPC 160 genes with 3’ deletions in 
their open reading frames were found to suppress the m afl-1 phenotypes when 
overexpressed, which identified Mafl as playing an important role in the regulation of 
tRNA biosynthetic capacity (Boguta et ah, 1997).
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5.1.2 Mafl is an essential mediator of diverse signals that repress 
transcription by pol III
Mafl is a novel hydrophilic protein of around 395 amino acids (Boguta et ah, 1997), which 
is conserved from yeast to humans, sharing around 30% identity at the amino acid level 
(Willis et aL, 2004). It is a non-essential, nuclear protein in yeast, where it was found to 
interact with pol III and act as a negative effector of pol III transcription (Pluta et aL,
2001). In vivo studies have shown that mafl-1 mutant phenotypes result in elevated levels 
of tRNAs, and that the rate of pol III transcription in vitro is significantly increased in 
mafl-1 mutant cells (Pluta et aL, 2001). Subsequent studies in yeast found that secretion- 
defective mutants cause transcriptional repression of the ribosome and result in repression 
of tRNA synthesis (Upadyha et aL, 2002), Importantly, deletion of Mafl was found to 
block the repression of pol III transcription in secretion-defective cells (Upadyha et aL,
2002), indicating a requirement for Mafl to mediate the pol III response.
In agreement with these studies, Mafl was found to be an essential mediator of repression
of transcription by pol III in response to a diverse range of cellular conditions. This
repression was demonstrated in cells following DNA damage, after growth to stationary
phase and by treatments with rapamycin or the anti-fungal compound chlorpromazine
(CPZ) (Upadhya et aL, 2002; Willis et aL, 2004; Des ai et aL, 2004). This suggests that
distinct pathways involving secretory signalling, TOR kinase and DNA damage response
pathways are involved in regulating Mafl. However, other conditions have since been
reported to require Mafl for the repression of pol III and include oxidative stress,
endoplasmic reticulum (ER) stress and carbon source starvation (Desai et aL, 2004).
Taken together, these data suggest a convergence of signals that mediate transcriptional
repression of ribosome synthesis and tRNA synthesis. Since many of these treatments are
not pol Ill-specific, it is thought that the repression is achieved via activation of distinct
signalling pathways that converge at or above M afl. The idea of a common mediator of
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stress lying upstream of Mafl is intriguing; however, the identity of any such protein is 
unknown.
5.1.3 Targets of M afl in yeast
After the discovery that diverse conditions require Mafl in order to down-regulate pol III 
transcription, attempts began to elucidate the mechanism by which this occurred. Upadhya 
et al. (2002) established an in vitro system to study Mafl-dependent repression of pol III 
transcription, and chose to focus on repression by CPZ. Whole cell extracts prepared after 
CPZ treatment of logaritlimically-growing cells were found to have 15-fold less pol III 
activity compared to untreated extract (Upadhya et a l, 2002). To examine the possibility 
that CPZ-induced signalling could target a component of the pol III transcription 
machinery, transcription reactions were supplemented with partially purified yeast TFIIIB, 
TFIIIC or pol III. No effect of adding TFIIIC or pol III was seen in either control or CPZ- 
treated extract, whereas adding TFIIIB to CPZ-treated extract restored transcription to 
similar levels found in the control extract (Upadhya et a l,  2002). These findings were the 
first to implicate TFIIIB as the target of transcriptional repression by CPZ. A mechanism 
for this repression was later discovered, when CPZ was found to inhibit pol III 
transcription in vitro by affecting TFIIIB complex assembly (Desai et a l,  2004). The Brfl 
subunit o f TFIIIB was proposed as a likely target of repression in yeast, as the specific 
activity of Brfl decreases 3-fold in the TFIIIB fraction from CPZ-treated extracts and 
supplementation of CPZ-treated extracts with Brfl minimizes the difference in 
transcriptional activity between CPZ-treated and control extracts (Desai et a l, 2004).
Based on the direct interaction of Mafl with pol III in yeast (Pluta et al 2001), and the
extensive range of conditions that have been found to be dependent on the presence of
Mafl to repress pol III transcription, Mafl has been placed at or near the end of several
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signalling pathways (Upadhya et aL, 2002; Willis et aL, 2004; Desai et aL, 2004). This 
suggests that a common mechanism functioning downstream of Mafl acts to repress the 
pol III transcription machinery in yeast. Indeed, several studies have shown that this 
regulation is via TFIIIB (Upadya et aL, 2003; Willis et aL, 2004; Desai et aL, 2004). 
Consistent with this conclusion, TFIIIB had previously been identified as a likely target of 
repression by rapamycin treatment and DNA damage in yeast (Zaragoza et aL, 1998; 
Ghavidel et aL, 2001).
Since the role of Mafl in the regulation of pol III had not been investigated in mammalian 
cells, this chapter focuses on this putative regulation of pol III by Mafl in fibroblasts and 
HeLa cells and identifies a possible mechanism by which this is achieved.
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5.2 Results
5.2.1 M afl inhibits pol III transcription
To study the effect of Mafl on pol III transcription in cells, I overexpressed Mus Musculus 
(Mm) Mafl (Mafl cDNA from Olivier Lefebvre, Seclay, France) in fibroblast cells, 
following sub-cloning of the construct into pCDNASHA. Asynclrronous fibroblasts were 
transiently transfected with pCDNA3-HA (Fig. 5.1 A, lane 4) or different concentrations of 
pCDNA3HA.Mafl (Fig. 5.1 A, lanes 1-3) for 48hrs and protein extracts were made. 
Samples were run on SDS-PAGE gels and immunoblotted with an anti-HA antibody. The 
optimum transfection efficiency was achieved by transfecting lOpg of pCDNA3HA.Mafl 
into cells (Fig. 5.1 A lane 2). In vitro radiolabelled Mafl was synthesised in vitro by 
translation with a reticulate lysate in the presence of [^ ^S] Cysteine (Fig. 5.1 A lane 5). This 
runs at the same size as Mafl expressed in cells and acts as a positive marker for this 
protein.
To test if Mafl affected the product levels of different pol III promoter types, cDNAs were 
prepared from RNA extracted from Mafl-transfected cells and compared to untransfected 
cells or those transfected with pCDNA3HA.Brfl. Subsequent PCR analysis of the cDNAs 
showed a substantial increase in the RNA levels of Mafl following transient transfection 
of pCDNA3HA.Mafl. The increase in levels of Mafl accompanied a decrease in B2, 58 
rRNA, tRNA^^", 7SK and U 6 (Fig. 5.IB, lane 2). These effects were specific, since there 
was no change in the level of the class II gene product ARPP PO mRNA (Fig. 5. IB, lower 
panel). Brfl has previously been found to be limiting for pol III transcription in fibroblast 
cells (Felton-Edkins et a i, 2003a). Therefore, Brfl was used as a positive control to induce 
pol III activity. Increases in B2, 58 rRNA and tRNA^®“ RNAs were observed in Brfl- 
transfected cells compared to im-transfected cells (Fig. 5.IB, lanes 1 and 3). In contrast to
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Fig 5.1: Mafl represses all tested class III genes in  vivo
(A) CCL39 cells growing in 10% serum were transiently transfected with 
pCDNA3-HA (lOpg; lane 4), pCDNA3HA-MmMaf (5pg; lane 1), pCDNA3HA- 
MmMaf (lOpg; lane 2) or pCDNA3HA-MmMaf (15pg; lane 3) for 48 hrs and 
protein extracts were made. -labelled Mafl (5pi; lane 5) was synthesised in 
vitro using a reticulocyte lysate. An aliquot of this was used as a positive control. 
Samples were subjected to SDS-PAGE analysis and Western blotting and were 
probed with an anti-HA antibody (upper panel) or actin (lower panel). Blots are 
representative of more than three independent experiments.
(B) RNA was extracted from asynchronously growing CCL39 cells which had 
been transiently transfected with pCDNA3HA (lOpg; lane 1), pCDNA3HA- 
MmMaf (lOpg; lane 2) or pCDNA3HA-Brfl (lOpg; lane 3) for 48hrs. cDNAs 
were generated by reverse transcription of the extracted RNA. These cDNAs were 
PCR amplified by using primers for Mafl (upper panel), B2 (second panel), 5S 
rRNA (third panel), tRNA^“ (fourth panel), 7SK (fifth panel), U6 (sixth panel) 
and ARPP PO (lower panel). Results are representative of at least three 
independent experiments.
(C) Asynchronously growing CCL39 fibroblasts were transfected for 48hrs with 
pVAl (0.25pg; all lanes), pGFP (0.25pg; all lanes), pCDNA3HA (2|ig, lane 1), 
pCDNA3HA.Mafl (lug, lane 2; 2ug, lane 3) and RNA extracted. VAl (upper 
panel) and GFP levels (lower panel) were assayed by primer extension as shown. 
Results are representative of two independent experiments.
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the type I (5S rRNA) and type II (tRNA and B2) promoter products, the level of the type 
III promoter products U6 and 7SK were not altered when cells were transfected with 
pCDNA3HA.Brfl (Fig. 5.IB, compare lanes 1 and 3). This is in agreement with findings 
that type III promoters do not use Brfl in transcription complex assembly (Schramm and 
Hernandez, 2002). To further investigate the reduction in pol III transcription by over 
expressing M afl, this construct was transiently transfected into fibroblast cells along with 
the adenoviral VAl gene and a pol Il-transcribed GFP control gene. VAl and GFP RNA 
levels were assayed by primer extension. Transfection of Mafl into cells causes a 
significant decrease of VAl transcription by pol III compared to un-transfected cells (Fig 
5.1C). The pol II reporter GFP was used to check transfection efficiency and shows that 
decreased VAl transcription was not accompanied by an effect on GFP transcription (Fig. 
5.1C). These data suggest that pol III transcription in mammalian cells is repressed by 
Mafl.
5.2.2 Knockdown of M afl using siRNA increases pol III transcript levels
Overexpression of M afl decreases pol III transcription; however, the function of 
endogenous Mafl can be investigated using an RNA-mediated interference (RNAi) 
approach. The term RNAi describes the use of double stranded RNA to target specific 
mRNAs for degradation, thereby silencing their expression (Zamore, 2000). The siRNA 
design involved the selection of nucleotide sequences within the Mafl target mRNA which 
began with an A A dinucleotide, were 21 nucleotides in length and had less than a 50% GC 
content. These sequences were then entered into the BLAST search engine to check that 
they did not have significant homology to other genes in the mouse genome database. Four 
siRNAs targeted to different regions of the Mafl gene were designed and prepared by in 
vitro transcription using Ambions Silencer™  siRNA Construction Kit. The Mafl siRNA 
cocktail was introduced directly into mammalian cells by transient transfection, as were
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Silencer™ GAPDH siRNA and Silencer™ scrambled GAPDH siRNA (all at 50nM final 
concentration). RNA was harvested 48hrs later and levels o f M afl, ARPP PO, GAPDH, 
B2, 5S rRNA and tRNA^^" were assayed by RT-PCR. The cocktail of Mafl siRNAs 
resulted in a substantial reduction in Mafl mRNA compared to controls (Fig 5.2A, upper 
panel) and this accompanied an increase in the levels of both 5S rRNA and tRNA^®“ pol 
III transcripts (Fig 5.2A, panels 4 and 5). This effect was specific, since levels of the pol II 
transcript ARPP PO remained virtually unchanged (Fig. 5,2A, panel 2). Transfection of 
Silencer™ GAPDH siRNA reduced the levels of the GAPDH mRNA, verifying that 
siRNAs had been transfected efficiently (Fig. 5.2A, panel 3). Scrambled GAPDH siRNA 
did not reduce the level of Mafl mRNA as compared to that of untransfected cells. This 
verifies that the siRNA delivery method does not result in changes to the gene expression 
profile o f M afl, as scrambled GAPDH siRNA does not code for any target and should not 
decrease mRNA level. These siRNA data suggest that targeted inhibition of Mafl by 
siRNA can increase pol III transcript levels.
5.2.3 Knockdown of M afl using siRNA does not alter Mafl protein levels
Since Mafl siRNAs led to a specific depletion of the targeted mRNA and consequently
increased levels of pol III transcripts, it was important to determine that Mafl protein
levels had also been reduced. Protein extracts prepared (in parallel to the RNA in Fig.
5.1 A) post-transfection of siRNAs were subjected to SDS-PAGE analysis and were
immunoblotted with an antibody against Mafl (SK-2966) (Fig. 5.2B, lanes 1-4).
Radio labelled Mafl was prepared in vitro by translation with a reticulocyte lysate as before
and was used to check the size of the protein (Fig 5.2B, lane 5). Actin was used as a
loading control (Fig 5.2B, lower panel). There was a slight decrease in the level of Mafl
protein in the siRNA Mafl-treated cells compared to the un-transfected control cells;
however, the level of Mafl protein was comparable in all the siRNA-treated cells (Fig.
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Fig 5.2: Depletion of endogenous M afl by RNAi increases tRNA^“ and 
5S rRNA gene expression
(A) Growing A31 cells were transfected using siPORT lipid (Ambion), with 
siRNAs against Mafl (lane 1 ), scrambled GAPDH siRNA (lane 2) or GAPDH (lane 
3) that were purchased from Ambion. All siRNAs were used at 50nM final 
concentration.Un-transfected cells were used as a negative control (lane 4). RNA 
was extracted 48hrs post-transfection and RT-PCR was performed. PCR was 
carried out using the templates Mafl (upper panel), ARPP PO (second 
panel),GAPDH (third panel), tRNA^“ (fourth panel) or 5S rRNA (lower panel). 
Results are representative of at least three independent experiments.
(B) Protein extracts prepared, following transfection of Mafl or control siRNAs (as 
described in [A]) were subjected to SDS-PAGE analysis and were immunoblotted 
with an antibody against Mafl (SK-2966, upper panel) or actin (lower panel). 
Methionine-labelled Mafl prepared by in vitro transcription and translation using 
reticulocyte lysate, was used as a size marker (lane 5). Blots are representative of 
two independent experiments.
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5.2B). Since the RNA levels of the tRNA^^" and 5S rRNA pol III transcripts increased 
when Mafl siRNA was knocked down, this implies that some decrease in the level of 
Mafl protein must have occurred. This result may also imply that pol III transcripts are 
extremely sensitive to small changes in Mafl concentration. As the Mafl protein was not 
knocked down this may suggest it is stable and has a long half-life. Long-term siRNA 
treatment could overcome this problem and can be achieved with either repeated 
transfections of the siRNA or the stable incorporation of the siRNA using a siRNA 
expression vector.
5.2.4 Mafl occupancy on tRNA^®“ promoters is reduced in serum-starved 
cells
Recently, ChIP analysis has shown that CPZ-treatment in yeast caused a marked M afl-
dependent reduction in the occupancy of tRNA genes by pol III (Desai et aL, 2004),
suggesting that the control of pol III occupancy on DNA is a Mafl-dependent regulatory
mechanism. Pol III transcription is known to be sensitive to serum and both TFIIIB and
TFIIIC have already been shown to be phosphorylated (and activated) in response to serum
addition (Felton Edkins, unpublished; Scott et aL, unpublished; Fig 4.8A and 4.9A). In
light of this, the occupancy of the pol III factors at tRNA promoters was investigated in
cells which were subject to serum starvation to repress pol III transcription. CCL39 cells
growing in either the presence (Fig 5.3A lanes 1-6), or absence of serum (Fig 5.3A, lanes
7-12), were formaldehyde cross-linked to preserve the in vivo protein/DNA interactions.
DNA complexes were then immunoprecipitated using antibodies to a pol III subunit,
TFIIIB subunit, TFIIIC subunit and control TFIIB. Cross-links were reversed, protein
digested and the DNA was screened by PCR to determine whether class III genes were
bound by the protein. Pol III occupancy at tRNA^^" promoters is reduced in serum-starved
cells (Fig 5.3A, compare lanes 1 and 7) and there is little change to the occupancy of
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Figure 5.3: Pol III, Brfl and Mafl occupancy at tRNA promoters 
is reduced in response to serum-starvation
(A) Asynchronous CCL39 hamster fibroblasts were cultured in the 
presence (lanes 1-6) or absence of 10% serum (lanes 7-12) for 4 hrs. 
Association of TFIIIC subunit TFIIIC 110, TFIIIB subunit Brfl and pol 
III subunit RPC 155 with tRNA^ ^^ *^  genes was then determined by ChIP 
analysis. This involved PCR with equivalent DNA input amounts as 
determined by PCR on diluted input chromatin. Control ChlPs were 
carried out with the TFIIB antibody. PCR reactions incorporated [a- 
^^P] dCTP and products were resolved on denaturing sequencing gels 
which were subjected to autoradiography. Results are representative of 
two independent experiments.
(B) Asynchronous CCL39 hamster fibroblasts were cultured in the 
presence (lanes 1-4) or absence of 10% serum (lanes 5-8) for 4 hrs. 
Association o f M afl (SK-2966 and SK- 2967) with tRNA^®“ genes 
was then determined by ChIP analysis as described in (A). Control 
ChlPs were carried out with theTFIIB antibody. PCR reactions 
incorporated [a-^^P] dCTP and products were resolved on denaturing 
sequencing gels which were subjected to autoradiography. Results are 
representative of two independent experiments.
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TFIIIC (Fig 5.3A, compare lanes 2 and 8 ), however, TFIIIB occupancy is reduced in 
response to serum-starvation (Fig 5.3A, compare lanes 3 and 9). Negligible levels of 
control TFIIB in both conditions indicated the specificity of the association, and input 
samples were equal for both conditions (Fig. 5.3A, lanes 4-6 and 10-12). Since Mafl has 
been reported to associate with pol III and TFIIIB in yeast (Pluta et al, 2001, Desai et aL,
2004), Mafl should assume the same pattern of promoter occupancy as these factors under 
the same enviromiiental conditions. To investigate whether Mafl is at tRNA promoters in 
mammalian cells, ChIP assays were used to compare promoter occupancy between serum- 
rich and serum-starved cells in vivo. Formaldehyde cross-linked soluble chromatin was 
prepared from asynchronously growing cells cultured in 10% serum (Fig. 5.3B, lanes 1-4) 
or 0% serum (Fig. 5.3B, lanes 5-8) for 16 hours. PCR analysis of precipitated DNA 
showed that occupancy of Mafl is blocked on tRNA^®“ promoters in response to serum 
starvation. The SK-2966 was better at immunoprecipitating Mafl at tRNA promoters than 
the SK-2967 Mafl antibody (Fig. 5.3B, compare lanes 1 and 2).
This ChIP data shows that Mafl is associated with tRNA promoters under normal growth 
conditions. Upon serum-starvation, Mafl is displaced from these promoters and this is 
accompanied by reduced occupancy at tRNA promoters of pol III and the transcription 
factor TFIIIB. This may suggest that Mafl interacts with pol III and/or TFIIIB in 
mammalian cells, under normal growth conditions.
5.2.5 Recombinant M afl inhibits pol III transcription in vitro
Purified recombinant Human (Hs) Mafl (HsMafl .His) was kindly given to us by Olivier
Lefebvre and this was used to test whether Mafl could repress pol III transcription in vitro
in HeLa cell extract. Varying concentrations (0-8 pg) of HsMafl .His was used in an in vitro
transcription assay (Fig. 5.4A). HeLa cell extracts treated with just 2 pg of HsMafl .His
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Fig 5.4 : Mafl specifically represses pol III transcription
(A) tRNA^®“ (250ng) was transcribed using 20pg of HeLa nuclear extract together 
without (lane 1), or with 2, 4, 6 , 8 pg (lanes 2-5 ) of recombinant purified 
HsMaf.Hisl or without (lane 6 ), or with 2, 4, 6 , 8 pg of control buffer (lanes 7- 
10). Incorporation of p^P]dUTP was detected by autoradiography after samples 
were run on a denaturing sequencing gel. Results are representative of more than 
three independent experiments.
(B) In vitro transcription was carried out using 20pg of HeLa nuclear extract plus 
control buffer (lane 1), 0.256ng (lane 2), 1.28ng (lane 3), 6.4ng (lane 4), 32ng 
(lane 5), 160ng (lane 6 ), 800ng (lane 7), and 4000ng (lane 8) of recombinant 
purified HsMafl .His on a tRNA^^“ template (250ng). Incorporation of p^P] dUTP 
was detected by autoradiography after samples were run on a denaturing 
sequencing gel. Results are representative of more than three independent 
experiments.
(C) HeLa nuclear extract (20pg) was used in an in vitro transcription assay using 
both tRNA^®“ (250ng) and pre-rRNA (250ng) templates together with control 
buffer (lane 1 and 2), 1.56 ng (lane 3), 3.125ng (lane 4), 6.25ng (lane5), 12.5ng 
(lane 6 ), 25ng (lane 7), 50ng (lane 8 ), lOOng (lane 9) or 200ng (lane 10) of 
recombinant purified Hs.Mafl .His. Incorporation of p^P] dUTP was detected by 
autoradiography after samples were run on a denaturing sequencing gel. Results 
are representative o f more than three independent experiments.
181
were unable to support transcription of tRNA^^" genes, whilst extracts treated with a 
control (from a fraction taken during the purification of HsMafl with no His Tag) were 
unaffected (Fig. 5.4A), Further titrations with the HsMafl .His protein were carried out 
using lower concentrations of HsMafl.His. In vitro transcription of tKNA^^" in HeLa cell 
extracts was abolished with as little as 6.4ng of HsMafl.His (Fig. 5.4B).
To ensure that the Maf 1 -mediated repression of transcription was specific to pol III 
transcription, a pol I template was included in an in vitro transcription reaction along with 
a pol III template. HeLa cell extracts were used to transcribe pol I and VAl genes during 
incubation with varying concentrations (0-200ng) of HsMafl .His. Transcription of VAl 
genes was significantly inhibited in HeLa cell extracts treated with 12.5ng of HsMafl .His 
whilst transcription by pol I of pre-ribosomal DNA remained unchanged in the presence of 
up to 200ng of HsMafl .His (Fig. 5.4C). These data show that Mafl specifically represses 
pol III transcription and this is in agreement with RT-PCR analysis of pol III transcript 
levels (Fig. 5.1). Since RT-PCR analysis had determined that all pol III promoter types 
were subject to repression by M afl, it was investigated whether repression of all class III 
genes also occurred in vitro. HeLa cell extracts treated with 200ng of HsMafl .His (Fig.
5.5, lane 1) or control buffer (lane 2), were assayed for their ability to transcribe a variety 
of pol III templates. In vitro transcription of 5S rRNA (Fig. 5.5, upper panel), tRNA^®“ 
(Fig. 5.5, second panel), B2 (Fig. 5.5, third panel), VAl (Fig. 5.5, fourth panel), 7SL (Fig.
5.5, fifth panel) and 7SK (Fig. 5.5, sixth panel) were significantly reduced in the presence 
of 200ng of HsMafl.His, whilst transcription of pol I was unaffected (Fig. 5.5, lower 
panel). This result confirms that Mafl can repress all types of class III genes.
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Fig 5.5: In vitro repression of all class III genes by recombinant purified Mafl
20pg of HeLa nuclear extract was used in an in vitro transcription assay using the 
templates (250ng) 5S rRNA (upper panel), tRNA^®“ (second panel), B2 (third 
panel), VAl (fourth panel),7SL (fifth, panel), 7SK (sixth panel) or pre-rRNA 
(lower panel), in the presence (lane 1) or absence (lane 2) of HsMafl .His (200ng). 
Incorporation of dUTP was detected by autoradiography after samples were 
run on a denaturing sequencing gel. Results are representative at least two 
independent experiments.
183
5.2.6 Mafl can repress pol III transcription whether added before, 
during or after initiation complex assembly.
Having provided both in vitro and in vivo evidence that Mafl can specifically repress pol 
III transcription we were interested to know the mechanism by which this occurred. We 
investigated whether assembly of a class III gene into a stable pre-initiation complex can 
influence the repressive effects of M afl. HsMafl .His (200ng) was added to a HeLa nuclear 
extract either 15mins prior to the addition of a VAl gene (Fig 5.6A, lanes 1 and 2), 
simultaneously with the addition of VAl DNA (Fig. 5.6A, lanes 3 and 4), or 15mins after 
the addition of VAl template (Fig. 5.6A, lanes 5 and 6 ). Nucleotides were then added to 
allow transcription. Since pol III factors assemble rapidly onto the VAl gene promoter, 
this assays tests the ability of Mafl to repress a pre-formed initiation complex. Mafl can 
inhibit transcription of VAl whether added before, during or after complex assembly (Fig. 
5.6 A). Relative to HeLa extract alone, Mafl was found to inhibit VAl transcription by 
90% when added prior to, or during complex assembly (0 and 15mins, respectively). 75% 
inhibition was observed when Mafl was added 15rains after the template (Fig. 5.6B). 
These observations suggest that the class III transcription factors are slightly more 
susceptible to Mafl when free in solution but do not receive substantial protection even 
when assembled into a pre-initiation complex.
5.2.7 TFIIIB is a specific target for repression by Mafl
Since Mafl can regulate each of the three pol III promoter types (Fig. 5.1 and 5.5), it 
seemed likely that it acts upon a general component of the pol III transcription apparatus. It 
has been suggested that in yeast, Mafl may function as a stochiometric inhibitor of 
TFIIIB-DNA complex assembly and o f polymerase recruitment through its interactions 
with Brfl and pol III, respectively (Pluta et al., 2001; Upadhya et al., 2002; Desai et a l,
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Fig. 5.6\ M afl represses pol III transcription whether added before, during 
or after initiation complex assembly.
(A) HeLa nuclear extract was pre-incubated for 15mins at 30°C (lanes 1 and 2), 
before the addition of the VAl DNA (lanes 3 and 4), after a further 15 mins at 
30°C, nucleotides were added and transcription was allowed to proceed (lanes 5 
and 6 ). Reactions were carried out in the presence (lanes 2, 4, and 6 ) or absence 
(lanes 1, 3 and 5) of HsMafl .His (200ng). Samples were run on a denaturing 
gel followed by autoradiography.
(B) The VAl signals from (A) were quantified by densitometry. The graph 
shows the mean and standard deviations from three independent experiments; 
values obtained for cells grown in absence of HsMafl .His recombinant protein 
were set as 1 0 0  and other values were calculated as a percentage of this.
* denotes statistically significant difference from control, at p < 0.05
** denotes statistically significant difference from 15 mins, at p < 0.05.
186
2004). It followed that if Mafl could repress class III genes by inactivating individual 
components of the pol III transcription apparatus, then it should be possible to overcome 
this repression by adding more of that factor to the system. Addback experiments were 
therefore carried out to determine which fraction would rescue Mafl-induced repression of 
pol III transcription. A fraction containing partially purified TFIIIB was found to stimulate 
pol III transcription when titrated into HeLa Extracts treated with recombinant Mafl (Fig. 
5.7, lanes 2-5). Little or no stimulation was observed in response to a fraction containing 
TFIIIC (Fig. 5.7, lanes 9-11) or pol III (Fig. 5.7, lanes 6 -8 ). The activity of all fractions had 
previously been confirmed using complementation assays (R.J. White, unpublished data). 
This implicates TFIIIB as a target for Mafl-mediated repression of pol III transcription in 
mammalian cells.
5.2.8 Mafl is a phosphoprotein
Several studies in yeast have proposed that Mafl is a common mediator of repression for
many cellular stresses and have suggested that Mafl lies near to or is at the end of stress-
sensing pathways (Upadhya et al,, 2002; Willis et a l, 2004; Desai et a l, 2004). In fact, a
link between the mTOR signalling pathway and Mafl has been reported in yeast (Upadhya
et a l, 2002; Willis et a l,  2004; Desai et a l, 2004). Since many signalling pathways rely on
phosphorylation for either activation or repression of their targets, it was interesting to find
if Mafl was regulated in this way. To this end, an in vitro kinase assay was carried out.
Recombinant Mafl or a buffer control was bound to Ni^ '*‘-NTA-resin , washed and
incubated for 2  hrs with extracts from growing fibroblasts that had been vehicle-treated
(Fig. 5.8A, lanes 1 and 3) or incubated with lOOnM rapamycin (Fig. 5.8A, lanes 2 and 4)
for 4hrs. Samples were y-[^^P] ATP-labelled for 30mins. Following incubation, samples
were washed extensively, run on SDS-PAGE, and dried gels were exposed to
autoradiography. No difference in the level of phosphorylation of Mafl was shown when
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Fig J. 7 : A component of TFIIIB is a target for repression of pol III 
transcription by Mafl
(A) 20pg of HeLa nuclear extract, was used in an in vitro transcription assay 
using the VAl template (250ng) in the presence of HsMafl .His (50ng ; all 
lanes). In addition the reactions were supplemented with 0, 1, 2, 3 or 4pl of 
fractions TFIIIB (A25 (15)16) (lanes 2-5), pol III (A25 (1.0)13), (lanes 6-8), 
or TFIIIC (CHep 1-15) (lanes 9-11). Samples were then run on a denaturing 
gel and exposed to film. Results are representative of more than three 
independent experiments.
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the recombinant protein was incubated with either the vehicle-treated or rapamycin-treated 
extracts (Fig. 5.8 A, lanes 1 and 2). This effect is specific, since samples which contained 
only vehicle-treated and rapamycin-treated extracts could not be phosphorylated (Fig. 
5.8A, lanes 3 and 4).
5.2.9 The in vivo phosphorylation of Mafl is reduced in serum-starved 
cells
The finding that Mafl could be phosphorylated in vitro prompted an investigation as to 
whether it could also be phosphorylated in vivo. Previous ChIP data had suggested that 
Mafl occupancy is sensitive to serum (Fig. 5.3). Therefore, we determined the 
phosphorylation status of Mafl when the cells were grown in the presence or absence of 
serum. CCL39 cells growing in a medium containing 10% serum were transfected with the 
construct pCDNA3HA.Brfl as a positive control, or pCDNA3HA.Mafl. Following 24hrs 
of transfection, cells were transferred to fresh media containing 10% serum (Fig. 5.8B, 
lanes 1 and 3) or to DMEM without serum (Fig. 5.8B, lane 2). Cells were transferred to 
phosphate-free DMEM 24hrs later, and incubated for 3his with [^^P] orthophosphate in the 
presence or absence of serum. Extracts were immunoprecipitated with HA antibody, run on 
SDS-PAGE gels and either subjected to autoradiography or immunoblotted for HA.
As shown previously, Brfl was found to be phosphorylated when cells were grown in the 
presence of serum (Felton-Edkins et ah, 2003a; Fig. 4.8A). Phosphorylation of Mafl 
decreased significantly in the absence of serum (Fig. 5.8B upper panel, compare lanes 2 
and 3). Some of this effect could be due to the finding that immunoprecipitated Mafl 
levels decreased slightly in the serum-free media, (Fig. 5.8B lower panel, lanes 2 and 3). 
However, quantification of [^^P]-labelled HA.Mafl and immunoprecipitated HA.Mafl
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Figure 5.8: M afl can be phosphorylated in vitro and in vivo
(A) CCL39 extracts (50pg) which had either been vehicle treated (lanes 1 and 3), 
or rapamycin (lOOnM) treated for 4 hours (lane 2 and 4), were incubated in the 
presence of recombinant HsMafl .His (2pg) (lanes 1 and 2) or control buffer 
(2pg) (lanes 3 and 4) an in vitro kinase assay was carried out using [y-^^P] ATP 
to label. Results are representative of more than three independent experiments.
(B) CCL39 cells transiently transfected with pCDNA3HA.Brfl (lane 1) or 
pCDNA3HA.Mafl (lanes 2 and 3) for 48hrs, were labelled with p^F] 
orthophosphate for 3 hrs. Cells in lane 2 were transferred to serum-free medium 
for 24 hrs prior to labelling. Cell extracts were prepared and Brfl or Mafl was 
immunoprecipitated with an anti-HA antibody, resolved by SDS-PAGE, and 
either visualised by autoradiography (upper panel, lanes 1-3) or transferred to 
PVDF membrane, followed by Western blotting with HA antibody (lower panel, 
lanes 1-3).
(C) The phospholabclling result described in (B) was quantified by densitometry 
and values normalised to the immunoprécipitation. The graph shows the average 
+/- the standard error of the mean from two independent experiments, where the 
cells grown in media containing serum is designated 100% and the serum-starved 
treatment is calculated as a percentage of this.
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show that serum-starved cells had 55% less Mafl phosphorylation than those cells grown 
in the presence of serum (Fig. 5.8C). This result suggests that during growth (serum-rich 
conditions), Mafl is phosphorylated and does not repress pol III transcription. However, 
under repressive growth conditions (in the absence of serum); Mafl is de-phosphorylated 
and acts as a negative effector of pol III transcription.
5.2.10 M afl phosphorylation in vivo is due in part to the mTOR pathway
A link between the mTOR signalling pathway and Mafl has been reported in yeast
(Upadhya et al., 2002; Willis et a l, 2004; Desai et a l,  2004), whereby rapamycin
treatment was found to repress pol III transcription, as had been previously reported
(Mahajan, 1994; Powers and Walter, 1999; Zaragoza et al., 1998; Chapter 3 and 4).
Remarkably, this inhibition can be blocked by deleting M afl, which places Mafl
downstream of the TOR kinases in yeast (Upadhya et al., 2002). We were interested to find
out whether the de-phosphorylation of Mafl was a common response to other conditions
known to repress pol III transcription in mammalian cells. Since inhibition of pol III has
been reported by blocking the mTOR pathway (Mahajan, 1994; Chapter 3 and 4) and the
effects of rapamycin on reducing pol III transcription was found to be a Mafl-dependent
response in yeast (Upadyha et al,, 2002; Desai et al., 2004), rapamycin was used to treat
cells to determine if Mafl phosphorylation was under the control of the mTOR pathway.
Cells growing in a medium containing 1 0% serum were transfected with the construct
pCDNA3HA.Mafl. They were then transferred to phosphate-free DMEM 48hrs later, and
incubated for 3hrs with [^^P] orthophosphate in the presence or absence of rapamycin.
Extracts were immunoprecipitated with HA antibody, run on SDS-PAGE gels and either
subject to autoradiography or immunoblotted for HA. Phosphorylation of Mafl decreased
greatly in the presence of rapamycin (Fig. 5.9A upper panel, compare lanes 2 and 3). In
fact, quantification of [^^P]-labelled HA.Mafl and immunoprecipitated HA.Mafl shows
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that rapamycin-treated cells had 55% less Mafl phosphorylation than those cells grown in 
the presence of serum (Fig. 5.9B). This result suggests that during growth, mTOR 
signalling results in the phosphorylation and inhibition of M afl. However, when mTOR 
signalling is blocked, Mafl is de-phosphorylated and acts as a negative effector of pol III 
transcription. This finding is inconsistent with the in vitro kinase result, whereby 
recombinant Mafl could still be phosphorylated when incubated with rapamycin-treated 
extracts (Fig. 5.8A). This difference could be due to the protein extraction method and will 
be discussed further.
To investigate whether the mTOR signalling pathway can influence the interaction 
between Mafl and pol III, co-immunoprecipitations were carried out in CCL39 cells which 
were transiently transfected with pCDNA3-HA.Mafl. In asynchronously growing cells, 
Mafl stably associates with the BN51 subunit of pol III (Fig. 5.9C, lane 1). Rapamycin 
treatment for 4 Iri’s does not prevent Mafl binding to pol III (Fig. 5.9C, lane 3). This effect 
is specific, since immunoprécipitations with control antibodies showed no interaction 
between HA.Mafl and pol III (Fig. 5.9C, lanes 2 and 4). The results presented in Figure 
5.9 suggest that the mTOR pathway does not regulate the interaction between Mafl and 
pol III, and that pol III can associate with Mafl in its active (dephosphorylated), or inactive 
(phosphorylated) state.
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Figure 5.9: Mafl phosphorylation is controlled by the mTOR pathway
(A) CCL39 cells growing in 10% serum were transiently transfected with 
pCDNA3HA.Brfl (lane 1) or pCDNA3-HA.Mafl (lanes 2 and 3) and labelled 
48 hrs later with [^^ P] orthophosphate for 3 hrs in the absence (lanes 1 and 2), or 
presence (lane 3) of rapamycin (lOOnM). Cell extracts were prepared and Brfl 
or Mafl was immunoprecipitated with an anti-HA antibody, resolved by SDS- 
PAGE, and either visualised by autoradiography (upper panel, lanes 1-3) or 
transferred to PVDF membrane followed by western blotting with anti-HA 
(lower panel, lanes 1-3). Results are representative of one experiment.
(B) The phospholabelling result described in (A) was quantified by 
densitometry and values normalised to the immunoprécipitation. The graph 
shows quantification from one experiment, where the cells grown in media 
containing serum are designated 100% and the cells that are rapamycin-treated 
are calculated as a percentage of this.
(C) CCL39 cells transiently transfected with pCDNA3HA.Mafl were incubated 
for 4hrs with vehicle (lanes 1 and 2) or rapamycin (lOOnM; lanes 3 and 4). 
Cell extracts (SOOpg) were immunoprecipitated with anti-HA antibody (lanes 
land 3) or anti-TAF;48 antibody as a control (lanes 2 and 4 ). Precipitates were 
resolved by SDS-PAGE and immunoblotted with anti-HA antibody (upper 
panel) or with anti-BN51 (lower panel). Lane 5 shows a 10% input of the 
vehicle -treated cell extract as a size marker. Blots are representative of two 
independent experiments.
5.2.11 M afl interacts with Brfl in vitro
The add-back experiment suggests that Mafl may target a component of TFIIIB in order to 
act as a repressor of pol III transcription (Fig. 5.7). This possibility was tested in pull-down 
assays using recombinant Mafl bound to Ni^'^-NTA-resin. Radiolabelled Mafl, Brfl or 
luciferase control were synthesised in vitro by translation with a reticulocyte lysate in the 
presence of [^^S]-Methionine and [^^S]-Cysteine. These were incubated with Hs.Mafl.His 
(pre-bound to Ni^'*'-NTA-resin), under stringent ionic conditions to prevent non-specific 
binding. After extensive washing, the bound proteins were analysed by SDS-PAGE and 
autoradiography (Fig. 5.10A). [^^S]-Mafl was found to bind to Brfl but not to control 
luciferase, indicating a specific interaction between Mafl and Brfl under these conditions 
(Fig. 5.10A, compare lanes 1 and 3).
A variation of the pull-down experiment was carried out to further test the interaction of 
Mafl and Brfl in vitro. Unlabelled FIA.Brfl was bound to anti-HA insoluble agarose 
beads. [^^S]-Mafl or [^^S]-STP3 control were incubated with Brfl-HA resin under 
stringent ionic conditions to prevent non-specific binding. After extensive washing, the 
bound proteins were analysed by SDS-PAGE and autoradiography. [^^S]-Mafl was found 
to bind Brfl (Fig. 5.1 OB, lane 1) but did not bind to [^^S]-labelled luciferase control (Fig. 
5.1 OB, lane 2), indicating the specificity of the interaction. [^^S]-labelled Mafl and Brfl 
were loaded as size markers (Fig. 5.1 OB, lanes 4 and 5).
In an attempt to determine which region of Brfl that Mafl bound to, a pull-down assay 
was carried out with recombinant fragments of the Brfl protein. The amino terminal half 
of Brfl shares a high degree of sequence similarity with TFIIB, hence these domains are 
referred to as TFIIB repeat domains (I and II) (see Fig. 5.IOC). The C-terminal half 
comprises of three Brfl homology domains which are responsible for most of its binding 
affinity with TBP (Wang and Roeder, 1995). Zinc finger-, H I- and H2-GST fusion
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Fig 5.10: Recombinant M afl associates with B rfl in vitro
(A) P^S]- Methionine-labelled M afl (lane 2), luciferase (lane 1) or Brfl (lane 
3) prepared using in vitro transcription and translation with reticulocyte lysate 
were incubated with NP'^- bound MmMafl.His at 4^C for 3 hrs under stringent 
ionic conditions. After extensive washing the bound proteins were analysed 
by SDS-PAGE and subjected to autoradiography. Lanes 4 and 5 are 10 % 
inputs of p^S]-labelled Mafl and Brfl used in the pull down assay. Results are 
representative of more than three independent experiments.
(B) p^S]- Methionine-labelled Mafl (lane 1) or luciferase (lane 2) prepared 
using in vitro transcription and translation with reticulocyte lysate was 
incubated at 4^C for 3 hrs with Brfl-HA resin under stringent ionic 
conditions. After extensive washing the bound proteins were analysed by 
SDS-PAGE and subjected to autoradiography. p^S]-labelled Mafl and Brfl 
were loaded as size markers (lanes 4 and 5). Results are representative of 
more than three independent experiments.
(C) The structural motifs of B rfl. Sequence similarity of its N-terminal half 
with TFIIB and three conserved regions in the C-terminal half are indicated.
(D) Zinc finger-, H I- and H2-GST fusion proteins of Brfl produced from 
bacterial cultures were immobilised onto glutathione-agarose beads. Pre­
cleared Recombinant Mafl protein was incubated at 4°C with each of the 
Brfl-GST fusion proteins (lanes 1-3) and with GST alone (lane 4) for 30mins 
in a pull down assay. After stringent washes, samples were subjected to SDS 
PAGE and coomassie-stained. p^S] signals were amplified and gels dried and 
exposed to film. Inputs of the Brfl-GST-fusion proteins are shown in lanes 5- 
8 . Results are representative of three independent experiments.
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proteins produced from bacterial cultures were immobilised onto glutathione-agarose 
beads. Radiolabelled Mafl was synthesised in vitro by translation with a reticulocyte 
lysate in the presence o f p^S]-Methionine and p^S]-Cysteine. p^S]-Mafl protein which 
had been pre-cleared with glutathione-agarose beads was incubated with each of the Brfl- 
GST fusion proteins and with GST alone. After stringent washes to prevent non-specific 
binding, samples were subjected to SDS-PAGE and coomassie-stained. p^S] signals were 
amplified and gels dried and exposed to film. Mafl bound to HI most strongly, although 
some interaction with the Zn-ribbon region was observed (Fig 5.10D, lanes 1 and 2). This 
effect was specific, since Mafl did not bind to GST alone and inputs show that equal 
amounts of the Brfl-GST-fusion protein were used (Fig. 5.10D, lanes 5-8).
5.3 Discussion
Mafl repression of pol III was investigated in mammalian cells where it was foimd to 
repress transcription of all class III genes, both in vitro and in vivo. Phospho-labelling and 
in vitro kinase assays determined that Mafl is a phosphoprotein. Moreover, serum- 
starvation led to reduced Mafl phosphorylation and decreased occupancy of M afl, pol III 
and Brfl on tRNA^^" promoters. Mafl was found to repress pol III transcription whether it 
was added before, during or after initiation complex assembly, and in vitro experiments 
determined Mafl interactions with a component of TFIIIB as being central to this 
regulation. Further in vitro studies identified that the Brfl subunit of TFIIIB is a binding 
partner of M afl. Consistent with these findings, TFIIIB has previously been identified as a 
likely target of repression by rapamycin-treatment, CPZ-treatment and DNA damage in 
yeast (Zaragoza et al., 1998; Ghavidel et a l, 2001; Desai et a l,  2004). Limited studies 
with rapamycin show that phosphorylation of Mafl is reduced in mammalian cells when 
the mTOR signalling pathway is blocked (Fig. 5.9A). Since Mafl was found to interact
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with Brfl and with pol III, this places Mafl near or at the end of at least two signalling 
pathways, and suggests that Mafl may be a common mediator of stress signals.
An early study carried out in yeast, demonstrated that mafl-1 deletion mutants had 
increased levels of tRNAs and this correlated with increased tRNA synthesis rate in vitro 
(Pluta et ah, 2001). In light of this, a Mafl construct was transfected into cells to find if it 
could repress levels of pol III transcripts in a mammalian system. All class III genes were 
found to be repressed by Mafl (Fig. 5.1), a finding which was backed up by in vitro 
findings (Fig. 5.5). In fact, it was determined that Mafl could repress transcription from all 
three promoter types at low ng quantities (Fig 5.5), without effects on pol I transcription 
(Fig. 5.4 and 5.5), which strengthens the notion of Mafl being a highly specific and potent 
inhibitor of pol III transcription. All three promoter types are repressed by M afl, which 
suggests that the polymerase may be targeted by this protein, since this is the common 
factor to all three promoters. However, the addback experiments show that adding more 
pol III made no difference to Mafl-mediated repression. Therefore, Mafl may have more 
than one target.
Chip data established that serum-starvation reduced the occupancy of Mafl at tRNA^^" 
promoters, which coincided with reduced occupancy of pol III and TFIIIB (Fig. 5.3 A and 
B). These findings suggest that Mafl may be directly bound to one or both of these factors 
in mammalian cells; indeed support for associations of Mafl with both Brfl and pol III 
have been reported in yeast (Pluta et a l, 2 0 0 1 ; Upadhya et a l, 2002; Desai et a l, 2004). 
Interestingly, reports in yeast find that Mafl-dependent transcriptional repression of pol III 
by CPZ-treatment does not detectably affect the occupancy of TFIIIC but does reduce the 
occupancy of Brfl and Bdpl (Desai et a l, 2004), which is in agreement with the ChIP data 
found from serum-starving mammalian cells (Fig. 5.3A and B). A striking reduction in 
polymerase occupancy was noted on tRNA genes after CPZ-treatment (Desai et a l, 2004),
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which was also consistent with the data obtained in serum-starved cells (Fig. 5.3). 
Polymerase occupancy was not reduced after CPZ-treatment of a M afl -deletion strain, and 
therefore it was concluded that Mafl is required for reduced pol III occupancy on tRNA 
genes (Desai et a l,  2004). The pattern of pol III, TFIIIB and Mafl occupancy observed in 
serum-rich and serum-starved fibroblasts is similar, which first suggested an association of 
Mafl with one or both of these components in a mammalian system.
Using siRNA to target Mafl does increase pol III transcript levels (Fig. 5.2A). However, 
despite successful knockdown of Mafl at the mRNA level, a corresponding change in 
protein levels was not observed (Fig. 5.2B), possibly due to a long half-life of the protein. 
Changes to the siRNA Mafl method may allow future success in the knockdown of Mafl 
and allow Mafl -dependent processes to be identified.
Fully-formed pol III transcription complexes are extremely stable and support multiple 
rounds of transcription without dissociating from the template (Lassar et al., 1983). 
However, Mafl is able to repress transcription when added before, or during initiation 
complex assembly and to a slightly lesser extent when added to pre-initiation complexes 
that had already assembled onto the adenoviral VAl gene (Fig. 5.6), suggesting that fully 
formed complexes are somewhat protected from the inhibitory effects M afl. It has been 
suggested that in yeast, Mafl may function as a stochiometric inhibitor of pol HI complex 
assembly through its interactions with Brfl (Desai et al., 2004). Consistent with this, 
TFIIIB fractions were found to restore transcription of Mafl-treated extract (Fig. 5.7) 
which provided the possibility that the activity of one or more components of the TFIIIB 
subunits was compromised in serum-free extracts. Indeed this is the case in yeast, where 
changes in the activity of Brfl underscored transcriptional differences between untreated 
and CPZ-treated extracts (Desai et a l, 2004).
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A specific interaction between Mafl and Brfl was demonstrated by in vitro pull-downs 
and this is consistent with pull-down assays in yeast, where recombinant Brfl associated 
with [^^S]-labelled Mafl in vitro (Desai et al., 2004). The Zn-ribbon and HI regions of 
Brfl were found to interact with Mafl by in vitro pull-down. Unfortunately, all the regions 
of full length Brfl were not available at the time of carrying out this experiment; therefore, 
it is possible that Mafl also interacts with additional regions of B rfl. It is known from 
work in mammalian systems that Brfl can be both activated and inhibited by 
phosphorylation (Jolinston et al., 2002; Fairley et a l, 2003; Felton-Edkins et a l,  2003a). 
Therefore, it remains possible that through its interaction with M afl, the activity of Brfl 
could be targeted for post-translational modifications. Interestingly, the phosphorylation of 
Mafl was found to be serum-dependent (Fig. 5.10A), and since serum-starvation is known 
to decrease pol III transcription (Mauck and Green, 1974), this links Mafl activity with the 
regulation of pol III transcription.
Studies in yeast have placed Mafl downstream of the TOR pathway (Upadhya et a l, 
2 0 0 2 ), however, the rapamycin-treated fibroblast cell extracts used in the in vitro kinase 
assay remained able to phosphorylate recombinant Mafl (Fig. 5.8). In contrast, the in vivo 
phosphorylation of Mafl was reduced when cells were treated with rapamycin (Fig. 5.9A). 
This apparent contradiction in findings may be explained by the recent deduction that the 
mTOR/raptor complex is sensitive to disruption by detergents (Fingar and Blenis, 2004). 
This review of recent experimental findings suggests that the in vitro kinase activity of 
mTOR may not correlate with the activation of downstream targets in vivo; therefore, 
protein should be extracted under different conditions to preserve the mTOR/raptor 
association. Also, the detergent-soluble extracts that were used in the in vitro kinase assay 
would contain rapamycin-sensitive as well as insensitive enzymes and so there may well 
be other kinases present in these crude extracts that could have phosphorylated the 
recombinant M afl. In support of this, the in vivo labelling assay showed that rapamycin
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does not completely block Mafl phosphorylation and so other rapamycin-insensitive 
kinases must also act to phosphorylate M afl. In conclusion, these data indicate that the 
control of pol III transcription by the mTOR pathway may be via M afl.
In summary, Mafl represses transcription of all class III genes in mammalian cells and this 
repression can be relieved by the addition of a purified fraction of TFIIIB. M afl, pol III 
and Brfl follow the same pattern of promoter occupancy on tRNA^^" genes in response to 
stress; moreover, Mafl was found to interact directly with both pol III and Brfl. These 
data, taken together with the finding that phosphorylation of Mafl is inhibited by both 
serum-starvation and rapamycin-treatment of cells, suggests that Mafl lies near to or at the 
end of a stress signalling pathway. Therefore it is possible that Mafl receives signals from 
this signalling pathway to co-ordinate pol III activity, and hence the growth capacity of the 
cell, with nutrient availability.
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Chapter 6
Final Discussion
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6.1 Introduction
In yeast and higher eukaryotes, cell growth is co-ordinately regulated with transcription of 
the protein synthetic machinery by pols I and III (Reviews by Grummt, 2003; White, 
2004b). The effectors of this co-ordinate regulation include p53, RB and its relatives p i07 
and p i 30. These repressors function by binding directly to components of the pol I and pol 
III transcription machinery and thereby preventing protein-protein interactions necessary 
for transcription. In addition, specific components of the pol I and pol III machinery were 
found to be substrates for phosphorylation by the MAPK BRK signalling pathway 
(Stefanovsky et aL, 2001; Zhao et al., 2003; Felton-Edkins et al., 2003a), providing a 
connection between growth factor signalling and the biosynthetic pathways that underlie 
growth.
Further studies have identified that, in addition to growth factor signalling by the ERK 
pathway, the mTOR pathway can also couple production of the biosynthetic machinery 
with the needs of the cell. mTOR has been found to co-ordinate pol I transcription in 
mammals with the availability of nutrients and/or growth factors (James and Zomerdijk, 
2004). Since the mTOR signalling pathway regulates components of pol I (Hannan et al., 
2003; Mayer et al., 2004), and there appears to be a common pol I target for growth factors 
and nutrient-dependent activation of ribosome biogenesis (Wang et al., 2001; Mayer et al., 
2004), it has been suggested that cross talk of the ERK and mTOR signalling pathways 
may be facilitated by components of the pol I machinery.
Since pol I transcription is regulated by mTOR (Hannan et a l,  2003; Mayer et al., 2004), 
the initial objectives of this project were to establish if pol III transcription is also under the 
control of the mTOR signalling pathway, and to investigate possible mechanisms by which 
this regulation occurs. A further objective, which developed during the course of this work,
was to identify whether Mafl is a negative regulator of pol III transcription in mammalian
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cells and to investigate how this regulation is achieved. This thesis describes how each of 
these aims has been met.
6.2 mTOR and PI3K inhibit pol III transcription
By using the inhibitors LY294002 and rapamycin, pol III transcription was shown to be 
under the control of both the PI3K and mTOR signalling pathways. This conclusion was 
drawn from evidence based on Northern analysis, in vitro transcription data, and RT-PCR 
and primer extension analysis (Chapter 3). Whilst all the available evidence showed that 
this down-regulation in pol III transcription occurs within a few hours of blocking the 
mTOR and PI3K pathways, the RT-PCR analysis, in particular, allowed some clue as to 
how this regulation was occurring. This was due to the finding that inhibition of the mTOR 
and PI3K pathways results in promoter-specific decreases in RNA levels. Those transcripts 
driven by type I and type II pol III promoters had decreased RNA levels, whereas levels of 
RNA driven by a type III promoter remain unaffected after incubation with LY294002 or 
rapamycin (Fig. 3.7). These findings were the first to suggest that the TFIIIB component 
Brfl, and/or TFIIIC are targets of the PI3K and/or mTOR pathways, since type III 
promoters do not utilise Brfl or TFIIIC.
As PI3K lies upstream of mTOR, LY294002 would prevent signalling through mTOR;
however, there is also an mTOR-independent effect, since Northern analysis shows that the
combination of rapamycin and LY294002 causes a further inhibition of pol III
transcription than either drug added alone (Fig. 3.3). The PI3K inhibitor LY294002 could
be exerting these effects through modulation of CK2 activity (Davies et al., 2000) and /or
ERK signalling, as these are published regulators of pol III transcription (Johnston et at.,
2002; Felton-Edkins et ah, 2003a). Alternatively, partial inhibition of the PI3K and mTOR
pathways may occur when LY294002 or rapamycin are added individually. If this is the
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case, a more complete inhibition of the mTOR pathway may occur when both inhibitors 
are added together.
6.3 Rapamycin-mediated inhibition of pol III transcription is not due to 
decreased abundance of TFIIIB or TFIIIC, or decreased activity or 
abundance of pol III
Previous reports have demonstrated that pol III transcription factors can become over­
expressed during transformation or infection by viruses, which serves to increase pol III 
transcriptional output (Felton-Edkins and White, 2002; Johnson et al., 2003). In contrast, 
specific transcription factors are decreased when cells differentiate, resulting in a down- 
regulation of pol III transcription (Alzuherri and White, 1999). In light of this. Western 
analysis was used in an attempt to clarify whether the inhibition of the PI3K or mTOR 
pathways results in a decrease in the abundance of TFIIIB or TFIIIC. This was not found 
to be the case (Fig 3.9 and 3.11). Moreover, the abundance and activity of pol III was also 
unaffected by inhibition of the mTOR and PI3K pathways (Fig. 3.10 and 3.12). Several 
alternative possibilities by which this inhibition occurred were considered. For example, 
the activity of one or more of the transcription factors might be compromised, mTOR 
signalling might be modulating protein-protein interactions between either the basal 
transcription machinery or co-regulators of pol III transcription, or signalling through 
mTOR could be modulating the accessibility of DNA.
208
6.4 Rapamycin-mediated inhibition of pol III transcription is not due to 
RB, c-Myc or ERK signalling
As in yeast, mTOR is required for cell cycle progression, and inhibition of mTOR activity 
by rapamycin arrests cells in the G1 phase of the cell cycle (Abraham and Weiderrecht 
1996; Jacinto and Hall, 2003). Expression of a rapamycin-resistant mutant of mTOR 
alleviates the effect of rapamycin on cell cycle progression (Hay and Sonenberg, 2004). 
This effect of mTOR on cell cycle progression is mediated, at least in part, by the increased 
translation of mRJSfAs encoding positive regulators of cell cycle progression, such as cyclin 
D1 and c-Myc, and by decreased translation of negative regulators of the cell cycle, such 
as p27^'‘’* (Gera et al., 2004). In agreement with these findings, c-Myc levels decrease 
when cells are exposed to rapamycin (Fig. 4.7), and RB phosphorylation was reduced (Fig. 
4.3), most likely due to a decrease in cyclin D1 levels. However, inhibition of the pol III 
system occurred before these effects on known regulators of pol III transcription (Fig. 3.5 
and 3.7). This suggests that the initial inhibitory effects of rapamycin are independent of c- 
Myc and RB.
As c-Myc is a transcription factor, a possibility to consider is that its activity rather than its
abundance is modulated by rapamycin treatment. Endogenous c-Myc is a regulator o f pol
III transcription at physiological concentrations, as demonstrated by using knock-out
fibroblasts and RNAi, and occupies tRNA and 5SrRNA promoters (Felton-Edkins et al.,
2003b; Gomez-Roman et ah, 2003). However, c-Myc appears to be recruited by protein-
protein interactions with TFIIIB, rather than direct DNA recognition by c-Myc (Gomez-
Roman et ah, 2003). c-Myc's role as a regulator of pol II transcription has been well-
documented, but it remains possible that c-Myc may recruit cofactors to modulate the
activity of pol III, in addition to its regulation of pol III through TFIIIB. Co-factors
function, in part, by affecting chromatin structure through their associated enzymatic
activities, including ATPases/ helicases, histone acetyl transferases (HATs) and histone
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deacetylases (HDACs) (Sudarsanam and Winston, 2000) and c-Myc dependent activation 
of (pol II) target genes is associated with an increase in histone H3 and histone H4 
acétylation (Frank et al., 2001). Therefore, further points for investigation include 
examining whether rapamycin treatment prevents H3 and H4 acétylation by c-Myc or 
stimulates the recruitment of HDACs.
6.5 Rapamycin-mediated inhibition of pol III is cell cycle-independent
In addition to data which suggested that rapamycin-mediated effects occurred before 
effects on the pol III and cell cycle regulators c-Myc and RB, experiments with 
cardiomyocytes demonstrated that rapamycin can block pol III transcription independently 
of the cell cycle (Fig. 4.5), as these cell types grow but do not divide. To verify this 
conclusion, FACS analysis could be used to ensure that fibroblast cells were cycling 
normally during the time points when decreased levels of pol III transcription were 
observed.
6.6 Regulation of pol III transcription by amino acid availability
Amino acids positively regulate mTOR signalling and activate S6K1. Conversely, amino 
acid deprivation impairs the activity and the phosphorylation of S6K1 (Hara et a l,  1998; 
Lynch et al., 2001). Since these effects can be mimicked by rapamycin this suggests that 
the effects of amino acids are mediated via the mTOR pathway. The data in this thesis 
show that depriving cells of amino acids results in down-regulation of pol III transcription 
(Fig. 3.13 and 3.14), suggesting that the amino acid sensitivity of pol III transcription is 
mediated by mTOR. This effect was independent of RB, c-Myc and ERK signalling (Figs. 
4.4, 4.6 and 4.7), and was not due to decreased abundance of TFIIIB, TFIIIC or pol III
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(Fig. 3.15). Further investigation into this control may involve both looking at the 
interactions of the transcription factors with each other and pol III through co- 
immunoprecipitations and investigating the phosphorylation status of pol III and its 
transcription factors in response to amino acid deprivation. Also, the activity of the 
polymerase was not assayed and this could be a mechanism by which this negative control 
is exerted.
6.7 Phosphorylation of TFIIIB and TFIIIC is due in part to the mTOR 
signalling pathway
Since changes in protein phosphorylation represent a mechanism that is frequently 
employed by cells to regulate transcription factor activity (Whitmarsh and Davis, 2000) 
and evidence exists that TFIIIB and TFIIIC require phosphorylation to be activated 
(Hoeffler et al, 1998, Felton-Edkins et al., 2003a), the phosphorylation status of these 
factors in response to rapamycin treatment was investigated. Phosphorylation of the Brfl 
subunit of TFIIIB and TFIIICllO was found to be due, in part, to the mTOR signalling 
pathway (Fig. 4.8B, 4.9B and Fig. 6.1). Since the abundance of these factors was not 
changed, (Fig. 3.9 and 3.11) they do not appear to be targeted for proteolytic degradation 
following phosphorylation by the mTOR pathway. Mass spectrometry would allow 
identification of the specific sites on Brfl and TFIIICllO which are phosphorylated by the 
mTOR signalling pathway. Subsequent point mutations of these residues into non- 
phosphorylatable forms could pinpoint whether the phosphorylation of these residues on 
Brfl and/or TFIIICllO is necessary for their function in activating pol III transcription. 
Future phospholabelling studies could also establish whether other subunits of TFIIIB 
and/or TFIIIC are phosphorylated by the mTOR signalling pathway. These approaches 
may provide insight into the molecular mechanism underlying mTOR-dependent 
regulation of pol III transcription.
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It is possible that TFIIIB and TFIIIC undergo nucleo-cytoplasmic transport upon 
phosphorylation by the mTOR pathway. Studies in yeast show that TOR regulates 
subcellular localisation of transcription factors (Beck and Hall., 1999); in fact, the control 
of nuclear import/export appears to be a general mechanism by which TOR regulates 
transcription (Rohde et ah, 2001). The possibility of mTOR-regulated nuclear localisation 
of TFIIIB and/or TFIIIC could be further investigated using GFP-tagged constructs which 
could be transiently transfected and viewed under immuno-fluoresence in rapamycin- 
treated cells.
An important question is whether mTOR itself or a downstream kinase phosphorylates 
Brfl and/or TFIIICllO. Since S6K1 is known to act downstream of mTOR (Pullen and 
Thomas, 1997) and primer extension analysis showed that increased S6K1 signalling 
increases pol III activity (Fig 4.10), there is a possibility that S6K1 directly phosphorylates 
Brfl and/or TFIIICllO. If S6K1 activity does control pol III transcription, then a future 
experiment could involve expressing a dominant negative form of S6K1 in exponentially 
growing cells to find out if it can repress pol III transcription.
Alternatively, mTOR could indirectly control the activity of the pol III transcription factors 
by the inhibition of a phosphatase. Several Ser/Tln protein phosphatases have been 
identified as components of the mTOR signalling pathway, these include PP2A, PP4 and 
PP6  (Dennis et al., 1999). Therefore, one of these phosphatases could dephosphorylate 
TFIIIB and/or TFIIIC subunits. A further experiment may be to inhibit these phosphatases 
specifically to find if they can protect either Brfl and/or TFIIICllO from inactivation by 
rapamycin during phospholabelling studies.
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Figure 6.1: Model of how mTOR regulates pol III transcription
The mTOR signalling pathway in conjunction with the PI3K pathway integrates signals 
from both growth factors and nutrients to control pol III transcription. This may occur via 
the direct/indirect phosphorylation and activation of TFIIIB and TFIIIC subunits by mTOR 
signalling. The phosphorylation of factors may occur in the nucleus, or may occur in the 
cytoplasm to facilitate entry of these factors to the nucleus. Ultimately, phosphorylation 
may allow the interaction of these factors with each other and pol III and result in initiation 
of transcription at pol III templates.
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6.8 The role of mTOR signalling in the modifîcation of chromatin 
structure
Chip assays show that TFIIIC, TFIIIB and pol III are excluded from pol III promoters 
when mTOR signalling is blocked (Fig. 4.1A/B). This may be because rapamycin-induced 
conformational changes of the chromatin inhibit TFIIIC’s ability to occupy DNA. 
Bandshift analysis showed that TFIIIC retained its DNA binding affinity (Fig. 4 .ID). This 
may suggest that the mTOR pathway can regulate pol III transcription factor binding by 
regulating and modifying chi'omatin structure. Histones are direct targets of protein kinases 
and are phosphorylated in response to growth factors (Mahadevan et aL, 1991; Thomson et 
aU, 1999). It has also been demonstrated that the activity of specific HATs can be 
increased or decreased by phosphorylation, whilst transcriptional repressors can participate 
in regulating chromatin structure through FIDACs (Whitmarsh and Davis, 2000). The 
present study could be extended to examine HDAC promoter occupancy on pol III 
templates upon exposure to rapamycin. This is an attractive prospect as TOR has already 
been reported to regulate ribosomal gene expression by histone acetylation/deacetylation 
(Rohde and Cardenas, 2003). A recent genome wide study in yeast shows that an HDAC 
(Rpd3p) binds to the promoters of rapamycin- repressible genes following treatment with 
the small molecule (Humphrey et aL, 2004). This study is in agreement with the finding 
that Rpd3p is recruited to rDNA promoters to control repression following rapamycin 
treatment (Tsang et aL, 2003). These results suggest a model whereby TOR regulates gene 
activity via controlling the recruitment of an HDAC to the promoters o f genes.
mTOR signalling was found to modulate protein-protein interactions between the basal pol
III transcription complex, as rapamycin blocked the interaction between TFIIIB and
TFIIIC and also between TFIIIB and pol III, Direct interaction of endogenous mTOR with
the pol III apparatus was not investigated as endogenous mTOR proved difficult to
coimmunoprecipitate. However, it is possible that mTOR does associate with pol III or its
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regulatory factors as mTOR has been found to shuttle between the cytoplasm and the 
nucleus (Kim and Chen, 2000; Zang et aL, 2002). Nuclear shuttling of mTOR may be 
required for its cytoplasmic signalling to TFIIIB and/or TFIIIC. The potential downstream 
effects of mTOR nuclear shuttling on TFIIIB and/or TFIIIC phosphorylation could be 
examined if an inhibitor of nuclear export such as leptomycin B (LMB) was incorporated 
into a future experiment. However, it must be remembered that LMB is a general inhibitor 
of nuclear export and all cellular proteins undergoing Crml-dependent nuclear export 
would be affected by this drug.
6.9 Rapamycin inhibition of pol III transcription may be partially 
mediated by S6K1 activity
The findings reported here suggest that mTOR-mediated inhibition of pol III transcription 
occurs in part though S6K1 signalling (Fig. 4.10). Recent studies have shown that the 
activity of two mammalian pol I-specific transcription factors, TIFIA and UBF, can be 
modulated by the mTOR inhibitor rapamycin (Claypool et aL, 2004; Mayer et aL, 2004). 
However, conflicting evidence exists, which reports that TIFIA is not regulated by mTOR 
but instead that mTOR, via S6K1, can activate rDNA transcription tlirough 
phosphorylation of the pol I transcription factor UBF (Hannan et aL, 2003). As UBF does 
not appear to be a direct substrate for S6K1, the implication is that an alternative kinase 
exists upstream of UBF. Since it is known that S6K1 is largely cytoplasmic (Dufner and 
Thomas, 1999), co-immunoprecipitations may determine whether TFIIIB and/ or TFIIIC 
are direct substrates for S6K1 in the regulation of pol III transcription, or whether, as in the 
pol I system, novel kinases exist upstream of the pol III transcription factors. Emerging and 
older data suggest that specific members of the mTOR family, including S6K1, may 
themselves be targets for oncogenic activation (Sansal and Sellers, 2004). Therefore,
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subversion of S6K1 would provide a direct mechanism by which an oncogene could co- 
ordinately increase the activity of transcription by pols I and III and translation.
6.10 MafI; a negative effector of pol III transcription in mammalian cells
Mafl was found to be a negative regulator of pol III transcription in mammalian cells. 
Both in vitro and in vivo data indicates that Mafl represses transcription of all class III 
genes (Fig. 5.1 and 5.5). An addback experiment determined that this repression can be 
relieved by the addition of a partially-purified fraction of TFIIIB (Fig. 5.7), which 
suggested that an activity within the TFIIIB fraction was able to relieve Mafl-mediated 
repression of pol III transcription. Although the TFIIIB fraction was gradient purified on 
Mono Q after an initial phosphocellulose step, it undoubtedly contains proteins other than 
TFIIIB. Therefore, a future experiment could be to test the effect of immunodepleting the 
fraction, with anti-serum against individual TFIIIB components. This would find if the 
fraction can still counteract the repression by Mafl and may identify the component 
responsible.
TFIIIB has previously been identified as a likely target of repression in rapamycin-treated 
cells in yeast (Zaragoza et aL, 1998; Desai et aL, 2004). Indeed, Mafl was found to be 
necessary for rapamycin-induced inhibition of pol III transcription (Upadhya et aL, 2002; 
Desai et aL, 2004), implying that Mafl lies downstream of the mTOR kinases. In the 
present study, phospho-labelling and in vitro kinase assays determined that Mafl can act as 
a phospho-acceptor (Fig. 5.8 and Fig. 5.9). Moreover, the phosphorylation of Mafl is 
reduced in mammalian cells where the mTOR signalling pathway is blocked (Fig 5.9), 
suggesting that mTOR controls the phosphorylation of M afl. This is in agreement with the 
finding in yeast that Mafl is downstream of TOR. Serum-starvation also led to reduced
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Mafl phosphorylation and decreased occupancy of M afl, pol III and Brfl on tRNA^®“ 
promoters. Since mTOR is considered a nutrient sensor, it is possible that the downstream 
effects of serum starvation on Mafl phosphorylation were transduced through changes in 
the activity of mTOR.
Mafl was found to inhibit pol III complex assembly whether added before, during or after 
complex assembly (Fig. 5.6), and in vitro experiments demonstrated that titrating in a 
TFIIIB component could relieve this inhibitory effect of Mafl on pol III transcription (Fig. 
5.7). Fuither studies showed that Mafl could interact with Brfl (Fig. 5.10) and with pol III 
(Fig. 5.9C). These data, together with the finding that phosphorylation of Mafl is inhibited 
by both serum-starvation and rapamycin-treatment of cells, suggests that Mafl lies at the 
end of a nutrient sensing signalling pathway. Therefore, it is possible that Mafl receives 
signals from the mTOR signalling pathway to regulate transcription by pol III thus 
providing a means to co-ordinate nutrient availability with the growth capacity of the cell 
(see Figure 6 .2 ).
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Figure 6.2: Model of how mTOR regulates pol III transcription through Mafl
The mTOR signalling pathway in conjunction with the PI3K pathway integrates signals 
from both growth factors and nutrients to control pol III transcription. This may occur via 
the direct/indirect phosphorylation and activation of TFIIIB and TFIIIC subunits by mTOR 
signalling along with the phosphorylation and inactivation of the repressor Mafl. S6K1, a 
downstream effector of mTOR signalling may phosphorylate Mafl and/or the pol III 
transcription factors TFIIIB and TFIIIC. A phosphatase could oppose this phosphorylation 
but will be held inactive by mTOR signalling so providing dual control. Upon 
phosphorylation by the mTOR pathway, TFIIIB becomes active and Mafl becomes 
inactive but the two remain associated at pol III promoters. Upon nutrient deprivation, an 
active phosphatase may dephosphorylate Mafl and inhibit TFIIIB, resulting in neither of 
them being bound at pol III promoters. The phosphorylation of factors may occur in the 
nucleus, or, may occur in the cytoplasm to facilitate entry of these factors into the nucleus. 
Ultimately phosphorylation may allow the interaction of these factors with each other and 
pol III and result in initiation of transcription at pol III templates.
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6.11 Importance of these findings; how mTOR signalling and pol III 
transcription are implicated in cancer
Historically, researchers searching for cancer therapeutics have focused on the proteins that 
control how a cell divides and multiplies, as opposed to those proteins involved in the 
regulation of cell size. This is understandable as, at a superficial level, cancer is a problem 
of uncontrollable cell proliferation. It has long been known that cell proliferation is 
dependent on cell growth but not vice versa (Hartwell, 1971; Nurse, 1975; Johnston, 
1977). Consequently, it is widely accepted that mutations in signalling proteins regulating 
cell growth, in addition to those regulating cell cycle progression, contribute to the 
formation of tumours (Vogt, 2001).
High rates of pol III transcription are necessary for cells to sustain growth (White, 2004b), 
and pol III is targeted directly by transforming agents (Brown et aL, 2000) and the tumour 
suppressors p53 and RB (White, 2004b). Therefore, it is not surprising that abnormal pol 
III activity is a feature of cancer cells (White, 2004a). Since mTOR controls the activity of 
pol III transcription (Chapter 3 and 4), and components of the mTOR signalling pathway 
have been identified as targets for oncogenic activation (Shamji et aL, 2003), we can see 
how deregulation of mTOR signalling to the pol III transcription apparatus could be one 
mechanism for increasing the growth potential of the cell. This is especially relevant given 
that the regulation of transcription of pol I and III by mTOR is due, in part, to signalling 
through S6K1 (Hannan et aL, 2003; Mayer et aL, 2004; Fig. 4.10), and that the activity of 
S6K1 is markedly up-regulated in tumours that carry mutations in FTEN and TSCl/2 
(reviewed in Ruggero and Pandolfi, 2003).
Preclinical data indicate that rapamycin and its derivatives inhibit proliferation and growth
of many tumour cell lines in culture (Huang and Houghton, 2003). Moreover, mTOR
inhibitors (CCI-779 and RADOOl) are now considered as promising anti-cancer drugs, and
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are being explored in phase II and III clinical trials. Recent reports have demonstrated their 
remarkable ability to suppress tumour growth (Hidalgo and Rowinsky, 2000; Neshat et al., 
2001; Podsypanina et al., 2001). It stands to reason that without cell growth there will be 
no sustained proliferation, therefore, it is possible that mTOR encourages proliferation 
indirectly by promoting cell growth via the co-ordinate regulation of translation and 
transcription by pols I and III.
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Appendices
Appendix 1: List of Suppliers
All materials and reagents used were of the highest quality available and were obtained 
from the following suppliers:
Ambion Inc. Austin, USA 
siPORT Lipid Transfection Agent 
siRNA oligonucleotides
Amersham Bio sciences UK Ltd. Little Chalfont, Buckinghamshire, UK 
a-[“ P] dATP 
a-[“ P] dCTP 
a-[“ P] UTP
[*^P] Orthophosphoric acid in water
ECL Western blotting detection reagents
Horseradish peroxidase (HRP)-conjugated donkey anti rabbit IgG antibody 
HRP-conjugated donkey anti mouse IgG antibody 
Megaprime DNA Labelling System RPN 1604/5/6/7 
Protein A Sepharose
Recombinant Protein Molecular Weight Markers (Range 100000-250000)
Ultrapure NTP set (lOOmM).
Anachem Ltd. Luton, Bedfordshire. UK 
30% acrylamide/bisacrylamide
Biomol Research Laboratories Inc. Plvmouth Meeting. USA 
PKB substrate peptide inhibitor (GRPRTSSFAEG)
Bio-Rad Laboratories Ltd, Hemel Hempstead. Hertfordshire, UK
Bradfords Reagent
Poly-Prep Chromatography Columns
BDH Laboratorv Supplies. Poole. Dorset. UK 
Acetic acid 
Calcium chloride 
Ethanol
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Magnesium acetate 
Magnesium chloride hexahydrate 
Magnesium sulphate heptahydrate 
Methanol
Potassium chloride
Sodium acetate 3-hydrate
Sodium dihydrogen orthophosphate dihydrate
Calbiochem tCN Bio-sciencesI Beeston. Nottingham, UK
Hepes
LY294002
MOPS
Rapamycin
Cell Signalling Technology Inc. Beverly, USA 
Antibodies (codes in Table 2.2)
Dako, Glostrup, Denmark
Peroxidase-Conjugated Swine anti-rabbit Immunoglobulins 
Peroxidase-Conjugated Rabbit anti-mouse Immunoglobulins
Eurogentec, Serains, Belgium 
Antibody (code in Table 2.2)
Fisher Scientific, Loughborough. Leicestershire. UK
Ammonium acetate
Chloroform
Dimethyl sulphoxide (DMSO)
Glycine
Hydrochloric acid 
Potassium hydroxide 
Sodium dodecyl sulphate (SDS)
Ethylenedi aminetetraacetic acid (EDTA)
Sodium Hydroxide
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Fisons Chemicals. Leicestershire, UK 
OptiFlow Safel scintillation fluid
Gibco BRL
1 X amino acids mix
dialysed Fetal Bovine Serum (dFBS)
Earle’s Balanced Salt Solution (BBSS)
L-Glutamine
Optimem
Phosphate-free Dulbecco’s Modified Eagle Medium (DMEM) 
T4 DNA ligase and lOx ligase buffer
Life Teclinologies Inc.
Lipofectamine
Invitrogen, Groningen,The Netherlands
5 X First Strand Buffer
Superscript II Reverse Transcriptase
Konica Europe. GmbH. Hohenbrunn, Germany 
Konica medical film
MWG Biotech, Germany 
Oligonucleotide primers
New England Biolabs fUKI Ltd. Hitchin. Herfordshire. UK 
Prestained protein marker, broad range (6-175)
Novagen, Madison. USA
Single Tube Protein System 3, T7 Kit
Oxoid Ltd, Hampshire, UK 
Bacteriological Agar
Premier Brands UK, Knighton Adbaston. Staffordshire. UK 
Marvel powdered milk
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Promesa, Southampton, UK 
All restriction enzymes 
Alkaline phosphatase 
Deoxynucleotide triphosphates (dNTPs)
Klenow
Nuclease-free water
RNasin Ribonucleotide Inhibitor
T4 polynucleotide Kinase (PNK) and 10 x PNK buffer
Taq polymerase
Roche Diagnostics, GmbH. Mannlieim. Germany 
Creatine phosphate 
Hexanucleotide mix 
Yeast tRNA
Stratagene
E.Coli XL-1 Blue Supercompetent Cells
Oiagen Ltd, Crawley, West Sussex, UK 
Plasmid maxi kit 
QIAprep gel extraction kit 
QIAprep spin miniprep kit
Santa Cruz Biotechnology Inc. Santa Cruz, California, USA 
Antibodies (codes in Table 2.2)
Schleicher & Schuell UK Ltd. Brunswick Park, London, UK 
Nitrocellulose membrane (0.45 pM)
Sigma Chemical Company Ltd., Poole, Dorset, U 
Actinomyciii D
Adenosine 5’-triphosphate (ATP)
Adenosine monophosphate (AMP)
Agarose 
a-Amanitin 
Ammonium sulphate
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Ampicillin
Amplify
Aprotinin from bovine lung 
Bestatin hydrochloride 
B-glycerophosphate 
Boric acid
Bovine serum albumin (BSA)
Bromophenol blue 
Coomassie Brilliant Blue R-250 
Ethidium bromide
Ethylenediamine-N,N,N’,N’-tetra acetic acid (EDTA)
D-Glucose
Diethyl pyrocarbonate (DEPC)
Dithiothreitol
Dulbecco’s Modified Eagle Medium (DMEM)
Dulbecco’s Modified Eagle Medium/Medium 199 (DMEM/M199) 
Dulbecco’s Phosphate Buffered Saline (D-PBS)
Fetal Bovine Serum (FBS)
Formaldehyde 
Formamide 
G418 Sulphate 
Gelatin
Glutathione-Agarose
Glycerol
Glycogen
Horse Serum (HS)
Igepal (CA-630)
Imidazole
Isoamyl alcohol
Isopropanol
N-lauroylsarcosine
Lithium chloride
Leupeptin trifluoroacetate salt
B-Mercaptoethanol
Monoclonal anti-HA agarose conjugate 
Penicillin
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Pepstatin A 
Phenol solution 
Phenylmethylsulfonyl fluoride 
Proteinase K 
Protein A Sepharose 
Sodium acetate 
Sodium chloride 
Sodium citrate (dihydrate)
Sodium deoxycholate 
Sodium fluoride 
Sodium orthovanadate 
Sucrose 
Streptomycin
N, N, N', N',-tetramethylethylenediamine (TEMED)
TRÏ Reagent
Tris acetate
Tris base
Triton X-100
Trypsin-EDTA
Trypsin Inliibitor from glycine max (soybean)
Tween 20
Urea
Xylene cyanol FF 
Upstate
PKA phospho-acceptor peptide (LRRASLG)
Whatman International Ltd., Maidstone. Kent. UK 
Whatman 3mm filter paper
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